US 12,697,385 B2Grant

Combination therapy for cancer with anti-B7-H4 antibodies and anti-PD-1 antibodies

Issue Date:2026-08-04

•41 Claims

•3 Drawing Sheets

Abstract

The present disclosure provides methods of administering antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 to a subject in need thereof, for example, a cancer patient, in combination with a PD-1/PD-L1 antagonist, such as an anti-PD-1 antibody.

Metadata

Assignee

FIVE PRIME THERAPEUTICS, INC.

Inventors

Sandeep P. Inamdar
Helen L. Collins
Hong Xiang
Xiang Zhang
Neyssa Marina

Application Information

Application Number:US 17/224,865

Filing Date:2021-04-07

Priority Date:2018-10-15

Art Unit:1674

Classifications

IPC:

A61P35/00A61K39/395A61K39/00C07K16/28

Field of Search:

A61K 39/3955A61P 35/00C07K 26/2827C07K 16/2818

Patent Drawings (3 sheets)

Description

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a Continuation Application of PCT/US2019/056210, filed internationally on Oct. 15, 2019, which claims the benefit of priority to U.S. Provisional Application 62/745,464, filed on Oct. 15, 2018, U.S. Provisional Application 62/802,091, filed on Feb. 6, 2019, and U.S. Provisional Application 62/854,494, filed on May 30, 2019, the disclosures of which are herein incorporated by reference in their entirety.

SUBMISSION OF SEQUENCE LISTING ON ASCII TEXT FILE

[0002] The content of the following submission on ASCII text file is incorporated herein by reference in its entirety: a computer readable form (CRF) of the Sequence Listing (file name: 204122000501SEQLIST.TXT, date recorded: Apr. 6, 2021, size: 46 KB).

FIELD

[0003] The present disclosure relates to methods of administering antibodies that specifically bind to human B7-H4 in combination with a PD-1/PD-L1 antagonist, such as pembrolizumab, for the treatment of diseases such as cancer. Advantageous dose regimens are provided.

1. BACKGROUND

[0004] B7-H4 (also known as B7x, B7-S1, and VTCN1) is an immune regulatory molecule that shares homology with other B7 family members, include PD-L1. It is a type I transmembrane protein comprised of both IgV and IgC ectodomains. While B7-H4 expression in healthy tissues is relatively limited at the protein level, B7-H4 is expressed in several solid tumors such as gynecological carcinomas of the breast, ovary, and endometrium. Expression of B7-H4 in tumors tends to correlate with poor prognosis. The receptor for B7-H4 is unknown, but it is believed to be expressed on T cells. B7-H4 is believed to directly inhibit T cell activity.

[0005] Given the expression and function of B7-H4, antibodies that specifically bind to B7-H4 are being developed for therapies involving the modulation of B7-H4 activity, e.g., for the treatment of cancer.

[0006] PD-1 is a key immune checkpoint receptor expressed by activated T and B cells and mediates immunosuppression. PD-1 is a member of the CD28 family of receptors, which includes CD28, CTLA-4, ICOS, PD-1, and BTLA. Two cell surface glycoprotein ligands for PD-1 have been identified, Programmed Death Ligand-1 (PD-L1) and Programmed Death Ligand-2 (PD-L2), that are expressed on antigen-presenting cells as well as many human cancers and have been shown to down regulate T cell activation and cytokine secretion upon binding to PD-1. Inhibition of the PD-1/PD-L1 interaction, e.g., by anti-PD-1 or anti-PD-L1 antibodies, mediates potent antitumor activity.

[0007] Accordingly, there is a need for efficacious dosing regimens for administration of antibodies that bind to B7-H4 and inhibitors of the PD-1/PD-L1 interaction.

2. SUMMARY

[0008] Provided herein are methods of administering anti-B7-H4 antibodies and antigen-binding fragments thereof, in combination with a PD-1/PD-L1 antagonist, using a therapeutically effective dose regimen. Anti-B7-H4 antibodies and antigen-binding fragments thereof may be the 20502 antibody or an antigen-binding fragment thereof; or an antibody or antigen-binding fragment comprising the heavy and light chain variable region CDRs of the 20502 antibody; or an antibody or antigen-binding fragment comprising the heavy and light chain variable regions of the 20502 antibody, including afucosylated forms of any of the foregoing. A PD-1/PD-L1 antagonist may be an anti-PD-1 antibody such as pembrolizumab, or an antibody or antigen-binding fragment comprising the heavy and light chain variable region CDRs of pembrolizumab; or an antibody or antigen-binding fragment comprising the heavy and light chain variable regions of pembrolizumab.

[0009] In certain aspects, a method of treating a solid tumor in a human subject comprises administering to the subject (a) about 0.1 to about 20 mg/kg of an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4 and comprises the heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3 and light chain variable region (VL) CDR1, VL CDR2, and VL CDR3 sequences of the 20502 antibody; and (b) about 200 mg of pembrolizumab. In certain embodiments, (a) and (b) are administered concurrently or sequentially.

[0010] In certain aspects, a method of treating a solid tumor in a human subject comprises administering to the subject (a) a pharmaceutical composition comprising (i) antibodies or antigen-binding fragment thereof, wherein the antibodies or antigen-binding fragments thereof specifically bind to human B7-H4 and comprise the heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3 and light chain variable region (VL) CDR1, VL CDR2, and VL CDR3 sequences of the 20502 antibody and (ii) a pharmaceutically acceptable excipient, wherein at least 95% of the antibodies or antigen-binding fragments thereof in the composition are afucosylated, and wherein about 0.1 to about 20 mg/kg of the antibodies or antigen-binding fragments thereof are administered; and (b) a pharmaceutical composition comprising pembrolizumab, wherein about 200 mg of pembrolizumab is administered. In certain embodiments, (a) and (b) are administered concurrently or sequentially.

[0011] In certain aspects, the CDRs of the antibodies or antigen-binding fragments are the Kabat-defined CDRs, the Chothia-defined CDRs, or the AbM-defined CDRs. In certain aspects, the VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and CDR3 sequences comprise the amino acid sequences set forth in SEQ ID NOs: 5-10, respectively.

[0012] In certain aspects, about 20 mg/kg or 20 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject. In certain aspects, about 10 mg/kg or 10 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject. In certain aspects, about 3 mg/kg or 3 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject. In certain aspects, about 1 mg/kg or 1 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject. In certain aspects, about 0.3 mg/kg or 0.3 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject. In certain aspects, about 0.1 mg/kg or 0.1 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

[0013] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment thereof and/or pembrolizumab are administered about once every three weeks.

[0014] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment thereof and/or pembrolizumab are administered intravenously.

[0015] In certain aspects, B7-H4 has been detected in the solid tumor using immunohistochemistry (IHC) prior to the administration.

[0016] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence set forth in SEQ ID NO:11 and/or a VL comprising the amino acid sequence set forth in SEQ ID NO:12. In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment comprises a heavy chain constant region and/or a light chain constant region. In certain aspects, the heavy chain constant region is a human immunoglobulins IgG1 heavy chain constant region and/or the light chain constant region is a human immunoglobulin IgGκ light chain constant region. In certain aspects, the antibody or antigen-binding fragment thereof comprises a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO:25 and/or a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO:23. In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:21 and/or a light chain comprising the amino acid sequence set forth in SEQ ID NO: 22.

[0017] In certain aspects, the antibody or antigen-binding fragment thereof is a human antibody or antigen-binding fragment thereof.

[0018] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment thereof is afucosylated.

[0019] In certain aspects, the antibody or antigen-binding fragment thereof is a full length antibody. In certain aspects, the antibody or antigen-binding fragment thereof is an antigen-binding fragment. In certain aspects, the antigen-binding fragment comprises or is a Fab, Fab′, F(ab′)₂, single chain Fv (scFv), disulfide linked Fv, V-NAR domain, IgNar, intrabody, IgGΔCH2, minibody, F(ab′)₃, tetrabody, triabody, diabody, single-domain antibody, DVD-Ig, Fcab, mAb2, (scFv)₂, or scFv-Fc.

[0020] In certain aspects, fucosylation is undetectable in the composition comprising anti-B7-H4 antibodies.

[0021] In certain aspects, the solid tumor expresses B7-H4.

[0022] In certain aspects, the solid tumor is unresectable, locally advanced, or metastatic.

[0023] In certain aspects, the solid tumor is selected from the group consisting of breast cancer, ductal carcinoma, endometrial carcinoma, ovarian cancer, urothelial cancer, non-small cell lung cancer, pancreatic cancer, thyroid cancer, kidney cancer and bladder cancer. In certain aspects, the solid tumor is breast cancer, ovarian cancer, endometrial cancer, or urothelial cancer. In certain aspects, the breast cancer is advanced breast cancer. In certain aspects, the breast cancer is HER2-negative. In certain aspects, the breast cancer is triple negative breast cancer. In certain aspects, the breast cancer is hormone receptor (HR)-positive breast cancer. In certain aspects, the non-small cell lung cancer is squamous cell carcinoma. In certain aspects, the subject has not received prior therapy with a PD-1/PD-L1 antagonist.

[0024] In certain aspects, the method further comprises monitoring the number of immune cells in the tumor. In certain aspects, the method further comprises monitoring the number of natural killer (NK) cells, CD4+ cells, and/or CD8+ cells in the tumor. In certain aspects, the method further comprises monitoring cytokine levels in the subject. In certain aspects, the method further comprises monitoring IL-2, IL-6, IL-10, TNF, and/or interferon gamma (IFNγ) levels in the subject.

[0025] In certain aspects, administration of the anti-B7-H4 antibody or antigen-binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof produces a synergistic effect.

[0026] In certain aspects, a method of treating a solid tumor in a human subject comprises administering to the subject (i) about 20 mg/kg of an anti-B7-H4 antibody that specifically binds to human B7-H4 and comprises a VH comprising the amino acid sequence of SEQ ID NO:11 and a VL comprising the amino acid sequence of SEQ ID NO: 12; and (ii) about 200 mg of an anti-PD-1 antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:32 and a VL comprising the amino acid sequence of SEQ ID NO:33, wherein the anti-B7-H4 antibody and the anti-PD-1 antibody are administered intravenously about once every three weeks.

[0027] In certain aspects, a method of treating a solid tumor in a human subject comprises administering to the subject (a) a pharmaceutical composition comprising (i) anti-B7-H4 antibodies that specifically bind to human B7-H4 and comprise a VH comprising the amino acid sequence of SEQ ID NO:11 and a VL comprising the amino acid sequence of SEQ ID NO:12 and (ii) a pharmaceutically acceptable excipient, wherein at least 95% of the anti-B7-H4 antibodies thereof in the composition are afucosylated, and wherein about 20 mg/kg of the antibodies are administered; and (b) a pharmaceutical composition comprising an anti-PD-1 antibody or antigen-binding fragment thereof comprising a VH comprising the amino acid sequence of SEQ ID NO:32 and a VL comprising the amino acid sequence of SEQ ID NO:33 and a pharmaceutically acceptable excipient, wherein about 200 mg of the antibody or antigen-binding fragment is administered, wherein the anti-B7-H4 antibody and the anti-PD-1 antibody are administered intravenously about once every three weeks.

[0028] In certain aspects, the anti-B7-H4 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:21 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:22. In certain aspects, the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:30 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:31.

[0029] In certain aspects, the solid tumor is breast cancer, optionally wherein the breast cancer is triple negative breast cancer, or ovarian cancer.

3. BRIEF DESCRIPTION OF THE FIGURES

[0030] FIGS. 1A, 1B, and 1C show in vivo anti-tumor efficacy of an anti-B7-H4 antibody in combination with an anti-PD-1 antibody. (See Example 4.)

[0031] FIG. 2 shows the dose-dependent anti-tumor activity of an anti-B7-H4 antibody. (See Example 4.)

[0032] FIG. 3 shows that an anti-B7-H4 antibody combines synergistically with an anti-PD1 antibody, even when the anti-B7-H4 antibody is administered at a dose that is not effective as a monotherapy. (Sec Example 4.)

4. DETAILED DESCRIPTION

[0033] Provided herein are methods of administering antibodies (e.g., monoclonal antibodies) and antigen-binding fragments thereof that specifically bind to B7-H4 (e.g., human B7-H4), in combination with a PD-1/PD-L1 antagonist (e.g., pembrolizumab). The anti-B7-H4 antibodies and antigen-binding fragments thereof can be administered in combination with a PD-1/PD-L1 antagonist (e.g., pembrolizumab), for example, to treat a solid tumor in a subject. In a particular embodiment, about 20 mg/kg, about 10 mg/kg, about 3 mg/kg, about 1 mg/kg, about 0.3 mg/kg, or about 0.1 mg/kg of the antibody or antigen-binding fragment thereof is administered in combination with about 200 mg of pembrolizumab to the subject, e.g., wherein the administration occurs about every three weeks.

4.1 Terminology

[0034] As used herein, the term “B7-H4” refers to mammalian B7-H4 polypeptides including, but not limited to, native B7-H4 polypeptides and isoforms of B7-H4 polypeptides. “B7-H4” encompasses full-length, unprocessed B7-H4 polypeptides as well as forms of B7-H4 polypeptides that result from processing within the cell. As used herein, the term “human B7-H4” refers to a polypeptide comprising the amino acid sequence of SEQ ID NO:1. A “B7-H4 polynucleotide,” “B7-H4 nucleotide,” or “B7-H4 nucleic acid” refer to a polynucleotide encoding B7-H4.

[0035] The term “antibody” means an immunoglobulin molecule that recognizes and specifically binds to a target, such as a protein, polypeptide, peptide, carbohydrate, polynucleotide, lipid, or combinations of the foregoing through at least one antigen recognition site within the variable region of the immunoglobulin molecule. As used herein, the term “antibody” encompasses intact polyclonal antibodies, intact monoclonal antibodies, chimeric antibodies, humanized antibodies, human antibodies, fusion proteins comprising an antibody, and any other modified immunoglobulin molecule so long as the antibodies exhibit the desired biological activity. An antibody can be of any the five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, or subclasses (isotypes) thereof (e.g. IgG1, IgG2, IgG3, IgG4, IgAQ1 and IgA2), based on the identity of their heavy-chain constant domains referred to as alpha, delta, epsilon, gamma, and mu, respectively. The different classes of immunoglobulins have different and well known subunit structures and three-dimensional configurations. Antibodies can be naked or conjugated to other molecules such as toxins, radioisotopes, etc.

[0036] The term “antibody fragment” refers to a portion of an intact antibody. An “antigen-binding fragment,” “antigen-binding domain,” or “antigen-binding region,” refers to a portion of an intact antibody that binds to an antigen. An antigen-binding fragment can contain an antigen recognition site of an intact antibody (e.g., complementarity determining regions (CDRs) sufficient to specifically bind antigen). Examples of antigen-binding fragments of antibodies include, but are not limited to Fab, Fab′, F(ab′)₂, and Fv fragments, linear antibodies, and single chain antibodies. An antigen-binding fragment of an antibody can be derived from any animal species, such as rodents (e.g., mouse, rat, or hamster) and humans or can be artificially produced.

[0037] The terms “anti-B7-H4 antibody,” “B7-H4 antibody” and “antibody that binds to B7-H4” refer to an antibody that is capable of specifically binding B7-H4 with sufficient affinity such that the antibody is useful as a diagnostic and/or therapeutic agent in targeting B7-H4. As used herein, the terms “specifically binding,” “immunospecifically binding,” “immunospecifically recognizing,” and “specifically recognizing” are analogous terms in the context of antibodies or antigen-binding fragments thereof. These terms indicate that the antibody or antigen-binding fragment thereof binds to an epitope via its antigen-binding domain and that the binding entails some complementarity between the antigen-binding domain and the epitope. Accordingly, an antibody that “specifically binds” to human B7-H4 (SEQ ID NO:1) may also bind to B7-H4 from other species (e.g., cynomolgus monkey, mouse, and/or rat B7-H4) and/or B7-H4 proteins produced from other human alleles, but the extent of binding to an un-related, non-B7-H4 protein (e.g., other B7 protein family members such as PD-L1) is less than about 10% of the binding of the antibody to B7-H4 as measured, e.g., by a radioimmunoassay (RIA). In a specific embodiment, provided herein is an antibody or antigen-binding fragment thereof that specifically binds to human, cynomolgus monkey, mouse, and rat B7-H4.

[0038] A “monoclonal” antibody or antigen-binding fragment thereof refers to a homogeneous antibody or antigen-binding fragment population involved in the highly specific binding of a single antigenic determinant, or epitope. This is in contrast to polyclonal antibodies that typically include different antibodies directed against different antigenic determinants. The term “monoclonal” antibody or antigen-binding fragment thereof encompasses both intact and full-length monoclonal antibodies as well as antibody fragments (such as Fab, Fab′, F(ab′)₂, Fv), single chain (scFv) mutants, fusion proteins comprising an antibody portion, and any other modified immunoglobulin molecule comprising an antigen recognition site. Furthermore, “monoclonal” antibody or antigen-binding fragment thereof refers to such antibodies and antigen-binding fragments thereof made in any number of manners including but not limited to by hybridoma, phage selection, recombinant expression, and transgenic animals.

[0039] As used herein, the terms “variable region” or “variable domain” are used interchangeably and are common in the art. The variable region typically refers to a portion of an antibody, generally, a portion of a light or heavy chain, typically about the amino-terminal 110 to 120 amino acids or 110 to 125 amino acids in the mature heavy chain and about 90 to 115 amino acids in the mature light chain, which differ in sequence among antibodies and are used in the binding and specificity of a particular antibody for its particular antigen. The variability in sequence is concentrated in those regions called complementarity determining regions (CDRs) while the more highly conserved regions in the variable domain are called framework regions (FR). Without wishing to be bound by any particular mechanism or theory, it is believed that CDRs of the light and heavy chains are primarily responsible for the interaction and specificity of the antibody with antigen. In certain embodiments, the variable region is a human variable region. In certain embodiments, the variable region comprises rodent or murine CDRs and human framework regions (FRs). In particular embodiments, the variable region is a primate (e.g., non-human primate) variable region. In certain embodiments, the variable region comprises rodent or murine CDRs and primate (e.g., non-human primate) framework regions (FRs).

[0040] The terms “VL” and “VL domain” are used interchangeably to refer to the light chain variable region of an antibody.

[0041] The terms “VH” and “VH domain” are used interchangeably to refer to the heavy chain variable region of an antibody.

[0042] The term “Kabat numbering” and like terms are recognized in the art and refer to a system of numbering amino acid residues in the heavy and light chain variable regions of an antibody or an antigen-binding fragment thereof. In certain aspects, CDRs can be determined according to the Kabat numbering system (see, e.g., Kabat E A & Wu T T (1971) Ann NY Acad Sci 190:382-391 and Kabat E A et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). Using the Kabat numbering system, CDRs within an antibody heavy chain molecule are typically present at amino acid positions 31 to 35, which optionally can include one or two additional amino acids, following 35 (referred to in the Kabat numbering scheme as 35A and 35B) (CDR1), amino acid positions 50 to 65 (CDR2), and amino acid positions 95 to 102 (CDR3). Using the Kabat numbering system, CDRs within an antibody light chain molecule are typically present at amino acid positions 24 to 34 (CDR1), amino acid positions 50 to 56 (CDR2), and amino acid positions 89 to 97 (CDR3). In a specific embodiment, the CDRs of the antibodies described herein have been determined according to the Kabat numbering scheme.

[0043] Chothia refers instead to the location of the structural loops (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)). The end of the Chothia CDR-H1 loop when numbered using the Kabat numbering convention varies between H32 and H34 depending on the length of the loop (this is because the Kabat numbering scheme places the insertions at H35A and H35B; if neither 35A nor 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34). The AbM hypervariable regions represent a compromise between the Kabat CDRs and Chothia structural loops, and are used by Oxford Molecular's AbM antibody modeling software.

[0044]



Loop	Kabat	AbM	Chothia

L1	L24-L34	L24-L34	L24-L34
L2	L50-L56	L50-L56	L50-L56
L3	L89-L97	L89-L97	L89-L97
H1	H31-H35B	H26-H35B	H26-H32 . . . 34
(Kabat Numbering)
H1	H31-H35	H26-H35	H26-H32
(Chothia Numbering)
H2	H50-H65	H50-H58	H52-H56
H3	H95-H102	H95-H102	H95-H102

[0045] As used herein, the term “constant region” and “constant domain” are interchangeable and have their common meanings in the art. The constant region is an antibody portion, e.g., a carboxyl terminal portion of a light and/or heavy chain which is not directly involved in binding of an antibody to antigen but which can exhibit various effector functions, such as interaction with the Fc receptor. The constant region of an immunoglobulin molecule generally has a more conserved amino acid sequence relative to an immunoglobulin variable domain. In certain aspects, an antibody or antigen-binding fragment comprises a constant region or portion thereof that is sufficient for antibody-dependent cell-mediated cytotoxicity (ADCC).

[0046] As used herein, the term “heavy chain” when used in reference to an antibody can refer to any distinct type, e.g., alpha (a), delta (8), epsilon (8), gamma (γ), and mu (u), based on the amino acid sequence of the constant domain, which give rise to IgA, IgD, IgE, IgG, and IgM classes of antibodies, respectively, including subclasses of IgG, e.g., IgG1, IgG2, IgG3, and IgG4. Heavy chain amino acid sequences are well known in the art. In specific embodiments, the heavy chain is a human heavy chain.

[0047] As used herein, the term “light chain” when used in reference to an antibody can refer to any distinct type, e.g., kappa (κ) or lambda (2) based on the amino acid sequence of the constant domains. Light chain amino acid sequences are well known in the art. In specific embodiments, the light chain is a human light chain.

[0048] The term “chimeric” antibodies or antigen-binding fragments thereof refers to antibodies or antigen-binding fragments thereof wherein the amino acid sequence is derived from two or more species. Typically, the variable region of both light and heavy chains corresponds to the variable region of antibodies or antigen-binding fragments thereof derived from one species of mammals (e.g. mouse, rat, rabbit, etc.) with the desired specificity, affinity, and capability while the constant regions are homologous to the sequences in antibodies or antigen-binding fragments thereof derived from another (usually human) to avoid eliciting an immune response in that species.

[0049] The term “humanized” antibody or antigen-binding fragment thereof refers to forms of non-human (e.g. murine) antibodies or antigen-binding fragments that are specific immunoglobulin chains, chimeric immunoglobulins, or fragments thereof that contain minimal non-human (e.g., murine) sequences. Typically, humanized antibodies or antigen-binding fragments thereof are human immunoglobulins in which residues from the complementary determining region (CDR) are replaced by residues from the CDR of a non-human species (e.g. mouse, rat, rabbit, hamster) that have the desired specificity, affinity, and capability (“CDR grafted”) (Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-327 (1988); Verhoeyen et al., Science 239:1534-1536 (1988)). In some instances, certain Fv framework region (FR) residues of a human immunoglobulin are replaced with the corresponding residues in an antibody or fragment from a non-human species that has the desired specificity, affinity, and capability. The humanized antibody or antigen-binding fragment thereof can be further modified by the substitution of additional residues either in the Fv framework region and/or within the non-human CDR residues to refine and optimize antibody or antigen-binding fragment thereof specificity, affinity, and/or capability. In general, the humanized antibody or antigen-binding fragment thereof will comprise variable domains containing all or substantially all of the CDR regions that correspond to the non-human immunoglobulin whereas all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody or antigen-binding fragment thereof can also comprise at least a portion of an immunoglobulin constant region or domain (Fc), typically that of a human immunoglobulin. Examples of methods used to generate humanized antibodies are described in U.S. Pat. No. 5,225,539; Roguska et al., Proc. Natl. Acad. Sci., USA, 91 (3): 969-973 (1994), and Roguska et al., Protein Eng. 9 (10): 895-904 (1996). In some embodiments, a “humanized antibody” is a resurfaced antibody.

[0050] The term “human” antibody or antigen-binding fragment thereof means an antibody or antigen-binding fragment thereof having an amino acid sequence derived from a human immunoglobulin gene locus, where such antibody or antigen-binding fragment is made using any technique known in the art. This definition of a human antibody or antigen-binding fragment thereof includes intact or full-length antibodies and fragments thereof.

[0051] An “afucosylated” antibody or antigen-binding fragment thereof or an antibody or antigen-binding fragment thereof “lacking fucose” refers to an IgG1 or IgG3 isotype antibody or antigen-binding fragment thereof that lacks fucose in its constant region glycosylation. Glycosylation of human IgG1 or IgG3 occurs at Asn297 as core fucosylated biantennary complex oligosaccharide glycosylation terminated with up to 2 Gal residues. In some embodiments, an afucosylated antibody lacks fucose at Asn297. These structures are designated as G0, G1 (a 1,6 or a 1,3), or G2 glycan residues, depending on the amount of terminal Gal residues. See, e.g., Raju, T. S., BioProcess Int. 1:44-53 (2003). CHO type glycosylation of antibody Fc is described, e.g., in Routier, F. FL, Glycoconjugate J. 14:201-207 (1997).

[0052] Methods of measuring fucose include any methods known in the art. For purposes herein, fucose is detected by the method described in Example 1 of WO2015/017600, which is herein incorporated by reference in its entirety. Briefly, glycan analysis is performed by releasing glycans from the antibody (e.g., by enzymatic release), labeling the glycans with anthranilic acid (2-AA), and then purifying the labeled glycans. Normal phase HPLC with fluorescent detection is used to separate the glycans and measure the relative amount of each glycan in the antibody. The glycans may be positively identified as lacking or including fucose by mass spectrometry. In some embodiments, fucose is undetectable in a composition comprising a plurality of afucosylated antibodies or antigen-binding fragments thereof. In some embodiments, an afucosylated antibody or antigen-binding fragment thereof has enhanced affinity for Fc gamma RIIIA. In some embodiments, an afucosylated antibody or antigen-binding fragment thereof has enhanced affinity for Fc gamma RIIIA(V158). In some embodiments, an afucosylated antibody or antigen-binding fragment thereof has enhanced affinity for Fc gamma RIIIA(F158).

[0053] “Binding affinity” generally refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody or antigen-binding fragment thereof) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody or antigen-binding fragment thereof and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (K_D). Affinity can be measured and/or expressed in a number of ways known in the art, including, but not limited to, equilibrium dissociation constant (K_D), and equilibrium association constant (K_A). The K_Dis calculated from the quotient of k_off/k_on, whereas K_Ais calculated from the quotient of k_on/k_off. k_onrefers to the association rate constant of, e.g., an antibody or antigen-binding fragment thereof to an antigen, and k_offrefers to the dissociation of, e.g., an antibody or antigen-binding fragment thereof from an antigen. The k_onand k_offcan be determined by techniques known to one of ordinary skill in the art, such as BIAcore® or KinExA.

[0054] As used herein, an “epitope” is a term in the art and refers to a localized region of an antigen to which an antibody or antigen-binding fragment thereof can specifically bind. An epitope can be, for example, contiguous amino acids of a polypeptide (linear or contiguous epitope) or an epitope can, for example, come together from two or more non-contiguous regions of a polypeptide or polypeptides (conformational, non-linear, discontinuous, or non-contiguous epitope). In certain embodiments, the epitope to which an antibody or antigen-binding fragment thereof specifically binds can be determined by, e.g., NMR spectroscopy, X-ray diffraction crystallography studies, ELISA assays, hydrogen/deuterium exchange coupled with mass spectrometry (e.g., liquid chromatography electrospray mass spectrometry), array-based oligo-peptide scanning assays, and/or mutagenesis mapping (e.g., site-directed mutagenesis mapping). For X-ray crystallography, crystallization may be accomplished using any of the known methods in the art (e.g., Giegć R et al., (1994) Acta Crystallogr D Biol Crystallogr 50 (Pt 4): 339-350; McPherson A (1990) Eur J Biochem 189:1-23; Chayen N E (1997) Structure 5:1269-1274; McPherson A (1976) J Biol Chem 251:6300-6303). Antibody/antigen-binding fragment thereof:antigen crystals can be studied using well known X-ray diffraction techniques and can be refined using computer software such as X-PLOR (Yale University, 1992, distributed by Molecular Simulations, Inc.; see, e.g., Meth Enzymol (1985) volumes 114 & 115, eds Wyckoff H W et al.,; U.S. 2004/0014194), and BUSTER (Bricogne G (1993) Acta Crystallogr D Biol Crystallogr 49 (Pt 1): 37-60; Bricogne G (1997) Meth Enzymol 276A: 361-423, ed Carter C W; Roversi P et al., (2000) Acta Crystallogr D Biol Crystallogr 56 (Pt 10): 1316-1323). Mutagenesis mapping studies can be accomplished using any method known to one of skill in the art. See, e.g., Champe M et al., (1995) J Biol Chem 270:1388-1394 and Cunningham B C & Wells J A (1989) Science 244:1081-1085 for a description of mutagenesis techniques, including alanine scanning mutagenesis techniques.

[0055] The terms “programmed cell death protein 1” and “PD-1” refer to an immunoinhibitory receptor belonging to the CD28 family. PD-1 is expressed predominantly on previously activated T-cells in vivo, and binds to two ligands, PD-L1 and PD-L2. The term “PD-1” as used herein includes human PD-1 (hPD-1), naturally occurring variants and isoforms of hPD-1, and species homologs of hPD-1.

[0056] The terms “programmed cell death 1 ligand 1” and “PD-L1” refer to one of two cell surface glycoprotein ligands for PD-1 (the other being PD-L2) that down regulate T-cell activation and cytokine secretion upon binding to PD-1. The term “PD-L1” as used herein includes human PD-L1 (hPD-L1), naturally occurring variants and isoforms of hPD-1, and species homologs of hPD-L1.

[0057] The term “PD-1/PD-L1 antagonist” refers to a moiety that disrupts the PD-1/PD-L1 signaling pathway. In some embodiments, the antagonist inhibits the PD-1/PD-L1 signaling pathway by binding to PD-1 and/or PD-L1. In some embodiments, the PD-1/PD-L1 antagonist also binds to PD-L2. In some embodiments, a PD-1/PD-L1 antagonist blocks binding of PD-1 to PD-L1 and optionally PD-L2. Nonlimiting exemplary PD-1/PD-L1 antagonists include PD-1 antagonists, such as antibodies that bind to PD-1, e.g., nivolumab (OPDIVO) and pembrolizumab (KEYTRUDA); PD-L1 antagonists, such as antibodies that bind to PD-L1 (e.g., atezolizumab (TECENTRIQ), durvalumab and avelumab); fusion proteins, such as AMP-224; and peptides, such as AUR-012.

[0058] “Pembrolizumab” refers to the humanized anti-PD-1 monoclonal antibody that is the active ingredient in the commercial pharmaceutical preparation referred to as KEYTRUDA®, marketed by Merck & Co.

[0059] A polypeptide, antibody, polynucleotide, vector, cell, or composition which is “isolated” is a polypeptide, antibody, polynucleotide, vector, cell, or composition which is in a form not found in nature. Isolated polypeptides, antibodies, polynucleotides, vectors, cell or compositions include those which have been purified to a degree that they are no longer in a form in which they are found in nature. In some embodiments, an antibody, polynucleotide, vector, cell, or composition which is isolated is substantially pure. As used herein, “substantially pure” refers to material which is at least 50% pure (i.e., free from contaminants), at least 90% pure, at least 95% pure, at least 98% pure, or at least 99% pure.

[0060] The terms “polypeptide,” “peptide,” and “protein” are used interchangeably herein to refer to polymers of amino acids of any length. The polymer can be linear or branched, it can comprise modified amino acids, and it can be interrupted by non-amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art. It is understood that, because the polypeptides of this invention are based upon antibodies, in certain embodiments, the polypeptides can occur as single chains or associated chains.

[0061] As used herein, the term “host cell” can be any type of cell, e.g., a primary cell, a cell in culture, or a cell from a cell line. In specific embodiments, the term “host cell” refers to a cell transfected with a nucleic acid molecule and the progeny or potential progeny of such a cell. Progeny of such a cell may not be identical to the parent cell transfected with the nucleic acid molecule, e.g., due to mutations or environmental influences that may occur in succeeding generations or integration of the nucleic acid molecule into the host cell genome.

[0062] The term “pharmaceutical formulation” refers to a preparation which is in such form as to permit the biological activity of the active ingredient to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered. The formulation can be sterile.

[0063] The terms “administer,” “administering,” “administration,” and the like, as used herein, refer to methods that may be used to enable delivery of a drug, e.g., an anti-B7-H4 antibody or antigen-binding fragment thereof to the desired site of biological action (e.g., intravenous administration). Administration techniques that can be employed with the agents and methods described herein are found in e.g., Goodman and Gilman, The Pharmacological Basis of Therapeutics, current edition, Pergamon; and Remington's, Pharmaceutical Sciences, current edition, Mack Publishing Co., Easton, Pa.

[0064] As used herein, the terms “subject” and “patient” are used interchangeably. The subject can be an animal. In some embodiments, the subject is a mammal such as a non-human animal (e.g., cow, pig, horse, cat, dog, rat, mouse, monkey or other primate, etc.). In some embodiments, the subject is a cynomolgus monkey. In some embodiments, the subject is a human.

[0065] The term “therapeutically effective amount” refers to an amount of a drug, e.g., an anti-B7-H4 antibody or antigen-binding fragment thereof, effective to treat a disease or disorder in a subject. In the case of cancer, the therapeutically effective amount of the drug can reduce the number of cancer cells; reduce the tumor size or burden; inhibit, to some extent, cancer cell infiltration into peripheral organs; inhibit, to some extent, tumor metastasis; inhibit, to some extent, tumor growth; relieve, to some extent, one or more of the symptoms associated with the cancer; and/or result in a favorable response such as increased progression-free survival (PFS), disease-free survival (DFS), overall survival (OS), complete response (CR), partial response (PR), or, in some cases, stable disease (SD), a decrease in progressive disease (PD), a reduced time to progression (TTP), or any combination thereof. To the extent the drug can prevent growth and/or kill existing cancer cells, it can be cytostatic and/or cytotoxic.

[0066] Terms such as “treating,” “treatment,” “to treat,” “alleviating,” and “to alleviate” refer to therapeutic measures that cure, slow down, lessen symptoms of, and/or halt progression of a pathologic condition or disorder. Thus, those in need of treatment include those already diagnosed with or suspected of having the disorder. In certain embodiments, a subject is successfully “treated” for cancer according to the methods of the present invention if the patient shows one or more of the following: a reduction in the number of or complete absence of cancer cells; a reduction in the tumor size; inhibition of or an absence of cancer cell infiltration into peripheral organs including, for example, the spread of cancer into soft tissue and bone; inhibition or an absence of tumor metastasis; inhibition or an absence of tumor growth; relief of one or more symptoms associated with the specific cancer; reduced morbidity and mortality; improvement in quality of life; reduction in tumorigenicity, tumorigenic frequency, or tumorigenic capacity, of a tumor; reduction in the number or frequency of cancer stem cells in a tumor; differentiation of tumorigenic cells to a non-tumorigenic state; increased progression-free survival (PFS), disease-free survival (DFS), overall survival (OS), complete response (CR), partial response (PR), stable disease (SD), a decrease in progressive disease (PD), a reduced time to progression (TTP), or any combination thereof.

[0067] The terms “cancer” and “cancerous” refer to or describe the physiological condition in mammals in which a population of cells are characterized by unregulated cell growth. Examples of cancer include, but are not limited to, gynecological cancers (e.g., breast cancer (including triple negative breast cancer, hormone receptor (HR)-positive breast cancer, ductal carcinoma, ovarian cancer, and endometrial cancer)), non-small cell lung cancer, pancreatic cancer, thyroid cancer, kidney cancer (e.g., renal cell carcinoma) and bladder cancer (e.g., urothelial cell carcinoma). The cancer can be a “cancer that expresses B7-H4” or a “B7-H4 expressing cancer” or a “B7-H4 positive cancer”. Such terms refer to a cancer comprising cells that express B7-H4. The cancer can be a solid tumor that expresses B7-H4. The cancer may be a primary tumor or may be advanced or metastatic cancer.

[0068] A “refractory” cancer is one that progresses even though an anti-tumor treatment, such as a chemotherapy, is administered to the cancer patient.

[0069] A “recurrent” cancer is one that has regrown, either at the initial site or at a distant site, after a response to initial therapy.

[0070] As demonstrated herein, administration of an anti-B7-H4 antibody or antigen-binding fragment thereof and an anti-PD-1 antibody or antigen-binding fragment thereof can provide “synergy” or be “synergistic,” i.e., the effect achieved when the active ingredients are used together is greater than the sum of the effects that results from using the active ingredients separately. A synergistic effect can be attained when the active ingredients are: (1) co-formulated and administered or delivered simultaneously in a combined, unit dosage formulation; (2) delivered serially, by alternation, or in parallel as separate formulations; or (3) by some other regimen. When delivered in alternation therapy, a synergistic effect can be attained when the compounds are administered or delivered sequentially, e.g., by different injections in separate syringes.

[0071] As used in the present disclosure and claims, the singular forms “a,” “an,” and “the” include plural forms unless the context clearly dictates otherwise.

[0072] It is understood that wherever embodiments are described herein with the language “comprising,” otherwise analogous embodiments described in terms of “consisting of” and/or “consisting essentially of” are also provided. In this disclosure, “comprises,” “comprising,” “containing” and “having” and the like can have the meaning ascribed to them in U.S. patent law and can mean “includes,” “including,” and the like; “consisting essentially of” or “consists essentially” likewise has the meaning ascribed in U.S. patent law and the term is open-ended, allowing for the presence of more than that which is recited so long as basic or novel characteristics of that which is recited are not changed by the presence of more than that which is recited, but excludes prior art embodiments

[0073] Unless specifically stated or obvious from context, as used herein, the term “or” is understood to be inclusive. The term “and/or” as used in a phrase such as “A and/or B” herein is intended to include both “A and B,” “A or B,” “A,” and “B.” Likewise, the term “and/or” as used in a phrase such as “A, B, and/or C” is intended to encompass each of the following embodiments: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0074] As used herein, the terms “about” and “approximately,” when used to modify a numeric value or numeric range, indicate that deviations of 5% to 10% above and 5% to 10% below the value or range remain within the intended meaning of the recited value or range.

[0075] Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.

4.2 Methods of Treating Cancer

[0076] In one aspect, presented herein are methods for treating cancer in a human subject comprising administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition thereof as described herein, in combination with (ii) a PD-1/PD-L1 inhibitor described herein or a pharmaceutical composition thereof as described herein, and wherein (i) and (ii) are administered concurrently or sequentially. For administration “concurrently,” in some embodiments, the agents as in (i) and (ii) are administered as separate formulations on the same day, with one being administered after the other; or in other embodiments, the agents as in (i) and (ii) are mixed together prior to administration and thus administered as a mixture. For example, in some embodiments, the agents as in (i) and (ii) may be packaged and stored in the same vial (i.e., fixed dose formulation), or alternatively, vials containing each separate agent may be mixed together just prior to administration. For administration “sequentially,” the agents as in (i) and (ii) are administered as separate formulations on different days. In various embodiments, the agents may be administered in vivo by various routes, including, but not limited to, intravenous.

[0077] The combination of the anti-B7-H4 antibody or antigen-binding fragment thereof and the PD-1/PD-L1 inhibitor can be synergistic.

[0078] In one aspect, the PD-1 inhibitor is pembrolizumab. The heavy and light chain sequences of pembrolizumab are listed in the following table. In the context of the heavy and light chain sequences, the CDR sequences are shown in bold, and the variable region sequences are underlined.

[0079]

TABLE 2

Pembrolizumab sequences
Domain	Amino Acid Sequence (SEQ ID NO)

Heavy	QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQ
	GLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSL
	QFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSSASTKGPSVF
	PLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHT
	FPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVD
	KRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPE
	VTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYR
	VVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPR
	EPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP
	ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE
	ALHNHYTQKSLSLSLGK (SEQ ID NO: 30)

Light	EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQK
	PGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPED
	FAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQL
	KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS
	KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR
	GEC (SEQ ID NO: 31)

VH	QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQ
	GLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSL
	QFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS (SEQ ID
	NO: 32)

VL	EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQK
	PGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPED
	FAVYYCQHSRDLPLTFGGGTKVEIK (SEQ ID NO: 33)

VH-CDR1	NYYMY (SEQ ID NO: 34)

VH-CDR2	GINPSNGGTNFNEKFKN (SEQ ID NO: 35)

VH-CDR3	RDYRFDMGFDY (SEQ ID NO: 36)

VL-CDR1	RASKGVSTSGYSYLH (SEQ ID NO: 37)

VL-CDR2	LASYLES (SEQ ID NO: 38)

VL-CDR3	QHSRDLPLT (SEQ ID NO: 39)

[0080] In one aspect, the PD-1 inhibitor is antibody or antigen-binding fragment comprising the heavy and light chain variable region CDRs of pembrolizumab; or an antibody or antigen-binding fragment comprising the heavy and light chain variable regions of pembrolizumab.

[0081] In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition thereof as described herein, wherein about 0.005 to about 20 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment of is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof as described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered concurrently or sequentially at a frequency of, e.g., about once every three weeks.

[0082] In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition thereof as described herein, wherein about 0.1 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof as described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered concurrently or sequentially at a frequency of, e.g., about once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition thereof as described herein, wherein about 0.3 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof as described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered concurrently or sequentially at a frequency of, e.g., about once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition thereof as described herein, wherein about 1 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof as described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered concurrently or sequentially at a frequency of, e.g., about once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition thereof as described herein, wherein about 3 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment of is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof as described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered concurrently or sequentially at a frequency of, e.g., about once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition thereof as described herein, wherein about 10 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof as described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered concurrently or sequentially at a frequency of, e.g., about once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition thereof as described herein, wherein about 20 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof as described herein, wherein about 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered concurrently or sequentially at a frequency of, e.g., about once every three weeks.

[0083] In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition thereof as described herein, wherein 0.1 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof as described herein, wherein 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered concurrently or sequentially at a frequency of once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition thereof as described herein, wherein 0.3 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof as described herein, wherein 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered concurrently or sequentially at a frequency of once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition thereof as described herein, wherein 1 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof as described herein, wherein 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered concurrently or sequentially at a frequency of once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition thereof as described herein, wherein 3 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment of is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof as described herein, wherein 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered concurrently or sequentially at a frequency of once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition thereof as described herein, wherein 10 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof as described herein, wherein 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered concurrently or sequentially at a frequency of once every three weeks. In one aspect, a method of treating cancer in a human subject comprises administering to a subject in need thereof (i) an anti-B7-H4 antibody or antigen-binding fragment thereof described herein or a pharmaceutical composition thereof as described herein, wherein 20 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered, and (ii) pembrolizumab or a pharmaceutical composition thereof as described herein, wherein 200 mg of pembrolizumab is administered, and wherein (i) and (ii) are administered concurrently or sequentially at a frequency of once every three weeks.

[0084] In certain embodiments of the methods provided herein, the anti-B7-H4 antibody or antigen-binding fragment thereof, or the pharmaceutical composition comprising anti-B7-H4 antibodies or antigen-binding fragments thereof, is administered intravenously. In certain embodiments of the methods provided herein, pembrolizumab or the pharmaceutical composition thereof is administered intravenously.

[0085] In certain embodiments, provided herein are methods of treating a cancer selected from the group consisting of: breast cancer (e.g., advanced breast cancer, triple negative breast cancer, hormone receptor (HR)-positive breast cancer, or ductal carcinoma), endometrial carcinoma, ovarian cancer, urothelial cancer, non-small cell lung cancer (e.g., squamous cell carcinoma), head and neck squamous cell cancer (HNSCC), Hodgkin's lymphoma (e.g., classical Hodgkin lymphoma), melanoma, pancreatic cancer, thyroid cancer, kidney cancer (e.g., renal cell carcinoma), bladder cancer (e.g., urothelial carcinoma), gastric cancer, cervical cancer and microsatellite instability-high cancer. In a certain embodiment, provided herein are methods of treating advanced breast cancer (including triple-negative breast cancer, hormone receptor (HR)-positive), ovarian cancer, endometrial cancer, or urothelial cancer. In a certain embodiment, provided herein are methods of treating a breast cancer. In a certain embodiment, the breast cancer is triple negative breast cancer. In a certain embodiment, provided herein are methods of treating a hormone-receptor (HR)-positive breast cancer. In a certain embodiment, provided herein are methods of treating an ovarian cancer. In a certain embodiment, provided herein are methods of treating an endometrial cancer. In a certain embodiment, provided herein are methods of treating a urothelial cancer. In a certain embodiment, provided herein are methods of treating a gastro-intestinal cancer. In a certain embodiment, provided herein are methods of treating a gynecologic cancer. In a certain embodiment, provided herein are methods of treating a head and neck cancer. In a certain embodiment, provided herein are methods of treating a genitourinary cancer. In a certain embodiment, provided herein, the subject has not received prior therapy with a PD-1/PD-L1 antagonist. In certain embodiments, such methods comprise administering an anti-B7-H4 antibody or antigen-binding fragment thereof provided herein, or a pharmaceutical composition comprising anti-B7-H4 antibodies or antigen-binding fragments thereof provided herein, in combination with a PD-1/PD-L1 inhibitor or a pharmaceutical composition thereof provided herein, to a patient (e.g., a human patient) in need thereof.

[0086] In some embodiments, the cancer is a B7-H4 expressing cancer. In certain embodiments, the cancer is a solid tumor solid tumor that expresses B7-H4. In certain embodiments, B7-H4 has been detected (e.g., using immunohistochemistry (IHC)) in a biological sample obtained from the subject.

[0087] A biological sample may be any biological sample obtained from a subject, cell line, tissue, or other source of cells potentially expressing B7-H4. Methods for obtaining tissue biopsies and body fluids from humans are well known in the art. Biological samples include peripheral mononuclear blood cells. A biological sample may also be a blood sample, in which circulating tumor cells (or “CTCs”) may express B7-H4 and be detected.

[0088] Assaying for the expression level of B7-H4 protein is intended to include qualitatively or quantitatively measuring or estimating the level of a B7-H4 protein in a first biological sample either directly (e.g., by determining or estimating absolute protein level) or relatively (e.g., by comparing to the protein level in a second biological sample). B7-H4 polypeptide expression level in the first biological sample can be measured or estimated and compared to a standard B7-H4 protein level, the standard being determined from a second biological sample that is not diseased or being determined by averaging levels from a population of samples that are not diseased. As will be appreciated in the art, once the “standard” B7-H4 polypeptide level is known, it can be used repeatedly as a standard for comparison.

[0089] In another embodiment, an anti-B7-H4 antibody or antigen-binding fragment thereof, or pharmaceutical composition, as described herein is administered to a patient (e.g., a human patient) diagnosed with cancer to increase the proliferation of T cells, CD4+ T cells, or CD8+T cells in the patient. In such embodiment, a PD-1/PD-L1 antagonist as described herein, e.g., pembrolizumab, is also administered to the patient to block binding of PD-1 to PD-L1 and PD-L2 and to activate T cells. In another embodiment, an anti-B7-H4 antibody or antigen-binding fragment thereof, or pharmaceutical composition, is administered to a patient (e.g., a human patient) diagnosed with cancer to increase interferon-gamma (IFNγ) production in the patient. In such embodiment, a PD-1/PD-L1 antagonist as described herein, e.g., pembrolizumab, is also administered to the patient to block binding of PD-1 to PD-L1 and PD-L2 and to activate T cells. In another embodiment, an anti-B7-H4 antibody or antigen-binding fragment thereof, or pharmaceutical composition, is administered to a patient (e.g., a human patient) diagnosed with cancer to block the inhibitory activity of B7-H4 against T cells in the patient. In such embodiment, a PD-1/PD-L1 antagonist as described herein, e.g., pembrolizumab, is also administered to the patient to block binding of PD-1 to PD-L1 and PD-L2 and to activate T cells. In another embodiment, an anti-B7-H4 antibody or antigen-binding fragment thereof, or pharmaceutical composition, is administered to a patient (e.g., a human patient) diagnosed with cancer to deplete B7-H4 expressing cancer cells in the patient. In such embodiment, a PD-1/PD-L1 antagonist as described herein, e.g., pembrolizumab, is also administered to the patient to block binding of PD-1 to PD-L1 and PD-L2 and to activate T cells.

[0090] In some embodiments, the present invention relates to an anti-B7-H4 antibody or antigen-binding fragment thereof or pharmaceutical composition provided herein for use in combination with a PD-1/PD-L1 antagonist, such as pembrolizumab or pharmaceutical composition thereof, as a medicament, wherein the medicament is for administration at about 0.1 mg/kg to about 20 mg/kg (e.g., about 0.1 mg/kg, about 0.3 mg/kg, about 1 mg/kg, about 3 mg/kg, about 10 mg/kg, or about 20 mg/kg) of the antibody or antigen-binding fragment thereof, and about 200 mg of the pembrolizumab. In such embodiments, the antibody or antigen-binding fragment thereof and the pembrolizumab may be co-formulated or separately formulated for administration concurrently or sequentially. In some aspects, the present invention relates to an anti-B7-H4 antibody or antigen-binding fragment thereof or pharmaceutical composition provided herein, for use in combination with a PD-1/PD-L1 antagonist, such as pembrolizumab or pharmaceutical composition thereof, in a method for the treatment of cancer wherein about 0.1 mg/kg to about 20 mg/kg (e.g., about 0.1 mg/kg, about 0.3 mg/kg, about 1 mg/kg, about 3 mg/kg, about 10 mg/kg, or about 20 mg/kg) of the antibody or antigen-binding fragment thereof is administered, and about 200 mg of the pembrolizumab is administered, and wherein the administrations are sequential or concurrent. In some aspects, the present invention relates to an ant-B7-H4 antibody or antigen-binding fragment thereof or pharmaceutical composition provided herein, for use in combination with a PD-1/PD-L1 antagonist, such as pembrolizumab, in a method for the treatment of cancer in a subject, comprising administering to the subject about 0.1 mg/kg to about 20 mg/kg (e.g., about 0.1 mg/kg, about 0.3 mg/kg, about 1 mg/kg, about 3 mg/kg, about 10 mg/kg, or about 20 mg/kg) of an antibody or antigen-binding fragment thereof or pharmaceutical composition provided herein, and administering about 200 mg pembrolizumab or a pharmaceutical composition provided herein, wherein the administrations are sequential or concurrent.

[0091] In some embodiments, the present invention relates to an anti-B7-H4 antibody or antigen-binding fragment thereof or pharmaceutical composition provided herein for use in combination with a PD-1/PD-L1 antagonist, such as pembrolizumab or pharmaceutical composition thereof, as a medicament, wherein the medicament is for administration at 0.1 mg/kg to 20 mg/kg (e.g., 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, or 20 mg/kg) of the antibody or antigen-binding fragment thereof, and 200 mg of the pembrolizumab. In such embodiments, the antibody or antigen-binding fragment thereof and the pembrolizumab may be co-formulated or separately formulated for administration concurrently or sequentially. In some aspects, the present invention relates to an anti-B7-H4 antibody or antigen-binding fragment thereof or pharmaceutical composition provided herein, for use in combination with a PD-1/PD-L1 antagonist, such as pembrolizumab or pharmaceutical composition thereof, in a method for the treatment of cancer wherein 0.1 mg/kg to 20 mg/kg (e.g., 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, or 20 mg/kg) of the antibody or antigen-binding fragment thereof is administered, and 200 mg of the pembrolizumab is administered, and wherein the administrations are sequential or concurrent. In some aspects, the present invention relates to an ant-B7-H4 antibody or antigen-binding fragment thereof or pharmaceutical composition provided herein, for use in combination with a PD-1/PD-L1 antagonist, such as pembrolizumab, in a method for the treatment of cancer in a subject, comprising administering to the subject 0.1 mg/kg to 20 mg/kg (e.g., 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, or 20 mg/kg) of an antibody or antigen-binding fragment thereof or pharmaceutical composition provided herein, and administering 200 mg pembrolizumab or a pharmaceutical composition provided herein, wherein the administrations are sequential or concurrent.

[0092] In certain aspects, the amino acid of human PD-1 is:

[0093]

(SEQ ID NO: 40)

MQIPQAPWPVVWAVLQLGWRPGWFLDSPDRPWNPPTFSPALLVVTEGDNAT

FTCSFSNTSESFVLNWYRMSPSNQTDKLAAFPEDRSQPGQDCRFRVTQLPN

GRDFHMSVVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPT

AHPSPSPRPAGQFQTLVVGVVGGLLGSLVLLVWVLAVICSRAARGTIGARR

TGQPLKEDPSAVPVFSVDYGELDFQWREKTPEPPVPCVPEQTEYATIVFPS

GMGTSSPARRGSADGPRSAQPLRPEDGHCSWPL.

[0094] In certain aspects, the amino acid sequence of human PD-L1 is:

[0095]

(SEQ ID NO: 41)

MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLA

ALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQIT

DVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHEL

TCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTN

EIFYCTFRRLDPEENHTAELVIPELPLAHPPNERTHLVILGAILLCLGVAL

TFIFRLRKGRMMDVKKCGIQDTNSKKQSDTHLEET.

4.3 B7-H4 Antibodies and Antigen-Binding Fragments Thereof

[0096] Provided herein are methods of treating cancer in a human subject comprising administering to the subject antibodies (e.g., monoclonal antibodies, such as chimeric, humanized, or human antibodies) and antigen-binding fragments thereof which specifically bind to B7-H4 (e.g., human B7-H4), in combination with a PD-1/PD-L1 antagonist, such as pembrolizumab. Exemplary B7-H4 antibodies and antigen-binding fragments thereof that can be used in the methods provided herein are known in the art. The amino acid sequences for human, cynomolgus monkey, murine, and rat B7-H4 are known in the art and also provided herein as represented by SEQ ID NOs: 1-4, respectively.

[0097]

Human B7-H4:

(SEQ ID NO: 1)

MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGED

GILSCTFEPDIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTA

VFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTGAFSMP

EVNVDYNASSETLRCEAPRWFPQPTVVWASQVDQGANFSEVSNTSFELNSE

NVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKVTESEIKRRSHLQLLN

SKASLCVSSFFAISWALLPLSPYLMLK

Cynomolgus monkey B7-H4:

(SEQ ID NO: 2)

MASLGQILFWSIISIIFILAGAIALIIGFGISGRHSITVTTVASAGNIGED

GILSCTFEPDIKLSDIVIQWLKEGVIGLVHEFKEGKDELSEQDEMFRGRTA

VFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTGAFSMP

EVNVDYNASSETLRCEAPRWFPQPTVVWASQVDQGANFSEVSNTSFELNSE

NVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKVTESEIKRRSHLQLLN

SKASLCVSSFLAISWALLPLAPYLMLK

Murine B7-H4

(SEQ ID NO: 3)

MASLGQIIFWSIINIIIILAGAIALIIGFGISGKHFITVTTFTSAGNIGED

GTLSCTFEPDIKLNGIVIQWLKEGIKGLVHEFKEGKDDLSQQHEMFRGRTA

VFADQVVVGNASLRLKNVQLTDAGTYTCYIRTSKGKGNANLEYKTGAFSMP

EINVDYNASSESLRCEAPRWFPQPTVAWASQVDQGANFSEVSNTSFELNSE

NVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKVTDSEVKRRSQLQLLN

SGPSPCVFSSAFVAGWALLSLSCCLMLR

Rat B7-H4

(SEQ ID NO: 4)

MASLGQIIFWSIINVIIILAGAIVLIIGFGISGKHFITVTTFTSAGNIGED

GTLSCTFEPDIKLNGIVIQWLKEGIKGLVHEFKEGKDDLSQQHEMFRGRTA

VFADQVVVGNASLRLKNVQLTDAGTYTCYIHTSKGKGNANLEYKTGAFSMP

EINVDYNASSESLRCEAPRWFPQPTVAWASQVDQGANFSEVSNTSFELNSE

NVTMKVVSVLYNVTINNTYSCMIENDIAKATGDIKVTDSEVKRRSQLELLN

SGPSPCVSSVSAAGWALLSLSCCLMLR

[0098] In certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein specifically binds to human B7-H4. In certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein specifically binds to human and cynomolgus monkey B7-H4. In certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein specifically binds to human, murine, and rat B7-H4. In certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein specifically binds to human, cynomolgus monkey, murine, and rat B7-H4.

[0099] B7-H4 contains an IgC ectodomain (amino acids 153-241 of SEQ ID NO:1) and an IgV ectodomain (amino acids 35-146 of SEQ ID NO:1). In certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein specifically binds to the IgV domain of human B7-H4. Accordingly, provided herein are methods of administering antibodies and antigen-binding fragments thereof that specifically bind to a polypeptide consisting of amino acids 35-146 of SEQ ID NO:1.

[0100] In certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein specifically binds to human B7-H4 and comprises the six CDRs of the 20502 antibody listed as provided in Tables 3 and 4. “20502” refers to the 20502 antibody, described herein.

[0101]

TABLE 3

VH CDR Amino Acid Sequences ¹
Anti-	VH CDR1	VH CDR2	VH CDR3
body	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)

20502	GSIKSGSYYWG	NIYYSGSTYYNP	AREGSYPNQFDP

	(SEQ ID NO: 5)	SLRS (SEQ	(SEQ ID NO: 7)

		ID NO: 6)

¹The VH CDRs in Table 1 are determined according to Kabat.

[0102]

TABLE 4

VL CDR Amino Acid Sequences ²
Anti-	VL CDR1	VL CDR2	VL CDR3
body	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)

20502	RASQSVSSNLA	GASTRAT	QQYHSFPFT

	(SEQ ID NO: 8)	(SEQ ID NO: 9)	(SEQ ID NO: 10)

²The VL CDRs in Table 2 are determined according to Kabat.

[0103] In certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein specifically binds to human B7-H4 and comprises the VH of the 20502 antibody listed in Table 5.

[0104]

TABLE 5

Variable Heavy Chain (VH) Amino Acid Sequences
Anti-
body	VH Amino Acid Sequence (SEQ ID NO)

20502	QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPP

	GKGLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSS

	VTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSS (SEQ ID

	NO: 11)

[0105] In certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein specifically binds to human B7-H4 and comprises the VL of the 20502 antibody listed in Table 6.

[0106]

TABLE 6

Variable Light Chain (VL) Amino Acid Sequences
Anti-
body	VL Amino Acid Sequence (SEQ ID NO)

20502	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQA

	PRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVY

	YCQQYHSFPFTFGGGTKVEIK (SEQ ID NO: 12)

[0107] In certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein specifically binds to human B7-H4 and comprises the VH and the VL of the 20502 antibody listed in Tables 5 and 6.

[0108] In certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein specifically binds to human B7-H4 and comprises the VH framework regions of the 20502 antibody listed in Table 7.

[0109]

TABLE 7

VH FR Amino Acid Sequences ³
Anti-	VH FR1	VH FR2	VH FR3	VH FR4
body	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)

20502	QLQLQESGPGLVK	WIRQPPGKGLE	RVTISVDTSKNQFSL	WGQGTLVT

	PSETLSLTCTVSG	WIG (SEQ ID	KLSSVTAADTAVYY	VSS (SEQ ID

	(SEQ ID NO: 13)	NO: 14)	C (SEQ ID NO: 15)	NO: 16)

³The VH framework regions described in Table 5 are determined based upon the boundaries of the Kabat numbering system for CDRs. Accordingly, the VH CDRs are determined by Kabat and the framework regions are the amino acid residues surrounding the CDRs in the variable region in the format FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0110] In certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein specifically binds to human B7-H4 and comprises the VL framework regions of the 20502 antibody listed in Table 8.

[0111]

TABLE 8

VL FR Amino Acid Sequences ⁴
Anti-	VL FR1	VL FR2	VL FR3	VL FR4
body	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)	(SEQ ID NO:)

20502	EIVMTQSPATLSVS	WYQQKPGQAP	GIPARFSGSGSGT	FGGGTKVEI

	PGERATLSC (SEQ	RLLIY (SEQ ID	EFTLTISSLQSEDF	K (SEQ ID

	ID NO: 17)	NO: 18)	AVYYC (SEQ ID	NO: 20)

			NO: 19)

⁴The VL framework regions described in Table 6 are determined based upon the boundaries of the Kabat numbering system for CDRs. Accordingly, the VL CDRs are determined by Kabat and the framework regions are the amino acid residues surrounding the CDRs in the variable region in the format FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4.

[0112] In certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein specifically binds to human B7-H4 and comprises the four VH framework regions and the four VL framework regions of the 20502 antibody listed in Tables 7 and 8.

[0113] In certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein specifically binds to human B7-H4 and comprises the heavy chain sequence of the 20502 antibody listed in Table 9.

[0114]

TABLE 9

Full-length heavy chain amino acid sequences
Anti-	Full-Length Heavy Chain Amino Acid Sequence
body	(SEQ ID NO)

20502	QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGK

	GLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSSVTAA

	DTAVYYCAREGSYPNQFDPWGQGTLVTVSSASTKGPSVFPLAPSS

	KSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS

	GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDK

	THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVS

	HEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD

	WLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDE

	LTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDG

	SFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

	(SEQ ID NO: 21)

[0115] In certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein specifically binds to human B7-H4 and comprises the light chain sequence of the 20502 antibody listed in Table 10.

[0116]

TABLE 10

Full-length light chain amino acid sequences
Anti-	Full-Length Light Chain Amino Acid Sequence
body	(SEQ ID NO)

20502	EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPR

	LLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQ

	YHSFPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCL

	LNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT

	LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID

	NO: 22)

[0117] In certain embodiments, an antibody or antigen-binding fragment for use in the methods described herein specifically binds to human B7-H4 and comprises the heavy chain sequence and the light chain sequence of the 20502 antibody listed in Tables 9 and 10.

[0118] In certain aspects, an antibody or antigen-binding fragment thereof for use in the methods described herein is described by its VL domain alone, or its VH domain alone, or by its 3 VL CDRs alone, or its 3 VH CDRs alone. See, for example, Rader C et al., (1998) PNAS 95: 8910-8915, which is incorporated herein by reference in its entirety, describing the humanization of the mouse anti-avβ3 antibody by identifying a complementing light chain or heavy chain, respectively, from a human light chain or heavy chain library, resulting in humanized antibody variants having affinities as high or higher than the affinity of the original antibody. See also Clackson T et al., (1991) Nature 352:624-628, which is incorporated herein by reference in its entirety, describing methods of producing antibodies that specifically bind a specific antigen by using a specific VL domain (or VH domain) and screening a library for the complementary VH domain or (VL domain). The screen produced 14 new partners for a specific VH domain and 13 new partners for a specific VL domain, which were strong binders, as determined by ELISA. See also Kim S J & Hong H J, (2007) J Microbiol 45:572-577, which is incorporated herein by reference in its entirety, describing methods of producing antibodies that specifically bind a specific antigen by using a specific VH domain and screening a library (e.g., human VL library) for complementary VL domains; the selected VL domains in turn could be used to guide selection of additional complementary (e.g., human) VH domains.

[0119] In certain aspects, the CDRs of an antibody or antigen-binding fragment thereof can be determined according to the Chothia numbering scheme, which refers to the location of immunoglobulin structural loops (see, e.g., Chothia C & Lesk A M, (1987), J Mol Biol 196:901-917; Al-Lazikani B et al., (1997) J Mol Biol 273:927-948; Chothia C et al., (1992) J Mol Biol 227:799-817; Tramontano A et al., (1990) J Mol Biol 215 (1): 175-82; and U.S. Pat. No. 7,709,226). Typically, when using the Kabat numbering convention, the Chothia CDR-H1 loop is present at heavy chain amino acids 26 to 32, 33, or 34, the Chothia CDR-H2 loop is present at heavy chain amino acids 52 to 56, and the Chothia CDR-H3 loop is present at heavy chain amino acids 95 to 102, while the Chothia CDR-L1 loop is present at light chain amino acids 24 to 34, the Chothia CDR-L2 loop is present at light chain amino acids 50 to 56, and the Chothia CDR-L3 loop is present at light chain amino acids 89 to 97. The end of the Chothia CDR-H1 loop when numbered using the Kabat numbering convention varies between H32 and H34 depending on the length of the loop (this is because the Kabat numbering scheme places the insertions at H35A and H35B; if neither 35A nor 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34).

[0120] In certain aspects, provided herein are methods of administering antibodies and antigen-binding fragments thereof that specifically bind to B7-H4 (e.g., human B7-H4) and comprise the Chothia VH and VL CDRs of the 20502 antibody listed in Tables 5 and 6. In certain embodiments, provided herein are methods of administering antibodies or antigen-binding fragments thereof that specifically bind to B7-H4 (e.g., human B7-H4) and comprise one or more CDRs, in which the Chothia and Kabat CDRs have the same amino acid sequence. In certain embodiments, provided herein are methods of administering antibodies and antigen-binding fragments thereof that specifically bind to B7-H4 (e.g., human B7-H4) and comprise combinations of Kabat CDRs and Chothia CDRs.

[0121] In certain aspects, the CDRs of an antibody or antigen-binding fragment thereof can be determined according to the IMGT numbering system as described in Lefranc M-P, (1999) The Immunologist 7:132-136 and Lefranc M-P et al., (1999) Nucleic Acids Res 27:209-212. According to the IMGT numbering scheme, VH-CDR1 is at positions 26 to 35, VH-CDR2 is at positions 51 to 57, VH-CDR3 is at positions 93 to 102, VL-CDR1 is at positions 27 to 32, VL-CDR2 is at positions 50 to 52, and VL-CDR3 is at positions 89 to 97. In a particular embodiment, provided herein are methods of administering antibodies and antigen-binding fragments thereof that specifically bind to B7-H4 (e.g., human B7-H4) and comprise the IMGT VH and VL CDRs of the 20502 antibody listed in Tables 5 and 6, for example, as described in Lefranc M-P (1999) supra and Lefranc M-P et al., (1999) supra).

[0122] In certain aspects, the CDRs of an antibody or antigen-binding fragment thereof can be determined according to MacCallum R M et al., (1996) J Mol Biol 262:732-745. See also, e.g., Martin A. “Protein Sequence and Structure Analysis of Antibody Variable Domains,” in Antibody Engineering, Kontermann and Dübel, eds., Chapter 31, pp. 422-439, Springer-Verlag, Berlin (2001). In a particular embodiment, provided herein are methods of administering antibodies or antigen-binding fragments thereof that specifically bind to B7-H4 (e.g., human B7-H4) and comprise VH and VL CDRs of the 20502 antibody listed in Tables 5 and 6 as determined by the method in MacCallum R M et al.

[0123] In certain aspects, the CDRs of an antibody or antigen-binding fragment thereof can be determined according to the AbM numbering scheme, which refers AbM hypervariable regions which represent a compromise between the Kabat CDRs and Chothia structural loops, and are used by Oxford Molecular's AbM antibody modeling software (Oxford Molecular Group, Inc.). In a particular embodiment, provided herein are methods of administering antibodies or antigen-binding fragments thereof that specifically bind to B7-H4 (e.g., human B7-H4) and comprise VH and VL CDRs of the 20502 antibody listed in Tables 5 and 6 as determined by the AbM numbering scheme.

[0124] In specific aspects, provided herein are methods of administering antibodies that comprise a heavy chain and a light chain.

[0125] With respect to the light chain, in a specific embodiment, the light chain of an antibody described herein is a kappa light chain. The constant region of a human kappa light chain can comprise the following amino acid sequence:

[0126]

(SEQ ID NO: 23)

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQS

GNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPV

TKSFNRGEC.

[0127] The constant region of a human kappa light chain can be encoded by the following nucleotide sequence:

[0128]

(SEQ ID NO: 24)

CGGACCGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAG

TTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCC

AGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAAC

TCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTC

AGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTAC

GCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTC

AACAGGGGAGAGTGT.

[0129] In a particular embodiment, an antibody which immunospecifically binds to a B7-H4 polypeptide (e.g., human B7-H4) for use in the methods described herein comprises a light chain wherein the amino acid sequence of the VL domain comprises the sequence set forth in Table 6, and wherein the constant region of the light chain comprises the amino acid sequence of a human kappa light chain constant region.

[0130] In a particular embodiment, an antibody which immunospecifically binds to B7-H4 (e.g., human B7-H4) for use in the methods described herein comprises a heavy chain wherein the amino acid sequence of the VH domain comprises the amino acid sequence set forth in Table 5 and wherein the constant region of the heavy chain comprises the amino acid sequence of a human gamma (γ) heavy chain constant region.

[0131] The constant region of a human IgG1 heavy chain can comprise the following amino acid sequence:

[0132]

(SEQ ID NO: 25)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH

TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKS

CDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHED

PEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKC

KVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF

YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVF

SCSVMHEALHNHYTQKSLSLSPGK.

[0133] The constant region of a human IgG₁heavy chain can be encoded by the following nucleotide sequence:

[0134]

(SEQ ID NO: 26)

GCCTCCACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGC

ACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCC

GAACCGGTGACGGTGTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCAC

ACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTG

GTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTG

AATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCT

TGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGG

GGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATC

TCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGAC

CCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCC

AAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGGGTGGTCAGC

GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGC

AAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAA

GCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGG

GATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTC

TATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAAC

AACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTC

TACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTC

TCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGC

CTCTCCCTGTCTCCGGGTAAA.

[0135] In a specific embodiment, an antibody which immunospecifically binds to B7-H4 (e.g., human B7-H4) for use in the methods described herein comprises a VH domain and a VL domain comprising an amino acid sequence of any VH and VL domain described herein, and wherein the constant regions comprise the amino acid sequences of the constant regions of an IgG (e.g., a human IgG) immunoglobulin molecule. In another specific embodiment, an antibody which immunospecifically binds to B7-H4 (e.g., human B7-H4) for use in the methods described herein comprises a VH domain and a VL domain comprising an amino acid sequence of any VH and VL domain described herein, and wherein the constant regions comprise the amino acid sequences of the constant regions of an IgG₁(e.g. human IgG₁) immunoglobulin molecule.

[0136] Antibodies with reduced fucose content have been reported to have an increased affinity for Fc receptors, such as, e.g., FcγRIIIA. Accordingly, in certain embodiments, an antibody or antigen-binding fragment thereof for use in the methods described herein has reduced fucose content or lacks fucose (i.e., is “afucosylated”). Such antibodies or antigen-binding fragments thereof can be produced using techniques known to one skilled in the art. For example, they can be expressed in cells deficient or lacking the ability to fucosylate. In a specific example, cell lines with a knockout of both alleles of the α1,6-fucosyltransferase gene (FUT8) can be used to produce antibodies or antigen-binding fragments thereof with reduced fucose content. The Potelligent® system (Lonza) is an example of such a system that can be used to produce antibodies and antigen-binding fragments thereof with reduced fucose content. Alternatively, antibodies or antigen-binding fragments thereof with reduced fucose content or no fucose content can be produced by, e.g.: (i) culturing cells under conditions which prevent or reduce fucosylation; (ii) posttranslational removal of fucose (e.g., with a fucosidase enzyme); (iii) post-translational addition of the desired carbohydrate, e.g., after recombinant expression of a non-glycosylated glycoprotein; or (iv) purification of the glycoprotein so as to select for antibodies or antigen-binding fragments thereof which are not fucsoylated. See, e.g., Longmore GD & Schachter H (1982) Carbohydr Res 100:365-92 and Imai-Nishiya H et al., (2007) BMC Biotechnol. 7:84 for methods for producing antibodies thereof with no fucose content or reduced fucose content.

[0137] In some embodiments, an afucosylated B7-H4 antibody or antigen-binding fragment thereof has enhanced ADCC activity in vitro compared to fucosylated B7-H4 antibodies or antigen-binding fragments thereof having the same amino acid sequence. In some embodiments, the afucosylated B7-H4 antibodies or antigen-binding fragments thereof cause specific lysis that is at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 65, at least 70, or at least 75 percentage points greater than specific lysis with fucosylated B7-H4 antibodies. Specific lysis may be determined as described in Example 2 herein.

[0138] In some embodiments, the B7-H4 antibody or antigen-binding fragment thereof has enhanced affinity for Fc gamma RIIIA compared to fucosylated B7-H4 antibodies or antigen-binding fragments thereof having the same amino acid sequence. In some embodiments, the afucosylated B7-H4 antibodies or antigen-binding fragments thereof bind to Fc gamma RIIIA with at least 2-fold, at least 3-fold, at least 4-fold, at least 5-fold, at least 7-fold, at least 10-fold, at least 12-fold, at least 15-fold, at least 17-fold, or at least 20-fold greater affinity than fucosylated B7-H4 antibodies or antigen-binding fragments thereof. In some embodiments, affinity for Fc gamma RIIIA is determined using surface plasmon resonance. In some embodiments, Fc gamma RIIIA is selected from Fc gamma RIIIA(V158) and Fc gamma RIIIA(F158). In some embodiments, Fc gamma RIIIA is Fc gamma RIIIA(V158).

[0139] In some embodiments, the presence of fucose can be determined by a method comprising high performance liquid chromatography (HPLC), capillary electrophoresis, or MALDI-TOF mass spectrometry.

[0140] In specific embodiments, an antibody or antigen-binding fragment thereof (i) comprises the CDR sequences of 20502, the VH and VL sequences of 20502, or the heavy and light chain sequences of 20502 and (ii) is afucosylated.

[0141] In specific embodiments, a composition comprises antibodies or antigen-binding fragments thereof that (i) comprises the CDR sequences of 20502, the VH and VL sequences of 20502, or the heavy and light chain sequences of 20502 and (ii) are afucosylated, e.g., wherein at least 95% of the antibodies in the composition are afucosylated or wherein fucosylation is undetectable in the composition.

[0142] Engineered glycoforms may be useful for a variety of purposes, including but not limited to enhancing or reducing effector function. Methods for generating engineered glycoforms in an antibody or antigen-binding fragment thereof described herein include but are not limited to those disclosed, e.g., in Umaña P et al., (1999) Nat Biotechnol 17:176-180; Davies J et al., (2001) Biotechnol Bioeng 74:288-294; Shields R L et al., (2002) J Biol Chem 277:26733-26740; Shinkawa T et al., (2003) J Biol Chem 278:3466-3473; Niwa R et al., (2004) Clin Cancer Res 1:6248-6255; Presta L G et al., (2002) Biochem Soc Trans 30:487-490; Kanda Y et al., (2007) Glycobiology 17:104-118; U.S. Pat. Nos. 6,602,684; 6,946,292; and 7,214,775; U.S. Patent Publication Nos. US 2007/0248600; 2007/0178551; 2008/0060092; and 2006/0253928; International Publication Nos. WO 00/61739; WO 01/292246; WO 02/311140; and WO 02/30954; Potillegent™ technology (Biowa, Inc. Princeton, N.J.); and GlycoMAb® glycosylation engineering technology (Glycart biotechnology AG, Zurich, Switzerland). See also, e.g., Ferrara C et al., (2006) Biotechnol Bioeng 93:851-861; International Publication Nos. WO 07/039818; WO 12/130831; WO 99/054342; WO 03/011878; and WO 04/065540.

[0143] In certain embodiments, any of the constant region mutations or modifications described herein can be introduced into one or both heavy chain constant regions of an antibody or antigen-binding fragment thereof described herein having two heavy chain constant regions.

[0144] In another particular embodiment, an antibody or antigen-binding fragment thereof described herein, which immunospecifically binds to B7-H4 (e.g., human B7-H4), comprises a heavy chain and a light chain, wherein (i) the heavy chain comprises a VH domain comprising the VH CDR1, VL CDR2, and VL CDR3 amino acid sequences of the 20502 antibody listed in Table 3 (SEQ ID NOs: 5, 6, and 7, respectively); (ii) the light chain comprises a VL domain comprising the VL CDR1, VH CDR2, and VH CDR3 amino acid sequences of the 20502 antibody listed in Table 4 (SEQ ID NOs: 8, 9, and 10, respectively); (iii) the heavy chain further comprises a constant heavy chain domain comprising the amino acid sequence of the constant domain of a human IgG₁heavy chain; and (iv) the light chain further comprises a constant light chain domain comprising the amino acid sequence of the constant domain of a human kappa light chain.

[0145] In another particular embodiment, an antibody or antigen-binding fragment thereof described herein, which immunospecifically binds to B7-H4 (e.g., human B7-H4), comprises a heavy chain and a light chain, wherein (i) the heavy chain comprises a VH domain comprising the amino acid sequence of the VH domain of the 20502 antibody listed in Table 5 (SEQ ID NO:11); (ii) the light chain comprises a VL domain comprising the amino acid sequence of the VL domain of the 20502 antibody listed in Table 6 (SEQ ID NO: 12); (iii) the heavy chain further comprises a constant heavy chain domain comprising the amino acid sequence of the constant domain of a human IgG₁heavy chain; and (iv) the light chain further comprises a constant light chain domain comprising the amino acid sequence of the constant domain of a human kappa light chain.

[0146] In specific embodiments, an antibody or antigen-binding fragment thereof described herein, which immunospecifically binds to B7-H4 (e.g., human B7-H4) exhibits T cell checkpoint blockade activity. In specific embodiments, an antibody or antigen-binding fragment thereof described herein, which immunospecifically binds to B7-H4 (e.g., human B7-H4) increases interferon-gamma (IFNγ) production in T cells. In specific embodiments, an antibody or antigen-binding fragment thereof described herein, which immunospecifically binds to B7-H4 (e.g., human B7-H4) increases T cell proliferation. In specific embodiments, an antibody or antigen-binding fragment thereof described herein, which immunospecifically binds to B7-H4 (e.g., human B7-H4) increases CD4+ T cell proliferation. In specific embodiments, an antibody or antigen-binding fragment thereof described herein, which immunospecifically binds to B7-H4 (e.g., human B7-H4) increases CD8+ T cell proliferation.

[0147] In specific embodiments, an antibody or antigen-binding fragment thereof described herein, which immunospecifically binds to B7-H4 (e.g., human B7-H4) exhibits antibody-dependent cellular cytotoxicity (ADCC) activity. In specific embodiments, an antibody or antigen-binding fragment thereof described herein, which immunospecifically binds to B7-H4 (e.g., human B7-H4) exhibits antibody-dependent cellular cytotoxicity (ADCC) activity on cell lines with at least 300,000 cell surface B7-H4 molecules (e.g., SK-BR-3 cells). In specific embodiments, an antibody or antigen-binding fragment thereof described herein, which immunospecifically binds to B7-H4 (e.g., human B7-H4) exhibits antibody-dependent cellular cytotoxicity (ADCC) activity on cell lines with at least 100,000 cell surface B7-H4 molecules (e.g., HCC1569 cells). In specific embodiments, an antibody or antigen-binding fragment thereof described herein, which immunospecifically binds to B7-H4 (e.g., human B7-H4) exhibits antibody-dependent cellular cytotoxicity (ADCC) activity on cell lines with at least 50,000 cell surface B7-H4 molecules (e.g., ZR-75-1 cells). In specific embodiments, an antibody or antigen-binding fragment thereof described herein, which immunospecifically binds to B7-H4 (e.g., human B7-H4) exhibits antibody-dependent cellular cytotoxicity (ADCC) activity on cell lines with at least 30,000 cell surface B7-H4 molecules (e.g., MDA-MB-468 cells). In specific embodiments, an antibody or antigen-binding fragment thereof described herein, which immunospecifically binds to B7-H4 (e.g., human B7-H4) exhibits antibody-dependent cellular cytotoxicity (ADCC) activity on cell lines with at least 15,000 cell surface B7-H4 molecules (e.g., HCC1964 cells).

[0148] In a specific aspect, an antigen-binding fragment as described herein, which immunospecifically binds to B7-H4 (e.g., human B7-H4), is selected from the group consisting of a Fab, Fab′, F(ab′)₂, and scFv, wherein the Fab, Fab′, F(ab′)₂, or scFv comprises a heavy chain variable region sequence and a light chain variable region sequence of an anti-B7-H4 antibody or antigen-binding fragment thereof as described herein. A Fab, Fab′, F(ab′)₂, or scFv can be produced by any technique known to those of skill in the art. In certain embodiments, the Fab, Fab′, F(ab′)₂, or scFv further comprises a moiety that extends the half-life of the antibody in vivo. The moiety is also termed a “half-life extending moiety.” Any moiety known to those of skill in the art for extending the half-life of a Fab, Fab′, F(ab′)₂, or scFv in vivo can be used. For example, the half-life extending moiety can include a Fc region, a polymer, an albumin, or an albumin binding protein or compound. The polymer can include a natural or synthetic, optionally substituted straight or branched chain polyalkylene, polyalkenylene, polyoxylalkylene, polysaccharide, polyethylene glycol, polypropylene glycol, polyvinyl alcohol, methoxypolyethylene glycol, lactose, amylose, dextran, glycogen, or derivative thereof. Substituents can include one or more hydroxy, methyl, or methoxy groups. In certain embodiments, the Fab, Fab′, F(ab′)₂, or scFv can be modified by the addition of one or more C-terminal amino acids for attachment of the half-life extending moiety. In certain embodiments the half-life extending moiety is polyethylene glycol or human serum albumin. In certain embodiments, the Fab, Fab′, F(ab′)₂, or scFv is fused to an Fc region.

4.4 Pharmaceutical Compositions

[0149] Provided herein are methods of administering compositions comprising an anti-B7-H4 antibody or antigen-binding fragment thereof having the desired degree of purity in a physiologically acceptable carrier, excipient, or stabilizer (Remington's Pharmaceutical Sciences (1990) Mack Publishing Co., Easton, PA). Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed. (See, e.g., Gennaro, Remington: The Science and Practice of Pharmacy with Facts and Comparisons: Drugfacts Plus, 20th ed. (2003); Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7th ed., Lippencott Williams and Wilkins (2004); Kibbe et al., Handbook of Pharmaceutical Excipients, 3rd ed., Pharmaceutical Press (2000)). The compositions to be used for in vivo administration can be sterile. This is readily accomplished by filtration through, e.g., sterile filtration membranes.

[0150] In some embodiments, methods of administering a pharmaceutical composition are provided, wherein the pharmaceutical composition comprises afucosylated anti-B7-H4 antibodies or antigen-binding fragments thereof and a pharmaceutically acceptable carrier. In specific embodiments, methods of administering a pharmaceutical composition are provided, wherein the pharmaceutical composition comprises afucosylated anti-B7-H4 antibodies or antigen-binding fragments e.g., wherein at least 80% of the antibodies in the composition are afucosylated. In specific embodiments, methods of administering a pharmaceutical composition are provided, wherein the pharmaceutical composition comprises afucosylated anti-B7-H4 antibodies or antigen-binding fragments e.g., wherein at least 85% of the antibodies in the composition are afucosylated. In specific embodiments, methods of administering a pharmaceutical composition are provided, wherein the pharmaceutical composition comprises afucosylated anti-B7-H4 antibodies or antigen-binding fragments e.g., wherein at least 90% of the antibodies in the composition are afucosylated. In specific embodiments, methods of administering a pharmaceutical composition are provided, wherein the pharmaceutical composition comprises afucosylated anti-B7-H4 antibodies or antigen-binding fragments e.g., wherein at least 95% of the antibodies in the composition are afucosylated. In specific embodiments, methods of administering a pharmaceutical composition are provided, wherein the pharmaceutical composition comprises afucosylated anti-B7-H4 antibodies or antigen-binding fragments e.g., wherein at least 96% of the antibodies in the composition are afucosylated. In specific embodiments, methods of administering a pharmaceutical composition are provided, wherein the pharmaceutical composition comprises afucosylated anti-B7-H4 antibodies or antigen-binding fragments e.g., wherein at least 97% of the antibodies in the composition are afucosylated. In specific embodiments, methods of administering a pharmaceutical composition are provided, wherein the pharmaceutical composition comprises afucosylated anti-B7-H4 antibodies or antigen-binding fragments e.g., wherein at least 98% of the antibodies in the composition are afucosylated. In specific embodiments, methods of administering a pharmaceutical composition are provided, wherein the pharmaceutical composition comprises afucosylated anti-B7-H4 antibodies or antigen-binding fragments e.g., wherein at least 99% of the antibodies in the composition are afucosylated. In specific embodiments, methods of administering a pharmaceutical composition are provided, wherein the pharmaceutical composition comprises afucosylated anti-B7-H4 antibodies or antigen-binding fragments wherein fucose is undetectable in the composition.

[0151] In some embodiments, methods of administering a pharmaceutical composition are provided, wherein the pharmaceutical composition comprises (i) an isolated antibody or antigen-binding fragment thereof that specifically binds to human B7-H4, comprising (a) the heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3 and light chain variable region (VL) CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 5-10, respectively, (b) a variable heavy chain region comprising the amino acid sequence of SEQ ID NO: 11 and a variable light chain region comprising the amino acid sequence of SEQ ID NO:12, or (c) a heavy chain comprising the amino acid sequence of SEQ ID NO:21 and a light chain comprising the amino acid sequence of SEQ ID NO:22, and (ii) a pharmaceutically acceptable excipient.

[0152] Also provided herein is a method of administering a pharmaceutical composition, wherein the a pharmaceutical composition comprising (i) antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 and comprise the heavy chain variable region (VH) complementarity determining region (CDR) 1, VH CDR2, VH CDR3 and light chain variable region (VL) CDR1, CDR2, and CDR3 sequences of SEQ ID NOs: 5-10, respectively and (ii) a pharmaceutically acceptable excipient, wherein at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% of the antibodies or antigen-binding fragments thereof in the composition are afucosylated. In one embodiment, (i) the antibody or antigen-binding fragment thereof comprises a variable heavy chain region comprising the amino acid sequence of SEQ ID NO:11 and a variable light chain region comprising the amino acid sequence of SEQ ID NO:12 or (ii) the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:21 and a light chain comprising the amino acid sequence of SEQ ID NO: 22.

[0153] Also provided herein is a method of administering a further pharmaceutical composition, in addition to a pharmaceutical composition comprising an anti-B7-H4 antibody or antigen-binding fragment thereof. In such embodiments, the further pharmaceutical composition comprises an PD-1/PD-L1 antagonist, such as pembrolizumab. In such embodiments, the further pharmaceutical composition comprising pembrolizumab is provided as 50 mg lyophilized powder in a single dose vial for reconstitution, or as 100 mg/4 ml (25 mg/ml) solution in a single dose vial. In such embodiments, an amount of the further pharmaceutical composition is provided to deliver 200 mg pembrolizumab to the patient in a given administration. The further pharmaceutical composition may be administered concurrently or sequentially with the pharmaceutical composition comprising an anti-B7-H4 antibody or antigen-binding fragment thereof. 4.5 Antibody Production and Polynucleotides

[0154] Antibodies and antigen-binding fragments thereof that immunospecifically bind to B7-H4 (e.g., human B7-H4) can be produced by any method known in the art for the synthesis of antibodies and antigen-binding fragments thereof, for example, by chemical synthesis or by recombinant expression techniques. The methods described herein employ, unless otherwise indicated, conventional techniques in molecular biology, microbiology, genetic analysis, recombinant DNA, organic chemistry, biochemistry, PCR, oligonucleotide synthesis and modification, nucleic acid hybridization, and related fields within the skill of the art. These techniques are described, for example, in the references cited herein and are fully explained in the literature. See, e.g., Sambrook J et al., (2001) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Ausubel F M et al., Current Protocols in Molecular Biology, John Wiley & Sons (1987 and annual updates); Current Protocols in Immunology, John Wiley & Sons (1987 and annual updates) Gait (ed.) (1984) Oligonucleotide Synthesis: A Practical Approach, IRL Press; Eckstein (ed.) (1991) Oligonucleotides and Analogues: A Practical Approach, IRL Press; Birren B et al., (eds.) (1999) Genome Analysis: A Laboratory Manual, Cold Spring Harbor Laboratory Press.

[0155] In certain aspects, provided herein are methods of administering an anti-B7-H4 antibody or antigen-binding fragment thereof or a pharmaceutical composition comprising such antibodies or fragments, wherein the antibodies or fragments are produced by recombinant expression of a polynucleotide comprising a nucleotide sequence in a host cell.

[0156] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises a heavy chain variable region encoded by a polynucleotide comprising the nucleotide sequence shown in Table 11 (i.e. SEQ ID NO:27). In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises a heavy chain variable region encoded by a polynucleotide comprising the nucleotide sequence shown in Table 11 (i.e. SEQ ID NO:27) and a nucleotide sequence encoding a human gamma (γ) heavy chain constant region. In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises a heavy chain variable region encoded by a polynucleotide comprising the nucleotide sequence shown in Table 11 (i.e. SEQ ID NO:27) and a heavy chain constant domain encoded by a polynucleotide comprising the nucleotide sequence of SEQ ID NO:26.

[0157]

TABLE 11

Heavy chain variable region-encoding polynucleotide
sequences
Anti-	Heavy Chain Variable Region-Encoding Poly-
body	nucleotide Sequence (SEQ ID NO)

20502	CAGCTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCG

	GAGACCCTGTCCCTCACCTGCACTGTCTCTGGTGGCTCCATCAAA

	AGTGGTAGTTACTACTGGGGCTGGATCCGCCAGCCCCCAGGGAAG

	GGGCTGGAGTGGATTGGGAACATCTATTATAGTGGGAGCACCTAC

	TACAACCCGTCCCTCAGAAGTCGAGTCACCATATCCGTAGACACG

	TCCAAGAACCAGTTCTCCCTGAAGCTGAGTTCTGTGACCGCCGCA

	GACACGGCGGTGTACTACTGCGCCAGAGAAGGATCTTACCCCAAT

	CAGTTTGATCCATGGGGACAGGGTACATTGGTCACCGTCTCCTCA

	(SEQ ID NO: 27)

[0158] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises a light chain variable region encoded by a polynucleotide comprising the nucleotide sequence shown in Table 12 (i.e., SEQ ID NO:28). In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises a light chain variable region encoded by a polynucleotide comprising the nucleotide sequence shown in Table 12 (i.e. SEQ ID NO:28) and a nucleotide sequence encoding a human lambda light chain constant region. In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises a light chain variable region encoded by a polynucleotide comprising the nucleotide sequence shown in Table 12 (i.e., SEQ ID NO:28) and a light chain constant domain encoded by a polynucleotide comprising the nucleotide sequence of SEQ ID NO:24.

[0159]

TABLE 12

Light chain variable region-encoding polynucleotide
sequences
Anti-	Light Chain Variable Region-Encoding Poly-
body	nucleotide Sequence (SEQ ID NO)

20502	GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCA

	GGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGC

	AGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGG

	CTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCC

	AGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATC

	AGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAG

	TACCACTCCTTCCCTTTCACTTTTGGCGGAGGGACCAAGGTTGAG

	ATCAAA (SEQ ID NO: 28)

[0160] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises a variable heavy chain encoded by a polynucleotide comprising the variable heavy chain-encoding nucleotide sequence shown in Table 11 (i.e. SEQ ID NO:27) and a variable light chain encoded by a polynucleotide comprising the variable light chain-encoding nucleotide sequence shown in Table 12 (i.e., SEQ ID NO:28).

[0161] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises (i) a heavy chain encoded by a polynucleotide comprising the variable heavy chain-encoding nucleotide sequence shown in Table 11 (i.e. SEQ ID NO: 27) and a nucleotide sequence encoding a human gamma (γ) heavy chain constant region and (ii) a light chain encoded by a polynucleotide comprising the variable light chain-encoding nucleotide sequence shown in Table 12 (i.e. SEQ ID NO:28) and a nucleotide sequence encoding a human lambda light chain constant region.

[0162] In certain aspects, the anti-B7-H4 antibody or antigen-binding fragment administered according to the methods provided herein comprises (i) a heavy chain encoded by a polynucleotide comprising the variable heavy chain-encoding nucleotide sequence shown in Table 11 (i.e. SEQ ID NO: 27) and the heavy chain constant domain-encoding nucleotide sequence of SEQ ID NO:26 and (ii) a light chain encoded by a polynucleotide comprising the variable light chain-encoding nucleotide sequence shown in Table 12 (i.e., SEQ ID NO:28) and the light chain constant domain-encoding nucleotide sequence of SEQ ID NO:24.

[0163] In certain aspects, the anti-B7-H4 antibodies or antigen-binding fragments administered according to the methods provided herein are encoded by polynucleotides encoding anti-B7-H4 antibodies or antigen-binding fragments thereof or a domain thereof that are optimized, e.g., by codon/RNA optimization, replacement with heterologous signal sequences, and elimination of mRNA instability elements. Methods to generate optimized nucleic acids encoding an anti-B7-H4 antibody or antigen-binding fragment thereof or a domain thereof (e.g., heavy chain, light chain, VH domain, or VL domain) for recombinant expression by introducing codon changes (e.g., a codon change that encodes the same amino acid due to the degeneracy of the genetic code) and/or eliminating inhibitory regions in the mRNA can be carried out by adapting the optimization methods described in, e.g., U.S. Pat. Nos. 5,965,726; 6,174,666; 6,291,664; 6,414,132; and 6,794,498, accordingly.

[0164] Polynucleotides can be, e.g., in the form of RNA or in the form of DNA. DNA includes cDNA, genomic DNA, and synthetic DNA. DNA can be double-stranded or single-stranded. If single stranded, DNA can be the coding strand or non-coding (anti-sense) strand. In certain embodiments, the polynucleotide is a cDNA or a DNA lacking one or more introns. In certain embodiments, a polynucleotide is a non-naturally occurring polynucleotide. In certain embodiments, a polynucleotide is recombinantly produced. In certain embodiments, the polynucleotides are isolated. In certain embodiments, the polynucleotides are substantially pure. In certain embodiments, a polynucleotide is purified from natural components.

[0165] In certain aspects, vectors (e.g., expression vectors) comprise nucleotide sequences encoding anti-B7-H4 antibodies and antigen-binding fragments thereof or a domain thereof for recombinant expression in host cells, preferably in mammalian cells. In certain aspects, cells, e.g. host cells, comprise such vectors for recombinantly expressing anti-B7-H4 antibodies or antigen-binding fragments thereof described herein (e.g., human or humanized antibodies or antigen-binding fragments thereof). Thus, a method for producing an antibody or antigen-binding fragment thereof described herein can comprise expressing such antibody or antigen-binding fragment thereof in a host cell.

[0166] An expression vector can be transferred to a cell (e.g., host cell) by conventional techniques and the resulting cells can then be cultured by conventional techniques to produce an antibody or antigen-binding fragment thereof described herein (e.g., an antibody or antigen-binding fragment thereof comprising the six CDRs, the VH, the VL, the VH and the VL, the heavy chain, the light chain, or the heavy and the light chain of 20502) or a domain thereof (e.g., the VH, the VL, the VH and the VL, the heavy chain, or the light chain of 20502).

[0167] In certain embodiments, anti-B7-H4 antibodies or antigen-binding fragment thereof (e.g., an antibody or antigen-binding fragment thereof comprising the CDRs of 20502) administered according to the methods provided herein are produced in Potelligent® CHOKISV cells.

[0168] In some embodiments, anti-B7-H4 antibodies or antigen-binding fragments thereof (e.g., an antibody or antigen-binding fragment thereof comprising the CDRs of 20502) administered according to the methods provided herein are produced in a host cell that lacks a functional alpha-1,6-fucosyltransferase gene (FUT8) gene. In some embodiments, the host cell is a CHO cell.

[0169] In specific embodiments, an antibody or antigen-binding fragment thereof administered according to the methods provided herein is isolated or purified. Generally, an isolated antibody or antigen-binding fragment thereof is one that is substantially free of other antibodies or antigen-binding fragments thereof with different antigenic specificities than the isolated antibody or antigen-binding fragment thereof. For example, in a particular embodiment, a preparation of an antibody or antigen-binding fragment thereof described herein is substantially free of cellular material and/or chemical precursors.

[0170] The following examples are offered by way of illustration and not by way of limitation.

5. EXAMPLES

[0171] The examples in this Section are offered by way of illustration, and not by way of limitation.

5.1 Example 1: Assessment of Prevalence of B7-H4 Expression in Multiple Indications

[0172] The B7-H4 mouse monoclonal antibody A57.1 (ATCC Catalog No. PTA-5180) was used to detect the presence of B7-H4 on archival samples, a mixture of whole sections, and tumor microarrays. The samples were treated with the primary antibody and detected using a polymer detection system attached to DAB (Ventana Medical Systems).

[0173] B7-H4 was readily detected in the membrane and the cytosol in tumor tissues harvested from a variety of cancer patients, including invasive ductal carcinoma, triple negative breast cancer, ovarian cancer, non-small cell lung cancer and endometrial cancer. Moreover, frequency of expression was also high in the indications listed in Table 13.

[0174]

TABLE 13

B7-H4 detection in tumors
			Percent
Tumor Type	#Total	#Positive	Positive

Triple Negative Breast Cancer	74	58	78%
Invasive Ductal Carcinoma	51	38	74.50%
Endometrial Carcinoma	77	54	70%
Ovarian Cancer	141	85	60%
Non-Small Cell Lung Cancer	47	19	40%
(Squamous)

[0175] B7-H4 is expressed in other cancers, such as breast cancer, kidney cancer (e.g., renal cell carcinoma), bladder cancer (e.g., urothelial cell carcinoma), pancreatic cancer, and thyroid cancer. See e.g., Zhu, J., et al., Asian Pacific J. Cancer Prev. 14:3011-3015 (2011), Krambeck A, et al., PNAS 103:10391-10396 (2006), Fan, M. et al., Int. J. Clin. Exp. Pathol. 7:6768-6775 (2014), Xu, H., et al., Oncology Letters 11:1841-1846 (2016), and Liu, W., et al., Oncology Letters 8:2527-2534 (2014).

5.2 Example 2: Afucosylated and Fucosylated 20502 Antibodies

[0176] Antibodies with Fc regions having reduced fucose content in glycan moieties may exhibit higher ADCC activity compared to a fully fucosylated antibody (Niwa R et al., Clinical Cancer Research 11 (6): 2327-36 (2005)). B7-H4 antibodies were generated in CHO-x cells (Yamane-Ohnuki N, et al. Biotechnology and Bioengineering 87 (5): 614-22 (2004)) to produce normally fucosylated antibodies and in a CHO cell line engineered to produce afucosylated antibodies (CHO-y cells) (id.).

[0177] The fucosylated and afucosylated 20502 antibodies were characterized by surface plasmon resonance (SPR). Briefly, anti-human Fab antibody was immobilized on a carboxyl-derivatized SPR chip surface, and anti-B7-H4 antibodies were captured on the resulting surface at 5 μg/ml for 30 seconds. B7-H4 IgV-huIgG1 at various concentrations (0 nM, 3.7 nM, 11.1 nM, 33.3 nM, 100 nM, and 300 nM) was then flowed over the surface and allowed to bind to the anti-B7-H4 antibodies during the association phase, followed by a buffer wash during the dissociation phase.

[0178]

B7-H4 IgV-huIgG1:

(SEQ ID NO: 29)

MASLGQILFWSIISIIIILAGAIALIIGFGISGRHSITVTTVASAGNIGED

GILSCTFEPDIKLSDIVIQWLKEGVLGLVHEFKEGKDELSEQDEMFRGRTA

VFADQVIVGNASLRLKNVQLTDAGTYKCYIITSKGKGNANLEYKTGAFSGS

EPKSSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDV

SHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGK

EYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCL

VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ

GNVFSCSVMHEALHNHYTQKSLSLSPGK

[0179] Data was fitted using a 1:1 binding model, and the fucosylated and afucosylated 20502 showed similar binding to human B7-H4 protein. Thus there is no impact of the glycosylation on binding.

[0180] The binding affinities of the Fc regions of fucosylated 20502 (Ab-F) and afucosylated 20502 (Ab-A) to FcγRIIIa (V158) were also characterized by surface plasmon resonance (SPR). Briefly, Protein A was covalently attached to a dextran chip using the amine coupling kit with 100 mM ethylenediamine in 100 mM Sodium Borate buffer, pH 8.0 as the blocking reagent. Ab-A or Ab-F was captured at 2 densities on separate flow cells, and a Protein A derivatized flow served as a reference control. Fc gamma RIIIA(V158) was diluted in HBS-P+running buffer and injected at 6 concentrations (0 nM, 1.37 nM, 12.3 nM, 37 nM, 111 nM, 333 nM, and 1000 nM) in duplicate. The association constant, dissociation constant, and affinity for Ab-A binding were calculated using the Biacore T200 Evaluation Software 1:1 binding model. The affinity constant for Ab-A and Ab-F binding were determined using the Biacore T200 Evaluation Software steady state affinity model. The afucosylated B7-H4 antibody has a 140-fold higher affinity for Fc gamma receptor IIIA(V158) than the same antibody with a fucosylated Fc (Ab-F) (Table 14).

[0181]

TABLE 14

Fcγ receptor IIIa (FcγRIIIa) V158 allele binding
	ka (1/Ms)	kd (1/s)	K_D(nM)

	Ab-A	6.46E+05	9.54E−10	15
	Ab-F	N/A	N/A	210

[0182] The T cell checkpoint blockade activity of fucosylated and afucosylated 20502 antibodies were also characterized. In these experiments, primary human T cells were enriched from PBMCs using the EasySep™ Human T Cell Enrichment Kit based on the manufacturer's instructions. Enriched T cells were incubated at 2×10⁵cell/mL with anti-CD3/anti-CD28 Dynabeads, at a one bead per cell ratio, at 37° C. Six days later, the beads were magnetically removed, and T cells were washed and incubated at 1×10⁶cell/mL with 10 U/mL IL-2 at 37° C. Four days later, T cells were washed and incubated at 1×10⁶cells/mL along with artificial antigen presenting cells (aAPCs) at a 2×10⁶cells/mL concentration at 37° C. in the presence of B7-H4 antibody dose titration. aAPCs were treated with Mitomycin C for one hour at 37° C. and then thoroughly washed prior to adding to the T cell co-culture. 72 hours after co-culture of T cells, aAPCs, and B7-H4 antibodies, plates were centrifuged and supernatants were harvested and assessed for IFNγ production by ELISA. IFNγ production was plotted vs. antibody concentration and the EC50 potency was calculated using nonlinear regression curve fit (GraphPad Prism).

[0183] The B7-H4 antibodies demonstrated potent T cell checkpoint blockade activity as measured by an increase in IFNγ production. Moreover, there was no demonstrable difference in potency between afucosylated and fucosylated antibodies (Table 15).

[0184]

TABLE 15

T Cell Checkpoint blockade potency
	aAPC Assay (EC50 +/− STD; nM)
	Antibody	BIN	Afucosylated	Fucosylated

	20502	3	0.89 +/− 0.44	0.74 +/− 0.39

[0185] In additional experiments, the ADCC activity of fucosylated and afucosylated 20502 antibodies was also characterized against a B7-H4-expressing target cell line. Specifically, primary human PBMCs cells were cytokine activated at 1×10⁶cells/mL with 200 IU/mL IL-2 at 37° C. The next day, cells were washed and incubated at a 40:1 Effector:Target ratio with SK-BR-3 target cells that were labeled with Calcein-AM. 4 hours after incubation, target cell lysis was quantified using a fluorimeter. A Triton/X treated sample served as the max lysis control sample, whereas a media alone treated sample served as the background lysis control sample. The percent (%) specific lysis was calculated as follows: [1-((sample-media control)/(max lysis-media control))]×100. The percent (%) specific lysis was plotted vs. antibody concentration and the EC50 potency was calculated using nonlinear regression curve fit (GraphPad Prism).

[0186] The B7-H4 antibodies demonstrated potent dose-dependent ADCC activity against the endogenous B7-H4 expressing breast cell line SK-BR-3. Moreover, the afucosylated antibodies demonstrated significantly more potent ADCC activity in comparison to the fucosylated antibodies (Table 16).

[0187]

TABLE 16

ADCC activity
	ADCC Assay (EC50 +/− STD; nM)
Antibody	BIN	Afucosylated	Fucosylated

20502	3	0.0007 +/− 1.1 × 10E−3	0.0370 +/− 6.2E−2

5.3 Example 3: Correlation of ADCC Activity with Receptor Density

[0188] B7-H4 density was quantified on the surface of SK-BR-3, HCC1569, ZR-75-1, MDA-MB-48, and HCC1964 cells by FACS according to the manufacturer's specifications. Specifically, 1×10⁵cells were incubated with 15 μg/mL B7-H4 antibody on ice for 25 minutes. In parallel, one drop of Quantum™ Simply Cellular (QSC) microspheres (pre-coated with increasing concentrations of anti-mouse IgG capture antibody) was also incubated with 15 μg/mL B7-H4 antibody on ice for 25 minutes. Following incubation, cells and QSC microspheres were pelleted and washed, and samples were acquired on a flow cytometer. Data was analyzed using the FlowJo software. Mean fluorescence intensity (MFI) was calculated and entered into the QuickCal® spreadsheet. A regression associating each bead's fluorescence channel value to its pre-assigned Antibody Binding Capacity (ABC) value will be calculated automatically. An ABC value was assigned once the MFI values for the labeled cells are also added into the template).

[0189] B7-H4 antibodies were assessed for ADCC activity against B7-H4 expressing target cell lines with different levels of B7-H4 cell surface density. Specifically, 1×10⁴SK-BR-3, HCC1569, ZR-75-1, MDA-MB-468, or HCC1964 target cells were co-incubated with dose-titrations of B7-H4 antibody at 4° C. 25 minutes later, a single use vial of Jurkat-huCD16 reporter cells from Promega was thawed, and 7.5×10⁴cells were added to the target cell/B7-H4 antibody mixture and incubated at 37° C. 24 hours later, the samples were brought to room temperature (RT) and incubated with Bio-Glo buffer. The substrate and luminescence were quantified on an En Vision multi-label reader. The data was plotted as luminescence vs. antibody concentration and the EC50 potency was calculated using nonlinear regression curve fit (GraphPad Prism).

[0190] B7-H4 antibody ADCC activity was dependent on B7-H4 cell surface density: as the numbers of cell surface molecules decreased, the amount of maximal ADCC activity also decreased. Moreover, afucosylated antibodies demonstrated improved ADCC activity in comparison to the fucosylated antibodies, especially against target cells with lower levels of B7-H4 cell surface density (FIG. 1).

5.4 Example 4: In Vivo Anti-Tumor Efficacy in Combination with Anti-PD-1 Antibody

[0191] Methods: Eight week old female BALB/c mice were purchased from Charles River Laboratories (Hollister, CA) and were acclimated for up to two weeks before the start of the study. The murine breast carcinoma cell line 4T1 was engineered to express a chimeric protein containing the extracellular domain of murine B7-H4 and the transmembrane domain of murine B7H3. Tumor cells were implanted orthotopically in the mammary fat pad of the mice at 0.5×10⁵cells/50 ul/mouse. Prior to inoculation, the cells were cultured for no more than three passages in RPMI 1640 medium supplemented with 10% heat-inactivated Fetal Bovine Serum (FBS). Cells were grown at 37° C. in a humidified atmosphere with 5% CO2. Upon reaching 80-85% confluence, cells were harvested and resuspended in serum-free RPMI 1640 on the ventral flank of each mouse into the mammary fat pad.

[0192] Mice were monitored twice weekly following cell implantation for tumor growth. The length and width of each tumor was measured using calipers, and the volume was calculated according to the formula: Tumor volume (mm3)=(width (mm)×length (mm)2)/2. On the day of treatment initiation, all tumors were measured, outliers were excluded, and mice were randomly assigned to treatment groups. For the anti-B7-H4 treatment, a mouse surrogate of 20502 called 20502-msIgG2γ-F, which contains the 20502 variable region fused to fucosylated mouse IgG2a, was utilized. As a control, mice were administered msIgG2a (anti-HEL). 20502-msIgG2a-F or msIgG2a were administered four times via intravenous (i.v.) injection twice weekly beginning on Day 11 after inoculation. Anti-PD-1 (a modified version of RMP1-14 (Bio X Cell) containing a Fc silent msIgG2a domain) was administered three times via intraperitoneal (i.p.) injection twice weekly beginning on Day 11 after inoculation. Tumors continued to be measured at least twice per week until tumor volume exceeded 10% of animal weight, or approximately 2000 mm3.

[0193] Results: The change in tumor size, the change in mean tumor volume, and the percent survival are shown in FIGS. 1A, 1B and 1C, respectively. Treatment with either 20502-msIgG2a-F or anti-PD-1 significantly reduced tumor growth compared to msIgG2a control (p<0.05). The co-administration of 20502-msIgG2a-F and anti-PD-1 significantly enhanced tumor growth inhibition compared to either monotherapy (p<0.05). Moreover, combination therapy resulted in complete tumor regression in 5 of 12 mice. P-values were calculated using One-Way ANOVA analyses of the calculated tumor volumes on each day of the study with multiple comparisons between each group.

[0194] In additional experiments, 20502-msIgG2a-F demonstrated dose-dependent anti-tumor activity as a monotherapy in the engineered 4T1 model at doses as low as 1 and 3 mg/kg (FIG. 2). Combining 20502-msIgG2a-F at doses of 0.3 mg/kg, 3 mg/kg or 30 mg/kg with the anti-PD-1 antibody (5 mg/kg) resulted in synergistic anti-tumor activity in both the engineered 4T1 model and a similarly engineered B16 (melanoma) model at nearly all doses of 20502-msIgG2a-F tested (FIG. 3). (The PD-1 antibody was administered to the 4T1 model three times on the same days as the first three doses of 20502-msIgG2a-F and to the B16 model twice on the same days as the second and fourth doses of 20502-msIgG2a-F.) This synergistic effect was particularly unexpected for the 0.3 mg/kg dose, given that administration of 20502-msIgG2a-F alone at that dose did not have a significant effect on tumor volume (FIG. 2). Moreover, the efficacy (percent survival) observed at the 0.3 mg/kg dose of 20502-msIgG2a-F in combination with anti-PD1 was surprisingly comparable, or even superior, to the efficacy observed at either the 3 mg/kg or 30 mg/kg dose in combination with anti-PD1. Thus, these results show that anti-PD1 combines synergistically with an anti-B7-H4 antibody at doses of the latter that are non-efficacious as a monotherapy, and this may have advantages not only in terms of efficacy, but also safety.

5.5 Example 5: Nonclinical Pharmacokinetics

[0195] The pharmacokinetics (PK) and toxicokinetics (TK) of afucosylated 20502 were evaluated following a single and/or repeat weekly intravenous (IV) administration in mice, rats, and cynomolgus monkeys. PK characteristics observed were consistent across all studies. In all species, afucosylated 20502 demonstrated linear PK and a dose proportional increase in exposure (area under serum concentration-time curve [AUC]) with increasing dose. There was an approximate 2-fold increase in weekly exposure (AUC_0-7days) following 4 weekly administrations of 20502 between first and last dose; however, steady state was not achieved. No substantial gender differences were apparent in the serum afucosylated 20502 concentration-time profiles. In the cynomolgus monkey (across 2 different studies), half-life estimated from recovery animals ranged from approximately 8.8 days to 12 days, with doses levels ranging from 1 to 100 mg/kg. The estimated half-life in rat following a single IV infusion administration at 40 mg/kg was approximately 13.2 days. The PK characteristics of afucosylated 20502 in animals support IV infusion in humans with a once every 3 week (Q3W) dose regimen.

5.6 Example 6: Toxicology

[0196] Toxicology studies with afucosylated 20502 were performed in rat and cynomolgus monkey. The studies included a pilot single dose pharmacokinetic (PK)/tolerability study in rats, a pilot repeat-dose toxicity study in cynomolgus monkeys, and investigational new drug (IND)-enabling Good Laboratory Practices (GLP) repeat-dose toxicity studies in rats and cynomolgus monkeys, as well as a GLP tissue cross-reactivity study with human, rat, and cynomolgus monkey tissues.

[0197] In the single dose pilot tolerability study in rats, the animals received doses up to 40 mg/kg as a 30-minute intravenous (IV) infusion. Afucosylated 20502 had no effect on clinical observations, body weights, food consumption, clinical pathology (serum chemistry or hematology) assessments, gross observations, organ weights, or histopathology assessment.

[0198] In the pilot repeat-dose toxicology study cynomolgus monkeys received 4 weekly IV doses of afucosylated 20502 up to 100 mg/kg as a 30-minute IV infusion. All doses were well tolerated by cynomolgus monkeys. There were no test article-related unscheduled mortalities or changes attributed to administration of afucosylated 20502 during assessment of clinical observations, body weights, clinical pathology, necropsy, organ weight, or histopathology parameters.

[0199] In the repeat-dose GLP toxicology studies, afucosylated 20502 was administered by IV at dose levels of 1, 10, and 100 mg/kg/dose to both rats and cynomolgus monkeys for 4 weekly doses. Reversibility of toxicity was evaluated during a 6-week recovery period following the final administration. Parameters for evaluation included ophthalmic examinations, clinical observations, body temperatures, body weights, food consumption, hematology, coagulation, clinical chemistry, urinalysis, organ weights, macroscopic, and microscopic evaluation. In the cynomolgus monkey study, electrocardiograms (ECGs) were also assessed to evaluate potential cardiac toxicities.

[0200] During the evaluation of the GLP rat study, afucosylated 20502 was generally well tolerated, and there were no toxic effects attributed to afucosylated 20502. The no-observed-adverse-effect level (NOAEL) in Sprague Dawley rats was considered to be 100 mg/kg/dose.

[0201] In the GLP cynomolgus monkey study, afucosylated 20502 was generally well tolerated, and there were no adverse events (AEs) attributed to afucosylated 20502 observed in any of the parameters evaluated. During the study, a higher incidence of diarrhea was observed at the end of the dosing phase in the higher dose groups. Due to the higher incidence of affected animals in the mid and high dose, as well as onset in the later phase of the dosing period, a relationship with afucosylated 20502 exposure is possible. There were no microscopic changes in the intestinal tract in animals treated with afucosylated 20502, including animals with diarrhea; therefore, this finding was considered non-adverse but possibly related to the test article. There was a single mortality in the study. One animal in the mid-dose recovery group was found dead on Study Day 35, 14 days post the last dose. Clinical observations, macroscopic and microscopic evaluation were consistent with the diagnosis of intestinal torsion. Intestinal torsions occasionally occur in cynomolgus monkeys, and this was considered a spontaneous condition in this animal and not test article-related. The NOAEL in cynomolgus monkey was considered to be 100 mg/kg/dose.

[0202] In addition to in vivo toxicology studies, a GLP-compliant tissue cross reactivity study was performed to compare the binding of afucosylated 20502 to a panel of 36 tissues from rat, cynomolgus monkey, and human. The results showed that the binding pattern of afucosylated 20502 was similar among the 3 species and limited to the mammary gland epithelium.

[0203] Thus, afucosylated 20502 was well tolerated in cynomolgus monkey and rat. The NOAEL in both species was considered to be 100 mg/kg/dose, the highest dose tested when given as 4 weekly IV doses.

5.7 Example 7: Phase 1a Dose Escalation/Safety Lead-In and Phase 1b Dose Expansion Studying Afucosylated 20502 in Combination with Pembrolizumab

For convenience, Afucosylated 20502 is referred to as A-20502 in this Example.

[0204] Title: A Phase 1a/1b Study of an Anti-B7-H4 Antibody in Combination with Pembrolizumab (an Anti-PD1 Antibody) in Patients with Advanced Solid Tumors

[0205]

TABLE 17

OBJECTIVES	ENDPOINTS


PRIMARY
Safety
A-20502 Combined with Pembrolizumab	A-20502 Combined with Pembrolizumab
To evaluate the safety and tolerability of A-20502	The incidence of AEs, clinical laboratory
in combination with pembrolizumab in patients	abnormalities, and ECG abnormalities
with advanced solid tumors	The incidence of Grade 3 and Grade 4 AEs and
To determine the maximum tolerated dose	clinical laboratory abnormalities defined as DLTs
(MTD) and/or recommended dose (RD) of A-
20502 in combination with pembrolizumab in
patients with advanced solid tumors
SECONDARY
Pharmacokinetics
A-20502 Combined with Pembrolizumab	A-20502 Combined with Pembrolizumab
To characterize the PK profile of A-20502 in	The following PK parameters will be derived from
combination with pembrolizumab in patients with	concentration-time data for A-20502 in combination with
advanced solid tumors	pembrolizumab when appropriate and applicable:
	AUC (Area under serum concentration time curve)
	C_max(Maximum serum concentration)
	C_trough(trough serum concentration at the end of a
	dose interval)
	CL (Clearance)
	t_1/2(Terminal half-life)
	V_ss(Volume of distribution at steady state)
	Other parameters, such as dose proportionality,
	accumulation ratio, attainment of steady state, will
	also be calculated if the data are available for A-
	20502
	Accumulation ratio of C_maxand C_troughfor
	pembrolizumab may be calculated if the data are
	available.
Immunogenicity
A-20502 Combined with Pembrolizumab	A-20502 Combined with Pembrolizumab
To characterize the immunogenicity of A-20502 in	Immune response (ADAs) to A-20502
combination with pembrolizumab in patients with	Immune response (ADAs) to pembrolizumab
advanced solid tumors
EXPLORATORY
Efficacy
A-20502 Combined with Pembrolizumab	A-20502 Combined with Pembrolizumab
To evaluate the clinical benefit of A-20502 in	Objective response rate (ORR), defined as the total
combination with pembrolizumab	number of patients with confirmed responses of either
	CR or PR per RECIST v1.1 divided by the total
	number of patients who are evaluable for a response
	Duration of response (DOR), defined as the time from
	onset of response (CR or PR) that is subsequently
	confirmed to the first observation of progressive
	disease or death due to any cause
	Progression free-survival (PFS), defined as the time
	from the patient's first dose to the first observation of
	progressive disease or death due to any cause
Pharmacodynamic Biomarkers
A-20502 Combined with Pembrolizumab	A-20502 Combined with Pembrolizumab
To characterize the pharmacodynamic profile of	Changes in markers of tumor immune infiltrate (eg,
A-20502 in combination with pembrolizumab	may include natural killer cells (NK), CD4, CD8,
through an analysis of the immune cell infiltrate in	and/or other select immune biomarkers) by IHC
pre-treatment and on-treatment tumor biopsies	and/or RNA analysis in patients treated with A-20502
To characterize the pharmacodynamic profile of	in combination with pembrolizumab
A-20502 in combination with pembrolizumab	Changes in cytokine levels (e.g., may include IL-2,
through evaluation of exploratory biomarkers in	IL-6, IL-10, TNF, IFNγ) as determined by multiplex
peripheral blood samples	analysis in patients treated with A-20502 in
	combination with pembrolizumab
	Changes in selected additional pharmacodynamic
	markers in peripheral blood in patients treated with A-
	20502 in combination with pembrolizumab

[0206]

TABLE 18

OBJECTIVES	ENDPOINTS


PRIMARY
Safety
A-20502 Combined with Pembrolizumab	A-20502 Combined with Pembrolizumab
To evaluate the safety and tolerability of A-20502	The incidence of AEs, clinical laboratory
in combination with pembrolizumab in selected	abnormalities, and ECG abnormalities in patients
patients with B7-H4 + advanced solid tumors	treated with A-20502 in combination with
treated at the MTD and/or RD	pembrolizumab
SECONDARY
Efficacy
A-20502 Combined with Pembrolizumab	A-20502 Combined with Pembrolizumab
To evaluate the clinical benefit of A-20502 in	ORR, defined as the total number of patients with
combination with pembrolizumab in selected	confirmed responses of either CR or PR per RECIST
patients with B7-H4 + advanced solid tumors	v1.1 divided by the total number of patients who are
treated at the MTD and/or RD	evaluable for a response to A-20502 combined with
	pembrolizumab
	DOR, defined as the time from onset of response (CR
	or PR) that is subsequently confirmed to the first
	observation of progressive disease or death due to any
	cause to A-20502 combined with pembrolizumab
	PFS, defined as the time from the patient's first dose
	to the first observation of progressive disease or death
	due to any cause to A-20502 combined with
	pembrolizumab
Pharmacokinetics
A-20502 Combined with Pembrolizumab	A-20502 Combined with Pembrolizumab
To characterize the PK profile of A-20502 in	The following PK parameters will be derived from
combination with pembrolizumab in patients with	concentration-time data for A-20502 in combination
B7-H4 + advanced solid tumors treated at the MTD	with pembrolizumab when appropriate and
and/or RD	applicable:
To characterize the PK profile of perbrolizimab in	AUC
combination with A-20502 in patients with	C_max
advanced solid tumors	C_trough
	CL
	t_1/2
	V_ss
	Other parameters, such as accumulation ratio,
	attainment of steady state, will also be calculated if
	the data are available for patients treated with A-
	20502 combined with pembrolizumab
	C_maxand C_troughas well as the accumulation ratio of
	C_maxand C_troughfor pembrolizumab may be calculated
	if the data are available.
Immunogenicity
A-20502 Combined with Pembrolizumab	A-20502 Combined with Pembrolizumab
To characterize the immunogenicity of A-20502 in	Immune response (ADAs) to A-20502
combination with pembrolizumab in selected	Immune response (ADAs) to pembrolizumab
patients with B7-H4 + advanced solid tumors
treated at the MTD and/or RD
To characterize the immunogenicity of
pembrolizumab in combination with A-20502
patients with with B7-H4 + advanced solid tumors
treated at the MTD and/or RD
EXPLORATORY
Pharmacodynamic Biomarkers
A-20502 Combined with Pembrolizumab	A-20502 Combined with Pembrolizumab
To characterize the pharmacodynamic profile of	Changes in markers of tumor immune infiltrate, (eg,
A-20502 in combination with pembrolizumab	may include natural killer cells (NK), CD4, CD8,
through an analysis of the immune cell infiltrate in	and/or other select immune biomarkers) by IHC
pre-treatment and on-treatment tumor biopsies	and/or RNA analysis for patients treated with A-
To characterize the pharmacodynamic profile of	20502 in combination with pembrolizumab
FP150 in combination with pembroliumab through	Changes in cytokine levels (e.g., may include IL-2,
evaluation of exploratory biomarkers in peripheral	IL-6, IL-10, TNF, IFNγ) as determined by multiplex
blood samples	analysis for patients treated with A-20502 in
	combination with pembrolizumab
	Changes in selected additional pharmacodynamic
	biomarkers in peripheral blood samples for patients
	treated with A-20502 in combination with
	pembrolizumab
Efficacy
A-20502 Combined with Pembrolizumab	A-20502 Combined with Pembrolizumab
To evaluate the clinical benefit of A-20502 in	Overall Survival (OS), defined as time from patient's
combination with pembrolizumab in selected	first dose to death due to any cause for patients
patients with B7-H4 + advanced solid tumors	treated with A-20502 in combination with
treated at the MTD and/or RD	pembrolizumab

[0207] In certain embodiments, pembrolizumab for injection is supplied as a sterile, preservative-free, white to off-white lyophilized powder in single-dose vials. Each vial may be reconstituted and diluted for intravenous infusion. Each 2 mL of such reconstituted solution contains 50 mg of pembrolizumab and is formulated in L-histidine (3.1 mg), polysorbate 80 (0.4 mg), and sucrose (140 mg). May contain hydrochloric acid/sodium hydroxide to adjust pH to 5.5. The lyophilized powder is reconstituted by adding 2.3 mL of Sterile Water for Injection, USP by injecting the water along the walls of the vial and not directly on the lyophilized powder (resulting concentration 25 mg/mL). The vial is slowly swirled (without shaking) and allowed up to 5 minutes for the bubbles to clear.

[0208] In other embodiments, pembrolizumab is available for injection as a 100 mg/4 mL (25 mg/mL) solution in a single use vial. The injection is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution that requires dilution for intravenous infusion. Each vial contains 100 mg of pembrolizumab in 4 mL of solution. Each 1 mL of solution contains 25 mg of pembrolizumab and is formulated in: L-histidine (1.55 mg), polysorbate 80 (0.2 mg), sucrose (70 mg) and Water for Injection, USP.

[0209] Study Design: This is a Phase 1a/1b open-label, multicenter, study to evaluate the dosing, safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of A-20502 in combination with pembrolizumab in advanced solid tumors.

[0210] This study includes a Phase 1a dose escalation/safety-lead in portion (Phase 1a Dose Escalation) and a Phase 1b dose expansion portion (Phase 1b Dose Expansion) for A-20502 in combination with pembrolizumab.

[0211] Archival tumor tissue (or fresh biopsy obtained if archival tissue is not available) may be pre-screened to test for B7-H4 (transmembrane protein of the B7 family also known as B7S1, B7×, or VTCN1) expression levels by immunohistochemistry (IHC) at a central laboratory for patients in Phase 1a Dose Exploration and Phase 1b Dose Expansion and for biomarker analysis.

[0212] In certain embodiments, Archival Tumor Tissue and/or Fresh Biopsies are provided as follows:

Phase 1a Dose Escalation:

- [0213] Provision of archival tumor tissue (or fresh biopsy obtained if archival tissue is not available) for retrospective biomarker analysis for patients.
  Phase 1a Dose Exploration:
- [0214] Archival tumor tissue to evaluate for B7-H4 expression levels through IHC testing performed at a central laboratory for pre-screening and for biomarker analysis; fresh biopsy tissue will be used for this test if archival tissue is not available.
- [0215] Fresh biopsies will be used during screening and post-treatment.
  Phase 1b Dose Expansion:
- [0216] Archival tumor tissue to evaluate for B7-H4 expression level through IHC testing performed at a central laboratory for pre-screening and for biomarker analysis; fresh biopsy tissue is used for this test if archival tissue is not available.
- [0217] Fresh biopsies will be used for a subset of patients (e.g., at least 10 patients per 30-patient cohort) during screening and post-treatment, for expanded pharmacodynamic analysis.

[0218] Additional details are provided below for each study phase under Phase 1a Dose Escalation and Phase 1b Dose Expansion sections of this Synopsis.

[0219] Phase 1a Safety Lead-in (A-20502 in combination with pembrolizumab): At least 3 patients will be enrolled at the maximum tolerated dose (MTD) and/or recommended dose (RD) of A-20502 as monotherapy combined with 200 mg pembrolizumab Q3W and evaluated for dose limiting toxicities (DLTs). Additional patients for a total of up to 10 patients may be treated at the RD of A-20520 and pembrolizumab. If required, the dose of A-20502 may be reduced in accordance with the algorithm for de-escalation described below. The proposed dose levels are:

- [0220] 1aC1: A-20502 (RD)+pembrolizumab 200 mg IV Q3W
- [0221] 1aC2: A-20502 (10 mg/kg)+pembrolizumab 200 mg IV Q3W
- [0222] 1aC3: A-20502 (3 mg/kg)+pembrolizumab 200 mg IV Q3W
  Abbreviations: IV=intravenous; Q3W=once every 3 weeks; RD=recommended dose.

[0223] In some embodiments, the RD is 20 mg/kg. In a phase 1a/1b monotherapy study in patients with advanced solid tumors, A-20502 was well tolerated at doses as high as 20 mg/kg with no dose limiting toxicities. Based on pharmacokinetic studies of the patients in that phase 1a/1b monotherapy study, the observed trough concentration of A-20502 at the RD of 20 mg/kg is projected to achieve ≥95% receptor saturation for both B7-H4 and FcγIlla based on affinities. A-20502 achieved dose-proportional exposures at doses ≥0.3 mg/kg and had a half-life of 1-2 weeks. The serum concentration of A-20502 at 20 mg/kg was similar over time across tumor types (breast, ovarian, and endometrial) and with or without pembrolizumab.

[0224] Other dose levels may be used (e.g., 0.1, 0.3, 1, or 20 mg/kg) in the combination study, e.g., based on safety, tolerability, objective response, PK, and pharmacodynamics and estimates of efficacious exposures extrapolated from nonclinical data. For example, lower or intermediate dose levels of A-20502 based on safety data may be used. The DLT criteria for the combination of A-20502 and pembrolizumab will be as follows:

[0225] DLTs during Phase 1a Dose Escalation are defined as any of the following events regardless of attribution (except for those events clearly due to the underlying disease or extraneous causes):

- [0226] Any Grade 3 or higher non-hematologic toxicity (except Grade 3 nausea, vomiting and diarrhea) occurring within the 21 days of treatment
- [0227] Grade 3 nausea, vomiting, diarrhea lasting >72 hours, despite optimal supportive care, occurring within first 21 days of treatment
- [0228] Febrile neutropenia and/or documented infection with absolute neutrophil count (ANC)<1.0×10⁹per L, Grade 4 neutropenia lasting for more than 7 days, Grade 4 thrombocytopenia (<25.0×10⁹per L), or Grade 3 thrombocytopenia (<50.0-25.0×10⁹per L) accompanied by bleeding within first 21 days of treatment
- [0229] Aspartate aminotransferase/alanine transaminase (AST/ALT)>3× upper limit of normal (ULN) and concurrent total bilirubin >2× ULN not related to liver involvement with cancer
- [0230] Any Grade 4 laboratory value regardless of clinical sequelae
- [0231] Other Grade 3 laboratory values that are not of clinical significance according to Investigator and Sponsor agreement that do not resolve within 72 hours
  Specific DLT Considerations for the Combination of A-20502 and Pembrolizumab
- [0232] Because pembrolizumab is a known immune checkpoint inhibitor and one of the proposed mechanisms of action of A-20502 is immune checkpoint blockade, immune-related adverse events (irAEs) are anticipated with this combination. An irAE is defined as a clinically significant AE that is associated with study drug exposure, of unknown etiology, and is consistent with an immune-mediated mechanism. Based on that background, the first occurrence of the following irAEs will not be considered a DLT because they are expected with immune therapy:
- [0233] Grade 3 tumor flare (defined as local pain, irritation, or rash localized at sites of known or suspected tumor),
- [0234] Grade 3 rash
- [0235] Grade 3 immune-related adverse event (irAE) that resolved to a Grade 1 or less within 14 days.
- [0236] Transient (resolving within 6 hours of onset) Grade 3 infusion-related AE

[0237] A second occurrence of these events (except Grade 3 tumor flare) either in the same or different patient will be considered a DLT.

[0238] The DLT evaluation interval begins on the first day of treatment upon start of infusion and continues for 21 days. The algorithm outlined in the table below will apply for dosing decisions. The dose of A-20502 may be lowered as needed in response to DLTs. The MTD and/or RD of A-20502 in combination with pembrolizumab will be a dose where ≤1/3-6 patients encounter a DLT.

[0239]

TABLE 19

Algorithm for Dose De-Escalation Decisions for A-20502 Safety Lead-in in Combination with Pembrolizumab in phase 1a:
Number of Patients with
DLT at a Given Dose Level	Dosing Decision Rule

0/3	Proceed with enrollment of up to 10
	total patients at that dose level for
	additional safety assessment
1/3	Enroll 3 additional patients at current
	dose level (current cohort)
≥2/3	Stop enrollment at current cohort and
	de-escalate A-20502 to one dose level
	below current dose
1/6	Proceed with enrollment of up to 10 total
	patients at that dose level
≥2/6	Stop enrollment at current cohort and
	de-escalate A-20502 to one dose level
	below current dose.

Phase 1b Combination Expansion:

[0240] Phase 1b may consist of cohorts of prospectively identified as having B7-H4 expression by IHC. In certain embodiments, there will be two cohorts of A-20502 in combination with pembrolizumab in the following selected tumor types:

- [0241] Cohort 1bC1: TNBC (A-20502 in combination with pembrolizumab)
- [0242] Cohort 1bC2: Ovarian cancer (A-20502 in combination with pembrolizumab)

[0243] In another embodiment, the Phase 1b Combination has one initial cohort, and other cohorts such as TNBC may be enrolled subsequently in the Phase 1b trial:

- [0244] Cohort 1bC1: Ovarian Cancer (A-20502 in combination with pembrolizumab)

[0245] In certain embodiments, up to 3 additional combination cohorts may be added.

[0246] Based on emerging available clinical and translational data from the study, cohorts for additional tumor types to be treated with A-20502 in combination with pembrolizumab may be opened during the trial (e.g., 30 patients or less in any individual cohort).

- [0247] Dosing: In certain embodiments, A-20502 will be administered as a single agent in a 60-minute (±5 minutes) IV infusion Q3W, on Day 1 of each 21-day cycle. The dose of A-20502 will be based on body weight at Cycle 1 Day 1 (C1D1). After Cycle 1, the A-20502 dose will be recalculated at each infusion visit only if the patient's weight has changed >10% from Cycle 1, Day 1.

[0248] Pembrolizumab will be administered after completion of A-20502 IV infusion at a dose of 200 mg by IV infusion over 30 minutes (±5 minutes) starting on Cycle 1, Day 1 and repeated Q3W on Day 1 of each 21-day cycle.

[0249] There is no pre-specified maximum number of doses of A-20502 in combination with pembrolizumab. Patients may continue receiving both drugs in combination according to their study specified cohort/dose until investigator assessed disease progression or the patient meets any of the other protocol-specified withdrawal criteria. If a patient discontinues one of the two drugs, the patient may continue to receive the other drug alone.

[0250] Treatment beyond disease progression may be allowed in patients with progressive disease according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) if the benefit/risk assessment favors continued administration of study treatment (e.g., if patients are continuing to experience clinical benefit as assessed by the Investigator and tolerating treatment).

[0251] Study Duration: The duration of study for an individual patient includes screening (up to 28 days), treatment, and an End of Treatment (EOT) follow-up period which will include visits at approximately 28 (±7) days and 100 (±7) days after the last dose. Since all patients are eligible to be treated until disease progression, the actual treatment duration for each individual patient will vary depending on the anticipated time to progression for their respective tumor type.

[0252] In addition, patients enrolled in Phase 1b Dose Expansion will be followed for survival (LTFU including scans and survival status Q12W) for up to 2 years.

- [0253] Number of Patients: The number of patients planned for this study is estimated as follows but this number may be adjusted as appropriate.

[0254] Phase 1a may enroll from 6 to 22 patients or 10 to 22 patients who will receive A-20502 in combination with pembrolizumab in the safety lead-in. The one or two additional cohorts evaluating A-20502 in combination with pembrolizumab will be enrolled, e.g., with 30 patients or less.

Eligibility Criteria:

Inclusion Criteria: Phase 1a Inclusion Criteria

[0255] Inclusion criteria for patients enrolling into Phase 1a are as follows:

- [0256] 1) Histologically confirmed solid tumors except primary central nervous system (CNS) tumors.
- [0257] 2) Disease that is unresectable, locally advanced, or metastatic.
- [0258] 3) Able to understand and sign an Institutional Review Board/Independent Ethics Committee (IRB/IEC)-approved Informed Consent Form (ICF) prior to any study-specific evaluation. 4) Patients should be refractory to or intolerant of existing therapy(ies) known to provide clinical benefit for their condition.
- [0259] 5) All patients must have at least one measurable lesion at baseline according to RECIST v1.1; tumor sites situated in a previously irradiated area, or in an area subjected to other loco-regional therapy, are not considered measurable unless there has been demonstrated progression in the lesion.
- [0260] 6) Adequate washout for prior anti-cancer therapy (ie, >5 half-lives or 4 weeks since the last dose, whichever is shorter).
- [0261] 7) Availability of archival tumor tissue and consent to providing archival tumor for retrospective biomarker analysis, or patient must undergo a fresh tumor biopsy during screening if archival tissue is not available (a biopsy is required for patients in the Phase 1a Dose Exploration portion).
- [0262] 8) Age >18 years at the time the ICF is signed.
- [0263] 9) Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- [0264] 10) Life expectancy of at least 3 months in the opinion of the Investigator.
- [0265] 11) Willing and able to comply with all study procedures.
- [0266] 12) Prior radiotherapy must be completed at least 2 weeks before the first dose of study drug.
- [0267] 13) Prior radiopharmaceuticals (e.g., strontium, samarium) must be completed at least 8 weeks before the first dose of study drug.
- [0268] 14) Prior surgery that requires general anesthesia must be completed at least 1 week before first dose of study drug administration. Surgery requiring local/epidural anesthesia must be completed at least 72 hours before first dose of study drug administration. Patients must have recovered from any surgery.
- [0269] 15) Screening laboratory values must meet the following criteria:
- [0270] Hematologic
  - [0271] a. Neutrophils ≥1200 cells/μL
  - [0272] b. Platelets ≥75×10³/μL
- [0273] c. Hemoglobin (Hb) ≥9.0 g/dL
- [0274] Renal:
- [0275] Serum creatinine <1.5× ULN or creatinine clearance (CrCl) of ≥40 mL/minute (using Cockcroft/Gault Formula)

[0276]

Female CrCl \frac{(140 - age in years) \times (weight in kg) \times 0.85}{72 \times (serum creatinine in mg / dL)}

Male CrCl \frac{(140 - age in years) \times (weight in kg)}{72 \times (serum creatinine in mg / dL)}

- [0277] Hepatic:
  - [0278] d. AST and ALT≤3× ULN (AST and ALT <5× ULN in patients with liver metastases is permitted)
  - [0279] e. Bilirubin <1.5× ULN (except patients with Gilbert's syndrome, who must have total bilirubin <3 mg/dL)
- [0280] 16) Negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test ≤96 hours prior to treatment on Cycle 1, Day 1 (women of childbearing potential only).
- [0281] 17) In sexually active patients (women of child bearing potential and males), willingness to use 2 effective methods of contraception, of which 1 must be a physical barrier method (condom, diaphragm, or cervical/vault cap) until 6 months after the last dose of A-20502. Other effective forms of contraception include:
  - [0282] Permanent sterilization (hysterectomy and/or bilateral oophorectomy, or bilateral tubal ligation with surgery, or vasectomy) at least 6 months prior to Screening
  - [0283] Women of childbearing potential who are on stable oral contraceptive therapy or intrauterine or implant device for at least 90 days prior to the study, or abstain from sexual intercourse as a way of living
    Phase 1b Inclusion Criteria are as Follows:
- [0284] 18) All Inclusion Criteria for Phase 1a (Exception: Inclusion Criterion #1).
- [0285] 19) Positive for B7-H4 expression in an archival or fresh tumor sample as evaluated by an accompanying validated central laboratory IHC assay.
- [0286] 20) History of other malignancy is permitted provided it has been definitively treated with no evidence of recurrence within the past 2 years (Exception: Definitively treated non-melanoma skin cancer, lobular cancer in situ, and cervical cancer in situ within 2 years are permitted).
  Additional Cohort-Specific Inclusion Criteria for Phase 1b
  Cohort 1bC1 Ovarian Cancer:
- [0287] Histologically or cytologically confirmed diagnosis of recurrent epithelial ovarian, primary peritoneal, or fallopian tube carcinoma that is refractory to existing therapy(ies) known to provide clinical benefit
- [0288] Progressive disease on or after at least two prior regimens of treatment including at least one platinum-containing regimen, or unable to tolerate additional chemotherapy
- [0289] No prior therapy with an anti-PD1 or PD-L1 directed agent
  Cohort 1bC2 TNBC:
- [0290] Histologically or cytologically confirmed metastatic TNBC.
- [0291] At least two prior lines of systemic chemotherapy with at least one being administered in the metastatic setting
- [0292] No prior therapy with an anti-PD1 or PD-L1 directed agent
  Eligibility Criteria: Exclusion Criteria (Phase 1a and Phase 1b)

[0293] Patients who meet any of the following criteria may be excluded:

- [0294] 1) Immunosuppressive doses of systemic medications, such as steroids or absorbed topical steroids (doses ≥10 mg/day prednisone or equivalent daily) must be discontinued at least 2 weeks before the first dose of study drug. Short courses of high dose steroids, continuous low dose (prednisone <10 mg/day), inhaled, intranasal, intraocular, and joint injections of steroids are allowed.
- [0295] 2) Decreased cardiac function with New York Heart Association (NYHA)>Class 2 at screening.
- [0296] 3) Uncontrolled or significant heart disorder such as unstable angina
- [0297] 4) QT interval corrected for heart rate (QTc) per institutional guidelines >450 msec for males or >470 msec for females at screening.
- [0298] 5) History of anti-drug antibodies (ADAs), severe allergic, anaphylactic, or other infusion-related reaction to a previous biologic agent.
- [0299] 6) Known hypersensitivity to any component of the investigational product (IP) formulation and/or to pembrolizumab.
- [0300] 7) Vaccines (e.g., human papilloma virus [HPV] vaccine) within 4 weeks before the first dose of study drug. The inactivated seasonal influenza vaccine can be given to patients before treatment and while on therapy without restriction. Influenza vaccines containing live virus or other clinically indicated vaccinations for infectious diseases (i.e., pneumovax, varicella, etc.) may be permitted, but must be discussed with the Sponsor's Medical Monitor and may require a study drug washout period prior to and after administration of the vaccine.
- [0301] 8) Current unresolved infection or history of chronic, active, clinically significant infection (viral, bacterial, fungal, or other) which, in the opinion of the Investigator, would preclude the patient from exposure to a biologic agent or may pose a risk to patient safety.
- [0302] 9) Patients with abnormal serum chemistry values that in the opinion of the Investigator are considered to be clinically significant. This includes patients who show clinical signs and symptoms related to their abnormal serum chemistry values, as well as patients whose serum chemistry values are asymptomatic, but clinically significant according to the Investigator (e.g., hypokalemia or hyponatremia).
- [0303] 10) Any uncontrolled medical condition or psychiatric disorder which, in the opinion of the Investigator, would pose a risk to patient safety or interfere with study participation or interpretation of individual patient results.
- [0304] 11) Pregnant or breastfeeding.
- [0305] 12) Active, known, or suspected autoimmune disease requiring treatment in the past 2 years. Patients with Type I diabetes mellitus, hypothyroidism requiring only hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger, are permitted to enroll.
- [0306] 13) Known history of testing positive for human immunodeficiency virus (HIV) 1 or 2 or known acquired immunodeficiency syndrome (AIDS).
- [0307] 14) Positive test for hepatitis B virus surface antigen (HBsAg) or detectable hepatitis C virus ribonucleic acid (HCV RNA) indicating acute or chronic infection.
- [0308] 15) Ongoing adverse effects from prior treatment >Grade 1 (with the exception of Grade 2 alopecia or peripheral neuropathy) based on National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE).
- [0309] 16) Symptomatic interstitial lung disease or inflammatory pneumonitis.
- [0310] 17) Untreated or active CNS or leptomeningeal metastases. Patients are eligible if metastases have been treated and patients are neurologically returned to baseline or neurologically stable (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks before the first dose of study drug.
- [0311] 18) Evidence of coagulopathy or bleeding diathesis. Patients receiving stable therapeutic doses of anti-coagulants will be permitted.
- [0312] 19) Transfusion of blood or platelets completed within 72 hours before the first dose of study drug.
- [0313] 20) Any uncontrolled inflammatory GI disease including Crohn's Disease and ulcerative colitis
  Tests and Observations: Safety assessments include vital signs, body weight, physical exam, ECOG score, laboratory tests (hematology, serum chemistries, and urinalysis), electrocardiograms (ECGs), and monitoring of adverse events (AEs) and concomitant medications.

[0314] Archival tumor tissue and consent to provide archival tumor (or willingness to undergo a fresh tumor biopsy during screening) will be collected for biomarker analysis to explore the relationship between baseline target levels, tumor immune phenotype and pharmacodynamic response.

[0315] Pre- and on-treatment tumor tissue may be collected for all patients in Phase 1a Dose Exploration and a subset of patients (up to 15 patients per cohort of 30 patients) in Phase 1b Dose Expansion for expanded pharmacodynamic analysis.

[0316] Efficacy assessments may consist of radiographic imaging performed every 6 weeks. Responses will be assessed according to RECIST v1.1.

Statistical Methods:

Efficacy Analysis

[0317] The ORR may be summarized by frequencies and percentages with 90% confidence interval (CI) by each dose/cohort. The duration of response (DOR) for complete response (CR) and partial response (PR) patients may be summarized with number of responders, number and percentage of event/censored, and Kaplan-Meier estimate of median DOR with 95% CI. Progression-free survival (PFS) for treated patients may be summarized with number and percentage of patients with PFS by each dose/cohort. PFS may also be summarized using Kaplan-Meier method with 95% CI. The ORR, DOR, and PFS may be determined using RECIST v1.1.

Pharmacokinetic Analysis

[0318] Individual and mean (±SD) serum A-20502 concentration-time data may be tabulated and plotted by dose level/cohort. PK parameters may be tabulated and summarized by dose level/cohort when appropriate and applicable. The impact of immunogenicity on A-20502 exposure may be assessed, tabulated, and summarized by dose level/cohort as data allow. Individual and mean (±SD) C_maxand C_troughof pembrolizumab concentration-time data may be tabulated and plotted by cohort. PK parameters, such as accumulation ratio and attainment of steady state, may be tabulated and summarized by dose level/cohort if the data are available.

Immunogenicity Analysis

[0319] A baseline ADA-positive subject is defined as a subject who has an ADA positive sample at baseline. An ADA-positive subject is a subject with at least one ADA-positive sample relative to baseline after initiation of the treatment. The frequency distribution of baseline ADA-positive subjects and ADA-positive subjects after initiation of the treatment may be summarized for A-20502 and pembrolizumab, respectively.

Pharmacodynamic Analysis

[0320] Selected pharmacodynamic biomarkers will be assessed for meaningful changes between pretreatment and on-treatment tumor and peripheral blood samples.

[0321] The invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

[0322] All references (e.g., publications or patents or patent applications) cited herein are incorporated herein by reference in their entirety and for all purposes to the same extent as if each individual reference (e.g., publication or patent or patent application) was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.

[0323] Other embodiments are within the following claims.

Claims

What is claimed:

1. A method of treating a solid tumor in a human subject, the method comprising administering to the subject

(i) about 0.1 to about 20 mg/kg of an anti-B7-H4 antibody or antigen-binding fragment thereof that specifically binds to human B7-H4 and comprises a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:5, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 6, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:7, a light chain variable region (VL) CDR1 comprising the amino acid sequence of SEQ ID NO:8, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:9, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 10; and

(ii) about 200 mg of an anti-PD-1 antibody or antigen-binding fragment thereof comprising a VH CDR1 comprising the amino acid sequence of SEQ ID NO:34, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:35, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:36, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 37, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:38, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:39.

2. The method of claim 1, wherein about 20 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

3. The method of claim 1, wherein about 10 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

4. The method of claim 1, wherein about 3 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

5. The method of claim 1, wherein about 1 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

6. The method of claim 1, wherein about 0.3 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

7. The method of claim 1, wherein about 0.1 mg/kg of the anti-B7-H4 antibody or antigen-binding fragment thereof is administered to the subject.

8. The method of claim 1, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof are administered concurrently.

9. The method of claim 1, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof are administered sequentially.

10. The method of claim 1, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is administered about once every three weeks.

11. The method of claim 1, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is administered about once every three weeks.

12. The method of claim 1, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof and the anti-PD-1 antibody or antigen-binding fragment thereof are each administered about once every three weeks.

13. The method of claim 1, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence set forth in SEQ ID NO:11 and/or a VL comprising the amino acid sequence set forth in SEQ ID NO: 12.

14. The method of claim 1, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a heavy chain constant region and/or a light chain constant region.

15. The method of claim 14, wherein the heavy chain constant region is a human immunoglobulin IgG1 heavy chain constant region and/or wherein the light chain constant region is a human immunoglobulin IgGκ light chain constant region.

16. The method of claim 1, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a heavy chain constant region comprising the amino acid sequence set forth in SEQ ID NO:25 and/or a light chain constant region comprising the amino acid sequence set forth in SEQ ID NO:23.

17. The method of claim 1, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:21 and/or a light chain comprising the amino acid sequence set forth in SEQ ID NO:22.

18. The method of claim 1, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is a human antibody or antigen-binding fragment thereof.

19. The method of claim 1, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is a full length antibody.

20. The method of claim 1, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is an antigen-binding fragment.

21. The method of claim 20, wherein the antigen-binding fragment comprises a Fab, Fab′, F(ab′)₂, single chain Fv (scFv), disulfide linked Fv, V-NAR domain, IgNar, intrabody, IgGΔCH2, minibody, F(ab′)₃, tetrabody, triabody, diabody, single-domain antibody, DVD-Ig, Fcab, mAb², (scFv)₂, or scFv-Fc.

22. The method of claim 1, wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises a VH comprising the amino acid sequence of SEQ ID NO:32 and a VL comprising the amino acid sequence SEQ ID NO:33.

23. The method of claim 1, wherein the anti-PD-1 antibody or antigen-binding fragment thereof is pembrolizumab.

24. The method of claim 1, the method comprising administering to the subject

(i) 3, 10 or 20 mg/kg of an anti-B7-H4 antibody or antigen-binding fragment thereof that specifically binds to human B7-H4 and comprises a VH comprising the amino acid sequence set forth in SEQ ID NO:11 and a VL comprising the amino acid sequence set forth in SEQ ID NO: 12, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is not detectably fucosylated; and

(ii) 200 mg of pembrolizumab;

wherein (i) and (ii) are administered intravenously as separate formulations on the same day.

25. The method of claim 24, wherein the anti-B7-H4 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:21 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:22.

26. The method of claim 1, the method comprising administering to the subject

(i) about 20 mg/kg of an anti-B7-H4 antibody that specifically binds to human B7-H4 and comprises a VH comprising the amino acid sequence of SEQ ID NO: 11 and a VL comprising the amino acid sequence of SEQ ID NO: 12; and

(ii) about 200 mg of an anti-PD-1 antibody comprising a VH comprising the amino acid sequence of SEQ ID NO:32 and a VL comprising the amino acid sequence of SEQ ID NO:33, wherein the anti-B7-H4 antibody and the anti-PD-1 antibody are administered intravenously about once every three weeks.

27. The method of claim 26, wherein the anti-B7-H4 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 21 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:22.

28. The method of claim 26, wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 30 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:31.

29. The method of claim 27, wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 30 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:31.

30. The method of claim 1, wherein the solid tumor is selected from the group consisting of breast cancer, ductal carcinoma, endometrial carcinoma, ovarian cancer, urothelial cancer, non-small cell lung cancer, pancreatic cancer, thyroid cancer, kidney cancer and bladder cancer.

31. The method of claim 30, wherein the solid tumor is triple negative breast cancer.

32. The method of claim 30, wherein the solid tumor is a hormone-receptor (HR)-positive breast cancer.

33. The method of claim 30, wherein the non-small cell lung cancer is squamous cell carcinoma.

34. The method of claim 1, wherein the patient has not received prior therapy with a PD-1/PD-L1 antagonist.

35. The method of claim 1, wherein the method further comprises monitoring the number of immune cells in the tumor and/or monitoring cytokine levels in the subject.

36. The method of claim 1, wherein the anti-B7-H4 antibody or antigen-binding fragment thereof is present in a pharmaceutical composition comprising a pharmaceutically acceptable excipient, wherein at least 95% of the anti-B7-H4 antibodies or antigen-binding fragments thereof in the composition are afucosylated.

37. The method of claim 36, wherein fucosylation of the anti-B7-H4 antibody or antigen-binding fragment thereof is undetectable in the composition.

38. The method of claim 36, the method comprising administering to the subject

(a) a pharmaceutical composition comprising (i) anti-B7-H4 antibodies that specifically bind to human B7-H4 and comprise a VH comprising the amino acid sequence of SEQ ID NO: 11 and a VL comprising the amino acid sequence of SEQ ID NO: 12 and (ii) a pharmaceutically acceptable excipient, wherein at least 95% of the anti-B7-H4 antibodies thereof in the composition are afucosylated, and wherein about 20 mg/kg of the antibodies are administered; and

(b) a pharmaceutical composition comprising an anti-PD-1 antibody or antigen-binding fragment thereof comprising a VH comprising the amino acid sequence of SEQ ID NO:32 and a VL comprising the amino acid sequence of SEQ ID NO:33 and a pharmaceutically acceptable excipient, wherein about 200 mg of the antibody or antigen-binding fragment thereof is administered,

wherein (a) and (b) are administered intravenously about once every three weeks.

39. The method of claim 38, wherein the anti-B7-H4 antibodies comprise a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 21 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:22.

40. The method of claim 38, wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 30 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:31.

41. The method of claim 39, wherein the anti-PD-1 antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 30 and a light chain comprising the amino acid sequence set forth in SEQ ID NO:31.

Patent Citations (270)

Patent	Date	Inventor	Cited By
US3817837(A)	1974-06-01	Rubenstein et al.	Applicant
US3850752(A)	1974-11-01	Schuurs et al.	Applicant
US3939350(A)	1976-02-01	Kronick et al.	Applicant
US3996345(A)	1976-12-01	Ullman et al.	Applicant
US4275149(A)	1981-06-01	Litman et al.	Applicant
US4277437(A)	1981-07-01	Maggio	Applicant
US4366241(A)	1982-12-01	Tom et al.	Applicant
US4472509(A)	1984-09-01	Gansow et al.	Applicant
US4938948(A)	1990-07-01	Ring et al.	Applicant
US5122464(A)	1992-06-01	Wilson et al.	Applicant
US5196066(A)	1993-03-01	Kusuda et al.	Applicant
US5223409(A)	1993-06-01	Ladner et al.	Applicant
US5225539(A)	1993-07-01	Winter	Applicant
US5403484(A)	1995-04-01	Ladner et al.	Applicant
US5427908(A)	1995-06-01	Dower et al.	Applicant
US5516637(A)	1996-05-01	Huang et al.	Applicant
US5571698(A)	1996-11-01	Ladner et al.	Applicant
US5580717(A)	1996-12-01	Dower et al.	Applicant
US5585097(A)	1996-12-01	Bolt et al.	Applicant
US5624821(A)	1997-04-01	Winter et al.	Applicant
US5648260(A)	1997-07-01	Winter et al.	Applicant
US5658727(A)	1997-08-01	Barbas et al.	Applicant
US5672694(A)	1997-09-01	Campbell et al.	Applicant
US5677425(A)	1997-10-01	Bodmer et al.	Applicant
US5693780(A)	1997-12-01	Newman et al.	Applicant
US5698426(A)	1997-12-01	Huse	Applicant
US5733743(A)	1998-03-01	Johnson et al.	Applicant
US5750753(A)	1998-05-01	Kimae et al.	Applicant
US5780225(A)	1998-07-01	Wigler et al.	Applicant
US5807715(A)	1998-09-01	Morrison et al.	Applicant
US5821047(A)	1998-10-01	Garrard et al.	Applicant
US5869046(A)	1999-02-01	Presta et al.	Applicant
US5965726(A)	1999-10-01	Pavlakis et al.	Applicant
US5969108(A)	1999-10-01	Mccafferty et al.	Applicant
US6121022(A)	2000-09-01	Presta et al.	Applicant
US6165745(A)	2000-12-01	Ward et al.	Applicant
US6174666(B1)	2001-01-01	Pavlakis et al.	Applicant
US6194551(B1)	2001-02-01	Idusogie et al.	Applicant
US6277022(B1)	2001-08-01	Melin	Applicant
US6291664(B1)	2001-09-01	Pavlakis et al.	Applicant
US6414132(B1)	2002-07-01	Pavlakis et al.	Applicant
US6602684(B1)	2003-08-01	Umana et al.	Applicant
US6737056(B1)	2004-05-01	Presta	Applicant
US6794498(B2)	2004-09-01	Pavlakis et al.	Applicant
US6891030(B2)	2005-05-01	Chen	Applicant
US6946292(B2)	2005-09-01	Kanda et al.	Applicant
US7214775(B2)	2007-05-01	Hanai et al.	Applicant
US7304149(B2)	2007-12-01	Murphy et al.	Applicant
US7504256(B1)	2009-03-01	Ogawa et al.	Applicant
US7619068(B2)	2009-11-01	Pilkington et al.	Applicant
US7622565(B2)	2009-11-01	Chen	Applicant
US7658921(B2)	2010-02-01	Dall et al.	Applicant
US7687061(B2)	2010-03-01	Hanai et al.	Applicant
US7709226(B2)	2010-05-01	Foote	Applicant
US7875702(B2)	2011-01-01	Chen	Applicant
US7888477(B2)	2011-02-01	Bangur et al.	Applicant
US7931896(B2)	2011-04-01	Chen	Applicant
US7964195(B2)	2011-06-01	Papkoff et al.	Applicant
US8129347(B2)	2012-03-01	Chen	Applicant
US8182813(B2)	2012-05-01	Brasel et al.	Applicant
US8206715(B2)	2012-06-01	Wong et al.	Applicant
US8236767(B2)	2012-08-01	Chen	Applicant
US8263079(B2)	2012-09-01	Doody et al.	Applicant
US8323645(B2)	2012-12-01	Veiby et al.	Applicant
US8444971(B2)	2013-05-01	Papkoff et al.	Applicant
US8513199(B2)	2013-08-01	Brasel et al.	Applicant
US8591886(B2)	2013-11-01	Ponath et al.	Applicant
US8609816(B2)	2013-12-01	Korman et al.	Applicant
US8652465(B2)	2014-02-01	Freeman et al.	Applicant
US8703916(B2)	2014-04-01	Chen	Applicant
US8759490(B2)	2014-06-01	Veiby et al.	Applicant
US8906369(B2)	2014-12-01	Papkoff et al.	Applicant
US9005616(B2)	2015-04-01	Langermann et al.	Applicant
US9011853(B2)	2015-04-01	Langermann et al.	Applicant
US9121853(B2)	2015-09-01	Kwon et al.	Applicant
US9221910(B2)	2015-12-01	Fertig et al.	Applicant
US9279008(B2)	2016-03-01	Scholler et al.	Applicant
US9296822(B2)	2016-03-01	Korman et al.	Applicant
US9421277(B2)	2016-08-01	Veiby et al.	Applicant
US9422351(B2)	2016-08-01	Scholler et al.	Applicant
US9447186(B2)	2016-09-01	Zang et al.	Applicant
US9555124(B2)	2017-01-01	Chen	Applicant
US9562099(B2)	2017-02-01	Leong et al.	Applicant
US9574000(B2)	2017-02-01	Langermann et al.	Applicant
US9676854(B2)	2017-06-01	Liu et al.	Applicant
US9926378(B2)	2018-03-01	Veiby et al.	Applicant
US9957312(B2)	2018-05-01	Langermann et al.	Applicant
US10059768(B2)	2018-08-01	Leong et al.	Applicant
US11306144(B2)	2022-04-01	Kaplan et al.	Applicant
US11814431(B2)	2023-11-01	Kaplan	Examiner
US2003/0055224(A1)	2003-03-01	Gao et al.	Applicant
US2003/0060612(A1)	2003-03-01	Goddard et al.	Applicant
US2003/0165504(A1)	2003-09-01	Retter et al.	Applicant
US2003/0181692(A1)	2003-09-01	Ni et al.	Applicant
US2003/0208058(A1)	2003-11-01	Fiscella et al.	Applicant
US2004/0014194(A1)	2004-01-01	Beyer et al.	Applicant
US2004/0126807(A1)	2004-07-01	Goddard et al.	Applicant
US2005/0163772(A1)	2005-07-01	Dong et al.	Applicant
US2006/0088523(A1)	2006-04-01	Andya et al.	Applicant
US2006/0223077(A1)	2006-10-01	Ni et al.	Applicant
US2006/0253928(A1)	2006-11-01	Bakker et al.	Applicant
US2007/0036783(A1)	2007-02-01	Humeau et al.	Applicant
US2007/0178551(A1)	2007-08-01	Gerngross	Applicant
US2007/0218032(A1)	2007-09-01	Kwon et al.	Applicant
US2007/0248600(A1)	2007-10-01	Hansen et al.	Applicant
US2008/0050370(A1)	2008-02-01	Glaser et al.	Applicant
US2008/0060092(A1)	2008-03-01	Dickey et al.	Applicant
US2008/0206235(A1)	2008-08-01	Chen	Applicant
US2009/0005301(A1)	2009-01-01	Ni et al.	Applicant
US2009/0118175(A1)	2009-05-01	Macina	Applicant
US2009/0176317(A1)	2009-07-01	Kwon et al.	Applicant
US2009/0226530(A1)	2009-09-01	Lassner et al.	Applicant
US2011/0020325(A1)	2011-01-01	Kwon et al.	Applicant
US2011/0085970(A1)	2011-04-01	Terrett et al.	Applicant
US2012/0014947(A1)	2012-01-01	Fu	Applicant
US2013/0078234(A1)	2013-03-01	Takahashi et al.	Applicant
US2014/0037551(A1)	2014-02-01	Zang et al.	Applicant
US2014/0294861(A1)	2014-10-01	Scholler et al.	Applicant
US2014/0322129(A1)	2014-10-01	Leong et al.	Applicant
US2014/0335541(A1)	2014-11-01	Kwon et al.	Applicant
US2014/0356364(A1)	2014-12-01	Liu et al.	Applicant
US2014/0364585(A1)	2014-12-01	Zhang et al.	Applicant
US2015/0315275(A1)	2015-11-01	Liu et al.	Applicant
US2016/0017040(A1)	2016-01-01	Leong et al.	Applicant
US2016/0146806(A1)	2016-05-01	Langermann et al.	Applicant
US2016/0159910(A1)	2016-06-01	Leong et al.	Applicant
US2016/0185870(A1)	2016-06-01	Van et al.	Applicant
US2016/0304581(A1)	2016-10-01	Zang et al.	Applicant
US2016/0304607(A1)	2016-10-01	Sadineni et al.	Applicant
US2017/0015758(A1)	2017-01-01	Hammond et al.	Applicant
US2017/0029525(A1)	2017-02-01	Zang et al.	Applicant
US2017/0044259(A1)	2017-02-01	Tipton et al.	Applicant
US2017/0044268(A1)	2017-02-01	Gurney et al.	Applicant
US2017/0143827(A1)	2017-05-01	Sadineni et al.	Applicant
US2017/0158771(A1)	2017-06-01	Glennie et al.	Applicant
US2017/0204185(A1)	2017-07-01	Chen	Applicant
US2017/0233808(A1)	2017-08-01	Haining et al.	Applicant
US2017/0334999(A1)	2017-11-01	Sathyanarayanan	Examiner
US2018/0106862(A1)	2018-04-01	Whetsel	Applicant
US2018/0106864(A1)	2018-04-01	Moeneclaey	Applicant
US2018/0118831(A1)	2018-05-01	Epstein et al.	Applicant
US2018/0186878(A1)	2018-07-01	Rosenthal	Applicant
US2019/0085080(A1)	2019-03-01	Kaplan et al.	Applicant
US2020/0081497(A1)	2020-03-01	Hung et al.	Applicant
US2020/0255528(A1)	2020-08-01	Kaplan et al.	Applicant
US2021/0070861(A1)	2021-03-01	Quan et al.	Applicant
US2021/0070862(A1)	2021-03-01	Inamdar et al.	Applicant
US2021/0079096(A1)	2021-03-01	Kaplan et al.	Applicant
US2024/0043542(A1)	2024-02-01	Kaplan et al.	Applicant
CN101951959(A)	2011-01-01		Applicant
CN104945508(A)	2015-09-01		Applicant
CN106804108(A)	2017-06-01		Applicant
CN107299085(A)	2017-10-01		Applicant
CN107405401(A)	2017-11-01		Applicant
CN111094352(A)	2020-05-01		Applicant
CN111868089(A)	2020-10-01		Applicant
CN111971308(A)	2020-11-01		Applicant
EP1331266(A1)	2003-07-01		Applicant
SG162030(A1)	2010-07-01		Applicant
WO1986/05807(A1)	1986-10-01		Applicant
WO1989/01036(A1)	1989-02-01		Applicant
WO1990/02809(A1)	1990-03-01		Applicant
WO1991/10737(A1)	1991-07-01		Applicant
WO1992/01047(A1)	1992-01-01		Applicant
WO1992/18619(A1)	1992-10-01		Applicant
WO1993/11236(A1)	1993-06-01		Applicant
WO1994/29351(A2)	1994-12-01		Applicant
WO1995/15982(A2)	1995-06-01		Applicant
WO1995/20401(A1)	1995-08-01		Applicant
WO1997/13844(A1)	1997-04-01		Applicant
WO1997/34631(A1)	1997-09-01		Applicant
WO1998/23289(A1)	1998-06-01		Applicant
WO1999/54342(A1)	1999-10-01		Applicant
WO2000/36107(A2)	2000-06-01		Applicant
WO2000/42072(A2)	2000-07-01		Applicant
WO2000/61739(A1)	2000-10-01		Applicant
WO2001/29246(A1)	2001-04-01		Applicant
WO2001/40269(A2)	2001-06-01		Applicant
WO2001/62891(A2)	2001-08-01		Applicant
WO2002/02587(A1)	2002-01-01		Applicant
WO2002/06317(A2)	2002-01-01		Applicant
WO2002/10187(A1)	2002-02-01		Applicant
WO2002/16581(A2)	2002-02-01		Applicant
WO2002/30954(A1)	2002-04-01		Applicant
WO2002/31140(A1)	2002-04-01		Applicant
WO2002/60919(A2)	2002-08-01		Applicant
WO2002/71928(A2)	2002-09-01		Applicant
WO2003/04989(A2)	2003-01-01		Applicant
WO2002/62203(A3)	2003-02-01		Applicant
WO2003/76579(A2)	2003-09-01		Applicant
WO2003/11878(A3)	2003-11-01		Applicant
WO2003/97802(A2)	2003-11-01		Applicant
WO2003/97803(A2)	2003-11-01		Applicant
WO2003/104399(A2)	2003-12-01		Applicant
WO2003/104438(A2)	2003-12-01		Applicant
WO2004/000221(A2)	2003-12-01		Applicant
WO2004/058167(A2)	2004-07-01		Applicant
WO2004/065540(A2)	2004-08-01		Applicant
WO2004/101756(A2)	2004-11-01		Applicant
WO2004/113500(A2)	2004-12-01		Applicant
WO2005/035724(A2)	2005-04-01		Applicant
WO2005/051990(A2)	2005-06-01		Applicant
WO2005/052121(A2)	2005-06-01		Applicant
WO2005/062788(A2)	2005-07-01		Applicant
WO2003/101400(A3)	2005-09-01		Applicant
WO2006/053110(A2)	2006-05-01		Applicant
WO2006/074418(A2)	2006-07-01		Applicant
WO2006/098887(A2)	2006-09-01		Applicant
WO2006/104677(A2)	2006-10-01		Applicant
WO2006/105021(A2)	2006-10-01		Applicant
WO2006/121991(A2)	2006-11-01		Applicant
WO2006/133396(A2)	2006-12-01		Applicant
WO2007/001459(A2)	2007-01-01		Applicant
WO2007/005874(A2)	2007-01-01		Applicant
WO2007/039818(A2)	2007-04-01		Applicant
WO2007/067991(A2)	2007-06-01		Applicant
WO2007/082154(A2)	2007-07-01		Applicant
WO2008/067283(A2)	2008-06-01		Applicant
WO2008/071447(A2)	2008-06-01		Applicant
WO2008/083228(A2)	2008-07-01		Applicant
WO2008/083239(A2)	2008-07-01		Applicant
WO2008/154333(A2)	2008-12-01		Applicant
WO-2008/156712(A1)	2008-12-01		Applicant
WO2009/009116	2009-01-01		Applicant
WO2009/036379(A2)	2009-03-01		Applicant
WO2009/073533(A2)	2009-06-01		Applicant
WO2010/105256(A1)	2010-09-01		Applicant
WO2011/020024(A2)	2011-02-01		Applicant
WO2011/028683	2011-03-01		Applicant
WO2012/009568(A2)	2012-01-01		Applicant
WO2012/130831(A1)	2012-10-01		Applicant
WO2012/145493(A1)	2012-10-01		Applicant
WO2013/025779(A1)	2013-02-01		Applicant
WO2013/067492(A1)	2013-05-01		Applicant
WO2013/079174(A1)	2013-06-01		Applicant
WO2014/100439(A2)	2014-06-01		Applicant
WO2014/100483(A1)	2014-06-01		Applicant
WO2014/100823(A1)	2014-06-01		Applicant
WO2014/159835(A1)	2014-10-01		Applicant
WO2014/194293(A1)	2014-12-01		Applicant
WO2015/017600(A1)	2015-02-01		Applicant
WO2015/031667(A2)	2015-03-01		Applicant
WO2015/069770(A1)	2015-05-01		Applicant
WO2016/040724(A1)	2016-03-01		Applicant
WO2016/070001(A1)	2016-05-01		Applicant
WO-2016137985(A1)	2016-09-01		Applicant
WO2016/168771(A2)	2016-10-01		Applicant
WO2016/197204(A1)	2016-12-01		Applicant
WO2017/011580(A2)	2017-01-01		Applicant
WO2017/015623(A2)	2017-01-01		Applicant
WO2017/019846(A1)	2017-02-01		Applicant
WO2017/048878(A1)	2017-03-01		Applicant
WO2017/058754(A1)	2017-04-01		Applicant
WO2017/079117(A1)	2017-05-01		Applicant
WO2017/106656(A1)	2017-06-01		Applicant
WO2017/129790(A1)	2017-08-01		Applicant
WO2017/147368(A1)	2017-08-01		Applicant
WO2017/149150(A1)	2017-09-01		Applicant
WO2017/201502(A1)	2017-11-01		Applicant
WO2018/049474(A1)	2018-03-01		Applicant
WO2018/075978(A1)	2018-04-01		Applicant
WO2018/078145(A1)	2018-05-01		Applicant
WO2018/098363(A2)	2018-05-01		Applicant
WO2018/106862(A1)	2018-06-01		Applicant
WO2018/106864(A1)	2018-06-01		Applicant
WO2019/040780(A1)	2019-02-01		Applicant
WO2019/165075(A1)	2019-08-01		Applicant
WO2019/165077(A1)	2019-08-01		Applicant
WO2019/169212(A1)	2019-09-01		Applicant
WO2020/081497(A1)	2020-04-01		Applicant

Non-Patent Literature (250)

Freshwater et al, 2017. Journal for Immunotherapy of Cancer: 5:43; 9 pages as printed.Examiner
Abadi et al., Host B7x promotes pulmonary metastasis of breast cancer, J. Immun., 190(7):3806-3814 (2013).Applicant
Abdiche et al., Assessing kinetic and epitopic diversity across orthogonal monoclonal antibody generation platforms, mAbs, 8:264-277 (2016).Applicant
Abdiche et al., Exploring blocking assays using octet, prote on, and biacore biosensors, Analytical Biochem., 386(2):172-180 (2009).Applicant
Al-Lazikani et al., Standard conformations for the canonical structures of Immunoglobulins, J. Mol. Biol., 273:927-948 (1997).Applicant
Ames et al., Conversion of murine fabs isolated from a combinatorial phage display library to full length immunoglobulins, J. Immunol. Methods, 184(2):177-186 (1995).Applicant
Anderson et al., Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study, J. Natl. Cancer Institute, 102(1):26-38 (2010).Applicant
Arigami et al., Expression of B7-H4 in blood of patients with gastric cancer predicts tumor progression and prognosis, J. Surgical Oncology, 102:748-752 (2010).Applicant
Arnold et al., The impact of glycosylation on the biological function and structure of human Immunoglobulins, Ann. Rev. Immun., 25: 21-50 (2007).Applicant
ATCC Catalog No. PTA-5180—Mouse hybridoma: Ovr110 A57.1, 2 pages.Applicant
Ausubel et al., Current protocols in molecular biology, Greene publishing and wiley interscience, New York, TOC, 7 (1987).Applicant
Awadallah et al., Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct, Pancreas, 36(2):200-6 (2008).Applicant
Azuma et al., Potential role of decoy b7-h4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data, PLOS Medicine, 6(10):1-15, e1000166, Public Library of Science, United States (2009).Applicant
Balwit et al., The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program, J. Translational Medicine, 9:18 (2011).Applicant
Barach et al., Tcell conihibition in prostate cancer: new immune evasion pathways and emerging therapeutics, Trends Mol. Med., 17(1):47-55 (2011).Applicant
Boyd et al., Deep sequencing and human antibody repertoire analysis, Current Opinion in Immunology, 40:103-109 (2016).Applicant
Bregar et al., Characterization of immune regulatory molecules b7-h4 and pd-l1 in low and high grade endometrial tumors, Gynecologic Oncology, 145(3):446-452 (2017).Applicant
Bricogne, Bayesian statistical viewpoint on structure determination: basic concepts and examples, Meth. Enzymol., 276:361-423 (1997).Applicant
Bricogne, Direct phase determination by entropy maximization and likelihood ranking: status report and perspectives, Acta. Crystallogr D. Biol. Crystallogr., D49(Pt 1):37-60 (1993).Applicant
Brinkman et al., Phage display of disulfide-stabilized fv fragments, J. Immunol. Methods, 182:41-50 (1995).Applicant
Burton et al., Human antibodies from combinatorial libraries, Advances in Imnunology, 57:191-280 (1994).Applicant
Carreno et al., Therapeutic opportunities in the b7/cd28 family of ligands and receptors, Current Opinion in Pharmacology, 5(4):424-430 (2005).Applicant
Champe et al., Monoclonal antibodies that block the activity of leukocyte function-associated antigen 1 recognize three discrete epitopes in the inserted domain of CD11a, J. Biol. Chem., 270:1388-1394 (1995).Applicant
Chayen, The role of oil in macromolecular crystallization, Structure, 5(10):1269-1274 (1997).Applicant
Chen et al., Analysis of B7-H4 expression in metastatic pleural adenocarcinoma and therapeutic potential of its antagonists, BMC Cancer, 17(1):652 (2017).Applicant
Chen et al., B7-H4 Expression associates with cancer progression and predicts patient's survival in human esophageal squamous cell carcinoma, Cancer Immunology Immunotherapy, 60(7):1047-1055 (2011).Applicant
Chen et al., Increase of circulating B7-H4-expressing CD68+macrophage correlated with clinical stage of lung carcinomas, J. Immunotherapy, 35(4):354-358 (2012).Applicant
Chen et al., Increased B7-H4 Expression during esophageal squamous cell carcinogenesis is associated with IL-6/STAT3 signaling pathway activation in mice, Oncology Letters, 13(4):2207-2215 (2017).Applicant
Chen et al., Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape, Cancer Letters, 317(1):99-105 (2012).Applicant
Chen et al., Nuclear localization of B7-H4 in pulmonary adenocarcinomas presenting as a solitary pulmonary nodule, Oncotarget, 7(36):58563-58568 (2016).Applicant
Chen et al., Overexpression of B7-H4 in Tumor infiltrated dendritic cells, J. Immun. Immunochemistry, 32(4):353-364 (2011).Applicant
Chen et al., The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer, Onco. Targets and Therapy, 7:1465-1472 (2014).Applicant
Cheung et al., Epitope-specific antibody response to the surface antigen of duck hepatitis b virus in infected ducks, Virology, 176(2):546-552 (1990).Applicant
Chinnadurai et al., B7-H4 Mediates inhibition of T cell responses by activated murine hepatic stellate cells, Hepatology, 52(6):2177-2185 (2010).Applicant
Choi et al., Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family, J. Immunology, 171(9):4650-4654 (2003).Applicant
Chothia et al., Canonical structures for the hypervariable regions of immunoglobulins, J. Moi. Biol., 196(4):901-917 (1987).Applicant
Chothia et al., Structural repertoire of the human VH segments, J. Mol. Biol., 227(3):799-817 (1992).Applicant
Chumsae et al., Discovery of a chemical modification by citric acid in a recombinant monoclonal antibody, Analytical Chemistry, 86(18):8932-8936 (2014).Applicant
Clackson et al., Making antibody fragments using phage display libraries, Nature, 352:624-628 (1991).Applicant
Coales et al., Epitope mapping by amide hydrogen/deuterium exchange coupled with immobilization of antibody, on-line proteolysis, liquid chromatography and mass spectrometry, Rapid Commun. Mass Spectrom., 23(5):639-647 (2009).Applicant
Cockett et al., High level expression of tissue inhibitor of metalloproteinases in chinese hamster ovary cells using glutamine synthetase gene amplification, Bio/Technology, 8(7):662-667 (1990).Applicant
Conroy et al., Antibodies: From novel repertoires to defining and refining the structure of biologically important targets, Methods, 116:12-22 (2017).Applicant
Cui et al., B7-H4 is predictive of poor prognosis in patients with gastric cancer, Med. Sci. Monitor, 22:4233-4237 (2016).Applicant
Cunningham et al., High-resolution epitope mapping of hGH-receptor interactions by alanine-scanning mutagenesis, Science, 244:1081-1085 (1989).Applicant
D'Aria et al., Abstract# 1601: B7-H4 (DD-O110) is overexpressed in endocervicai adenorcarcinoma in situ and invasive adenocarcinoma, Cancer Research, retrieved from https//cacerres.aacrjournals.org/content/59/9_Supplement/1601, last visited Apr. 30, 2020, 4 (2009).Applicant
Dall'Acqua et al., Properties of human IgG1s engineered for enhanced binding to the neonatal Fe receptor (FcRn), J. Biol. Chem., 281(33):23514-23524 (2006).Applicant
Damschroder et al., Analysis of human and primate CD2 molecules by protein sequence and epitope mapping with anti-human CD2 antibodies, Molecular Immunology, 41:985-1000 (2004).Applicant
Dangaj et al., Blocking the B7-H4 pathway with novel recombinant antibodies enhances T cell-mediated antitumor responses, Oncolmmunology, 2:8 e25913 (2013).Applicant
Dangaj et al., novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate t-cell antitumor responses, Cancer Research, 73(15):4820-4829 (2013).Applicant
Davies et al., Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII, Biotechnol. Bioeng., 74(4):288-294 (2001).Applicant
Driessens et al., Costimulatory and coinhibitory receptors in anti-tumor immunity, Immunol. Rev., 229(1):126-144 (2009).Applicant
Li et al., Progress in molecular typing of triple negative breast cancer, Journal of New Medicine, No. 2 (2018).Applicant
Wang et al., B7-H4 Overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer, Cancer Cell International, 18:100 (2018).Applicant
Wang et al., Could B7-H4 serve as a target to activate anti-cancer immunity? International Immunopharmacology, 38: 97-103 (2016).Applicant
Wang et al., Roles of coinhibitory molecules B7-H3 and B7-H4 in esophageal squamous cell carcinoma, Tumour Biology, Online Publication, Springer Publishing, United States 1-11 (2015).Applicant
Wilcox et al., CD14+ hla-DR-/Lo Myeloid-derived suppressor cens express immunosuppressive B7-H family members and are depleted following taxane-based chemotherapy in melanoma, Blood, 114(22):464, 2020, 6 (2009).Applicant
Wu et al., Abstract 547: Development of antigen-targeted vaccines and immune checkpoint inhibitors for cancer therapy, immune response modifiers: Cancer Vaccines, 1 (No Date).Applicant
Xu et al., Addressing polyspecificity of antibodies selected from an in vitro yeast presentation system: a FAGS-based, high-throughput selection and analytical tool, PEDS, (26)10: 663-70 (2013).Applicant
Xu et al., B7-H3 and B7-H4 Are independent predictors of a poor prognosis in patients with pancreatic cancer, Oncol. Letters, 11(3):1841-1846 (2016).Applicant
Yamane-Ohnuki et al., Establishment of FUT8 knockout chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity, Wiley Interscience, Advance Publication Online, 1-9 (2004).Applicant
Ye et al., Does B7-H4 expression correlate with clinicopathologic characteristics and survival in ovarian cancer?: a systematic review and prisma-compliant meta-analysis, Medicine, 97(32):e11821 (2018).Applicant
Zang et al., B7-H3 and B7x Are highly expressed in human prostate cancer and associated with disease spread and poor outcome, Proc. Natl. Acad. Sci., 104(49):19458-19463 (2007).Applicant
Zang et al., B7x: a Widely expressed B7 family member that inhibits T cell activation, Proc. Natl. Acad. Sci., 100(18):10388-10392 (2003).Applicant
Zhang et al., B7-H4 Promotes tumor growth and metastatic progression in lung cancer by impacting cell proliferation and survival, Oncotarget, 8(12):18861-18871 (2017).Applicant
Zhang et al., Circulating B7-H4 in serum predicts prognosis in patients with hepatocellular carcinoma, Genetics and Molecular Research, 14(4):13041-13048 (2015).Applicant
Zhang et al., Preparation and characterization of monoclonal antibody against human B7-H4 molecule, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 33(4):270-274 (2014).Applicant
Zhang et al., The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus, Oncogene, 32(46): 5347-5358 (2013).Applicant
Zhou et al., Silencing of B7-H4 suppresses the tumorigenicity of the Mgc-803 human gastric cancer cell line and promotes cell apoptosis via the mitochondrial signaling pathway, Int. J. Oncology, 52(4):1267-1276 (2018).Applicant
Zhou et al., Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors, Cell, 161:1280-1292 (2015).Applicant
Zhu et al., B7-H4 Expression is associated with cancer progression and predicts patient survival in human thyroid cancer, Asian Pacific J. Cancer Prevention, 14(5):3011-3015 (2013).Applicant
Zou, Immunosuppressive networks in the tumour environment and their therapeutic relevance, Nature Reviews, 5:263-274 (Apr. 2005, e-pub. Mar. 18, 2015).Applicant
Arosio, P. et al, Aggregation mechanism of an IgG2 and two IgG1 monoclonal antibodies at low pH: from oligomers to larger aggregates, Pharm Res., 30(3): 641-54 (2013).Applicant
Caldas et al. Humanization of the anti-CD18 antibody 6.7: an unexpected effect of a framework residue in binding to antigen, Mol. Immunol., 39(15):941-952 (2003).Applicant
Casadevall et al., Immunoglobulin isotype influences affinity and specificity, Proceedings of the National Academy of Sciences, 109(31):12272-12273 (2012).Applicant
Daugherty et al., “Chapter 8: Formulation and delivery issues for monoclonal antibody therapeutics”, Curr. Tren. in Mon. Ant. Dev. Man., 103-129 (2010).Applicant
Du et al., Molecular Basis of Recognition of Human Osteopontin by 23C3, a Potential Therapeutic Antibody for Treatment of Rheumatoid Arthritis, Journal of Molecular Biology, 382(4):835-842 (2008).Applicant
Hyungjun J. et al., Structure and Cancer Immunotherapy of the B7 Family Member B7x, Cell Reports, Elesvier Ind., 9(3): 1089-1098 (2014).Applicant
Kunik et al., Structural Consensus among Antibodies Defines the Antigen Binding Site, PLOS Computational Biology, 8(2):e1002388 (2012).Applicant
Pozsgai, E., et al., β-Sarcoglycan Gene Transfer Leads to Functional Improvement in a Model of LGMD2E (S61.002), Neurology, 82(10):1-3 (2014).Applicant
Stanton et al., Clinical significance of tumor-infiltrating lymphocytes in breast cancer, J. Immunotherapy Cancer, 4:59 (2016).Applicant
Shimazaki, Japanese Journal of Zootechnical Science, 61(7): 655-660 (1990).Applicant
Wang et al., Antibody Structure, Instability, and Formulation, Journal of Pharmaceutical Sciences, 96(1):1-26 (2007).Applicant
Presta et al., Engineering therapeutic antibodies for improved function, Biochemical Society Transactions, 30(4):487-490 (2002).Applicant
Qian et al., B7-H4 Expression in various tumors determined using a novel developed monoclonal antibody, Clinical and Experimental Medicine, 11(3):163-170 (2011).Applicant
Qian et al., Development of a novel monoclonal antibody to B7-H4: characterization and biological activity, European Journal of Medical Research, 16(7):295-302 (2011).Applicant
Rabinovich et al., Immunosuppressive strategies that are mediated by tumor cells, Annu. Rev. Immunol., 25:267-296 (2007).Applicant
Rader et al., A phage display approach for rapid antibody humanization: designed combinatorial v gene libraries, PNAS., 95:8910-8915 (1998).Applicant
Rahbar et al., B7-H4 Expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity, Cancer Immunology Research, 3(2):184-195 (2015).Applicant
Rahbar et al., B7-H4 is a positive regulator of antitumor immunity, Oncoimmunology, 5(1):e1050575 (2016).Applicant
Raju, Glycosylation variations with expression systems and their impact on biological activity of therapeutic Immunoglobulins, BioProcess International, 1(4):44-53 (2003).Applicant
Riechmann et al., Reshaping human antibodies for therapy, Nature, 332:323-329 (1988).Applicant
Roguska et al., A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing, Protein Eng., 9(10):895-904 (1996).Applicant
Roguska et al., Humanization of murine monoclonal antibodies through variable domain resurfacing, Proc. Natl. Acad. Sci. USA, 91(3):969-973 (1994).Applicant
Routier et al., Tile glycosylation pattern of a humanized IgGI antibody (01 .3) expressed in CHO cells, Glycoconjugate Journal, 14:201-207 (1997).Applicant
Roversi et al., Modelling prior distributions of atoms for macro-molecular refinement and completion, Acta. Crystallogr. D. Biol. Crystallogr., 56(Pt 10):1316-1323 (2000).Applicant
Sadun et al., Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy, Cancer Therapy: Preclinical, 13(13):4016-4025 (2007).Applicant
Salceda et al., The immunomodulatory protein B7-H4 is overexpressed in breast and ovarian cancers and promotes epithelial cell transformation, Experimental Cell Research, 306(1):128-141 (2005).Applicant
Sambrook et al., Molecular cloning: a laboratory manual, 3rd edition, J.F. Sambrook and D.W. Russell, ed., Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2:107 (2001).Applicant
Sankin et al., The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: What lies beneath the tip of the iceberg, PD-L1, Urologic Oncology, 36(10):459-468 (2018).Applicant
Schalper et al., Differential expression and significance of PD-L1, IDO-1, and B7-H4 in human lung cancer, Clin. Cancer Research, 23(2):370-378 (2017).Applicant
Seliger et al., 'The complex role of B7 molecules in rumor immunology., Trends Mol. Med., 14(12):550-559 (2008).Applicant
Shaffer et al., Dissecting the tumor micro-environment in triple negative breast cancer identifies a mutually exclusive expression pattern of the immune co-inhibitory molecules B7-H 4 and PD-L1, Journal for Immunotherapy of Cancer, 3(2):017 (2015).Applicant
Sheehan et al., Phage and yeast display, Microbiol. Spectr., 3(1):AID-0028-2014 (2015).Applicant
Shen et al., B7-H4 Is a prognostic biomarker for poor survival in patients with pancreatic cancer, Human Pathology, 66:79-85 (2017).Applicant
Shi et al., Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer, World Journal of Surgical Oncology, 12:188 (2014).Applicant
Shields et al., High resolution mapping of the binding site on human IgG1 for FcyRI, FcyII. FcyIII, and FcRn and design of IgG1 variants with improved binding to the FcyR, J. Biol. Chem., 276(9):6591-6604 (2001).Applicant
Shields et al., Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcyRIII and antibody-dependent cellular toxicity, J. Biol. Chem., 277:26733-26740 (Jul. 26, 2002, e-pub. May 1, 2002).Applicant
Shinkawa et al., The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity, J. Biol. Chemistry, 278(5):3466-3473 (2003).Applicant
Shrestha et al., Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma, Frontiers in Oncology, 8:269 (2018).Applicant
Sica et al., B7-H4, a Molecule of the B7 family, Negatively regulates T cell immunity, Immunity, 18(6):849-861 (2003).Applicant
Siegel et al., High efficiency recovery and epitope-specific sorting of an scFv yeast display library, J. Immunol. Methods, 286(1-2):141-153, (2004).Applicant
Simon et al., B7-H4 is a novel membrane-bound protein and a candidate serum and tissue biomarker for ovarian cancer, Cancer Research, 66(3):1570-1575 (2006).Applicant
Simon et al., B7-H4 Is over-expressed in early-stage ovarian cancer and is independent of CA125 expression, Gynecologic Oncology, 106(2):334-341 (2007).Applicant
Simon et al., Evaluation of B7-H4 (DD-O110) as a prognostic marker in tissue and serum of ovarian cancer patients, Cancer Research, Abstract 4882, retrieved from https://cancerres.aacrjournals.org/content/65/9_Supplement/1153.2, last visited Apr. 30, 2020, 4 (2005).Applicant
Smith et al., B7-H4 as a potential target for immunotherapy for gynecologic cancers: A closer look, Gynecologic Oncology, 134(1):181-189 (2014).Applicant
Smith et al., Mouse model recapitulating human fey receptor structural and functional diversity, PNAS, 109(16):6181-6186 (Apr. 17, 2012, e-pub. Apr. 2, 2012).Applicant
Smith et al., Tumor regression and delayed onset toxicity following B7-H4 car T cell therapy, Mol. Therapy, 24(11):1987-1999 (2016).Applicant
Song et al., Prognostic role of high B7-H4 expression in patients with solid tumors: a meta-analysis, Oncotarget, Advance Publications:1-11, Impact Journals, United States (2016).Applicant
Sood, PDEF and PDEF-induced proteins as candidate tumor antigens for T cell and antibody-mediated immunotherapy of breast cancer, Immunol. Res., 46:206-215 (2010, e-pub. Sep. 10, 2009).Applicant
Sun et al., B7-H3 and B7-H4 expression in non-small-cell lung cancer, Lung Cancer, 53(2):143-151 (2006).Applicant
Tan et al., Prognostic role of B7-H4 in patients with non-small cell lung cancer: A meta-analysis, Oncotarget, 8(16):27137-27144 (2017).Applicant
Terrett et al., Preclinical development of anti B7-H4 therapeutic antibodies, Cancer Research, Abstract 4986, retrieved from https://canerres.accrjournals.org/content/68/9 Supplement/4986, last visited Apr. 30, 2020, 3 (2008).Applicant
Thompson et al., B7-H1, Glycoprotein blockade: A novel strategy to enhance immunotherapy in patients with renal cell carcinoma., Urology, 66(Suppl. 5A):10-14 (2005).Applicant
Thompson et al., Serum-soluble B7x Is elevated in renal cell carcinoma patients and is associated with advanced stage, Cancer Research, 68(15):6054-6058 (2008).Applicant
Tramontano et al., Framework residue 71 is a major determinant of the position and conformation of the second hypervariable region in the vh domains of Immunoglobulins, J. Mol. Biol., 215(1):175-182 (1990).Applicant
Tringler et al., B7-H4 is highly expressed in ductal and lobular breast cancer, Clinical Cancer Research, 11(5):1842-1848 (2005).Applicant
Tringler et al., B7-H4 overexpression in ovarian tumors, Gynecologic Oncology, 100(1):44-52 (2006).Applicant
Umana et al., Engineered glycoforms of an antineuro-Biastoma IgG 1 with optimized antibody-dependent cellular cytotoxic activity, Nat. Biotechnol., 17:176-180 (1999).Applicant
Van Regenmortel, MHV., Development of a preventive HIV vaccine requires solving inverse problems which is unattainable by rational vaccine design, Front. Immunol., 8:2009 (2018).Applicant
Verhoeyen et al., Reshaping human antibodies: Grafting an antilysozyme activity, Science, 239(4857):1534-1536 (1988).Applicant
Wagener et al., Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: a systematic approach for the determination of epitope specificities of monoclonal antibodies, J. Immunol., 130(5):2308-2315 (1983).Applicant
Wagener et al., Use of biotin-labeled monoclonal antibodies and avidin-peroxidase conjugates for the determination of epitope specificities in a solid-phase competitive enzyme immunoassay, J. Immunol. Methods, 68(1-2):269-274 (1984).Applicant
Jun Gong et al., “Development of PD-1 and PDL1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations”, Journal for Immuno Therapy of Cancer, vol. 6, No. 8, pp. 1-18 (2018).Applicant
Epstein, A.L., B7-H4 as a target for breast cancer immunotherapy, Research Grant W81XWH-11-1-0466, 18 (2012).Applicant
Estep et al., High throughput solution-based measurement of antibody-antigen affinity and epitope binning, MAbs, 5(2):270-278 (2013).Applicant
Fan et al., B7-H4 expression is Correlated With Tumor Progression and Clinical Outcome in Urothelial Cell Carcinoma, International Journal of Clinical and Experimental Pathology, 7(10):6768-6775 (Oct. 1, 2014, e-pub. Sep. 15, 2014).Applicant
Ferrara et al., Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of golgi enzyme localization domain and co-expression of heterologous b1, 4-n-acetylglucosaminyltransferase III and golgi a-mannosidase, Biotechnology and Bioengineering, 93(5):851-861 (2006, e-pub. Jan. 24, 2006).Applicant
Ferrara et al., Recombinant renewable polyclonal antibodies, mAbs, 7:32-41 (2015).Applicant
Ferreira et al., Circulating tumor cell technologies, Mol. Oncol., 10(3):374-94 (2016).Applicant
Filies et al., The new B7s: Playing a pivotal role in tumor immunity, J. Immunother., 30:251-260 (2007).Applicant
Foecking et al., Powerful and versatile enhancer-promoter unit for mammalian expression vectors, Gene, 45(1):101-105 (1986).Applicant
Fukuda et al., Higher preoperative serum levels of pd-l1 and b7-h4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma, Cancer Medicine, 5(8):1810-1820 (2016).Applicant
Gao et al., Effect of VTCN1 on progression and metastasis of ovarian carcinoma in vitro and vivo, Biomedicine & Pharmacotherapy, 73:129-134 (2015).Applicant
GCC Office Action, dated Jan. 20, 2020, for GCC Patent Application No. GC2018-35987, 6 pages.Applicant
Geng et al., Expression of costimulatory molecules B7-H1, B7-H4 and Foxp3+tregs in gastric cancer and its clinical significance, Int. J. Clin. Oncology, 20(2):273-281 (2015).Applicant
Giege et al., Crystallogenesis of biological macromolecules: Facts and perspectives, Acta Crystallogr D. Biol. Crystallogr., 50(Pt 4):339-350 (1994).Applicant
Goding, Production of monoclonal antibodies, Chapter 3 in monoclonal antibodies: Principles and Practice, Academic Press, New York, 59-103 (1986).Applicant
Goldberg et al., Abstract C243: B7-H4 protein expression in invasive ductal carcinoma and its association with tumor progression, Molecular Cancer Therapeutics, retrieved from https://mct.aacrjournals.org/content/8/12_Supplement/C243, last visited Apr. 30, 2020, 4 (2009).Applicant
Hammerling et al., Production of antibody-producing hybridomas in the rodent systems, in research monographs in immunology, Elsevier/North-Holland Biomedical Press, 3:563-587 (1981).Applicant
Han et al., Negative roles of B7-H3 and B7-H4 in the microenvironment of cervical cancer, Experimental cell research, Author's accepted manuscript, Academic Press, United States (2018).Applicant
Han et al., Roles of immune inhibitory molecule B7-H4 in cervical cancer, Oncology Reports, 37(4):2308-2316 (2017).Applicant
Hansen et al., The B7 family of Immunoregulatory receptors: a comparative and evolutionary perspective, Mol. Immun., 46(3):457-472 (2009).Applicant
Harlow et al., Antibodies a Laboratory Manual, Cold Spring Harbor Press, 89 (1988).Applicant
He et al., The inhibitory role of B7-H4 in antitumor immunity: association with cancer progression and survival, Clinical & Developmental Immunology, 2011:695834, (8 pages), Hindawi Publishing Corporation, Egypt (2011).Applicant
Herber et al., Meeting report: mechanism and therapeutic reversal of immune suppression in cancer, Cancer Res., 67(11):5067-5069 (2007).Applicant
Horsten et al., Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase, Glycobiology, 20(12):1607-18 (2010).Applicant
Huang et al., B7-H3, B7-H4, Foxp3 and IL-2 Expression in cervical cancer: Associations with patient outcome and clinical significance, Oncology Reports, 35(4):2183-2190 (2016).Applicant
Huang et al., Clinical significance of the B7-H4 as a novel prognostic marker in breast cancer, Gene, Author's Manuscript, Elsevier, Netherlands (2017).Applicant
Ichikawa et al., Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of t-cell immunity: novel cancer escaping mechanisms, Frontiers in Bioscience, 10:2856-2860 (2005).Applicant
Iida et al., Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood, BMC Cancer, 9:58 (12 pages), BioMed Central, England (2009).Applicant
Iizuka et al., Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy, Oncology Reports, 36(5):2625-2632 (2016).Applicant
Imai-Nishiya Harue et al., Double knockdown of a1 ,6-fucosyltransferase (FUT8) and GDP-mannose 4,6-dehydratase (GMD) In antibody-producing cells: A new strategy for generating fully non-fucosylated therapeutic antibodies with enhanced ADCC, BMC Biotechnology, 7:84 (2007).Applicant
International Preliminary Report on Patentability, issued Aug. 27, 2020, for PCT Application No. PCT/US2019/018965, filed Feb. 21, 2019.Applicant
International Preliminary Report on Patentability, issued Aug. 27, 2020, for PCT Application No. PCT/US2019/018966, filed Feb. 21, 2019.Applicant
International Preliminary Report on Patentability, issued Sep. 8, 2020, for PCT Application No. PCT/US2019/020189, filed Mar. 1, 2019.Applicant
International Search Report and Written Opinion for International Application No. PCT/US2018/047805, International Search Authority, United States, mailed on Dec. 12, 2018.Applicant
International Search Report and Written Opinion, mailed Jan. 28, 2020, for PCT Application No. PCT/US2019/056210, filed Oct. 15, 2019.Applicant
International Search Report and Written Opinion, mailed Jun. 12, 2019, for PCT Application No. PCT/US2019/018965, filed Feb. 21, 2019, 11 pages.Applicant
International Search Report and Written Opinion, mailed Jun. 14, 2019, for PCT Application No. PCT/US2019/018963, filed Feb. 21, 2019.Applicant
International Search Report and Written Opinion, mailed May 17, 2019, for PCT Application No. PCT/US2019/020189, filed Mar. 1, 2019.Applicant
Janakiram et al., The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3, Immunological Reviews, 276(1):26-39, (2017).Applicant
Jennewein et al., The Immunoregulatory roles of antibody glycosylation, Trends in Immunology, 38(5):358-372 (2017).Applicant
Jeon et al., Structure and cancer immunotherapy of the B7 family member B7x, Cell. Rep., 9(3):1089-98 (2014).Applicant
Jiang et al., Tumor expression of B7-H4 predicts poor survival of patients suffering from gastric cancer, Cancer Immunology, 59(11):1707-1714 (2010).Applicant
Jiang et al.,, B7-H4 expression and increased death risk of cancer patients: A meta-analysis, J. Cancer Res. Clin. Oncol., 8:229-234 (2011).Applicant
Jones et al., Replacing the complementarity-determing regions in a human antibody with those from a mouse, Nature, 321:522-525 (1986).Applicant
Kabat et al., Attempts to locate complementarity-determining residues in the variable positions of light and heavy chains, Ann. NY Acad. Sci., 190:382-391 (1971).Applicant
Kabat et al., Sequences of proteins of immunological interest, 5th ed., public health service, National Institutes of Health, Bethesda, MO. TOC, 21 (1991).Applicant
Kamimura et al., Possible involvement of soluble B7-H4 in T cell-mediated inflammatory immune responses, Biochem. Biophysical Res. Communications, 389(2):349-353 (2009).Applicant
Kanda et al., Comparison of biological activity among nonfucosylated therapeutic Igg1 antibodies with three different N-linked Fc oligosaccharides: The high-mannose, Hybrid, and Complex Types, Glycobiology, 17(1):104-118 (Jan. 2007, e-pub. Sep. 29, 2006).Applicant
Kaplan et al., FPA 150, a novel B7-H4 therapeutic antibody with checkpoint blockade and ADCC activities, ESMO 2017 Congress, Madrid, Spain; Poster, 1 (2017).Applicant
Kettleborough et al., Isolation of tumor cell-specific single-chain Fv from immunized mice using Page-antibody libraries and the Re-construction of whole antibodies from these antibody fragments, Eur. J. Immunol., 24(4):952-958 (1994).Applicant
Khan et al., Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library, Sci. Rep., 7:45163; doi: 10.1038/srep45163, 12 (2017).Applicant
Kim et al., Guided selection of human antibody light chains against TAG-72 using A phage display chain shuffling approach, J. Microbiol., 45:572-577 (2007).Applicant
Kim et al., Immune signature of metastatic breast cancer: identifying predictive markers of immunotherapy response, Oncotarget, Advance Publications:1-12, Impact Journals, United States (2017).Applicant
Kirkland et al., Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies, J. Immunol., 137(11):3614-3619 (1986).Applicant
Kitamura et al., Prognostic biomarkers of renal cell carcinoma: Recent advances, Indian J. Urol., 24(1):10-15 (2008).Applicant
Klatte et al., Best of the 2006 AUA annual meeting: highlights from the 2006 annual meeting of the Am. Urological Assoc., 8(3):120-164 (2006).Applicant
Kohler et al., Continuous cultures of fused cells secreting antibody of predefined specificity, Nature, 256:495-497 (1975).Applicant
Konitzer et al., Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor, mAbs, 9:536-549 (2017).Applicant
Krambeck et al., B7-H4 expression in renal cell carcinoma and tumor vasculature: Associations with cancer progression and survival, Proc. Nat. Acad. Sci. USA, 103(27):10391-10396 (2006).Applicant
Kryczek et al., B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma, J. Experimental Med., 203(4):871-881 (2006).Applicant
Kryczek et al., Relationship between B7-H4, regulatory t cells, and patient outcome in human ovarian carcinoma, Cancer Research, 67(18):8900-8905(2007).Applicant
Kuroki et al., Biochemical characterization of 25 distinct carcinoembryonic antigen (CEA) Epitopes recognized by 57 monoclonal antibodies and categorized into seven groups in terms of domain structure of the CEA molecule, Hybridoma, 11(4):391-407 1992).Applicant
Kuroki et al., Determination of epitope specificities of a large number of monoclonal antibodies by solid-phase mutual inhibition assays using biotinylated antigen, Immunol. Invest., 21(6):523-538 (Oct. 1992, e-pub. Jul. 7, 2009).Applicant
Kuroki et al., Serological mapping of the tag-72 tumor-associated antigen using 19 distinct monoclonal antibodies, Cancer Res., 50:4872-4879 (1990).Applicant
Lee et al., Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal Influenza vaccination, Nature Medicine, 22:1456-1464 (2016).Applicant
Lefranc et al., IMGT, The intenational immuno Genetics database, Nucleic Acids Res., 27(1):209-212 (1999).Applicant
Lefranc, The IMGT unique numbering for Immunoglobulins, t-cell receptors, and Ig-like domains, The Immunologist., 7(4):132-136 (1999).Applicant
Leong et al., An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer, Mol. Pharm., 12(6):1717-1729 (2015).Applicant
Leung et al., Host B7-H4 regulates antitumor t cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model, J. Immunology, 190(12):6651-6661 (2013).Applicant
Leung et al., Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model, Cancer Immunology, 66(4):491-502 (2017).Applicant
Li et al., Co-inhibitory molecule b7 superfamily member 1 expressed by tumor-infiltrating myeloid cells induces dysfunction of anti-tumor CD8+ T cells, Immunity Cell Press, 48:1-14 (2018).Applicant
Li et al., Summary of the primer on tumor immunology and the biological therapy of cancer, J. Translational Medicine, 7:11 (2009).Applicant
Liu et al., B7-H4 expression in bladder urothelial carcinoma and immune escape mechanisms, Oncology Letters, 8(6):2527-2534.Applicant
Liu et al., B7-H4 Expression in human infiltrating ductal carcinoma-associated macrophages, Molecular Medicine Report, 14(3):2135-2142 (2016).Applicant
Liu et al., Expression of immune checkpoint molecules in endometrial carcinoma, Experimental and Therapeutic Medicine, 10(5):1947-1952 (2015).Applicant
Liu et al., High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy, MAbs, 6(2):483-492 (2014).Applicant
Loke et al., Emerging mechanisms of immune regulation: the extended 87 family and regulatory T cells, Arthritis Research & Therapy, 6(5):208-214 (2004).Applicant
Longmore et al., Product-identification and substrate-specificity studies of the GDP-L-fucose:2-acetamido-2-deoxy-beta-D-glucoside (FUC To Asn-Linked GlcNAc) 6-alpha-L-fucosyltransferase in a golgi-rich fraction from porcine liver, Carbohydr. Res., 100:365-392 (1982).Applicant
MacCallum et al., Antibody-antigen interactions: contact analysis and binding site topography, J. Mol. Biol., 262:732-745 (1996).Applicant
MacGregor et al., Molecular pathways: evaluating the potential for B7-H4 as an immunoregulatory target, Clin. Cancer Res., 23(12):2934-2941 (2017).Applicant
Mao et al., Recombinant human B7-H4 expressed in Escherichia coli inhibits T lymphocyte proliferation and IL-2 secretion in vitro, Acta. Pharmacologica. Sinica., 27(6):741-746 (2006).Applicant
Martin, Protein sequence and structure analysis of antibody variable domains, in antibody engineering, Kontermann and Dithei, eds., Chapter 31, 422-439 (2001).Applicant
Matsunaga et al., Increased B7-H1 and B7-H4 expressions on circulating monocytes and tumor-associated macrophages are involved in immune evasion in patients with gastric cancer, Yonago Acta Medica, 54(1):1-10 (2011).Applicant
McPherson, Crystallization of proteins from polyethylene glycol, J. Biol. Chem., 251(20):6300-6303 (1976).Applicant
McPherson, Current approaches to macromolecular crystallization, Eur. J. Biochem., 189:1-23 (1990).Applicant
Meng et al., B7-H4 as an Independent prognostic indicator of cancer patients: a meta-analysis, Oncotarget, 8(40):68825-68836 (2017).Applicant
Miyatake et al., B7-H4 (DO-O110) immunocytochemistry improves tile sensitivity of cancer cell detection in pelvic wash specimens of metastatic ovarian cancer, Cancer Research, Abstract 4502, retrieved from https://cancerres.aacrjounals.org/content/66/8_Supplement/1056.4, last visited Apr. 30, 2020, 4 (2006).Applicant
Miyatake et al., B7-H4 (DD-0110) is overexpressed in uterine endometrioid carcinomas independent of tumor grade, T cell infiltration, or apoptotic index, Cancer Research, Abstract 3604, retrieved from https://canceres.aacrjournals.org/content/65/9_Supplement/849.5, last visited May 1, 2020, 4 (2005).Applicant
Miyatake et al., B7-H4 (DD-O110) Is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor t-cell infiltration, Gynecologic Oncology, 106(1):119-127 (2007).Applicant
Moldenhauer et al., Identity of HML-1 antigen on intestinal intraepithelial T celis and of B-ly7 antigen on hairy cell leukaemia, Scand J. Immunol., 32(2):77-82 (1990).Applicant
Morel et al., Monoclonal antibodies to bovine serum albumin: Affinity and specificity determinations, Mol. Immunol., 25(1):7-15 (1988).Applicant
Mugler et al., B7-H4 Expression in a range of breast pathology: correlation with tumor t-cell infiltration, Applied Immunohistochemistry and Molecular Morphology, 15(4):363-370 (2007).Applicant
Murillo et al., Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies, Clinical Cancer Research, 9:5454-5464 (2013).Applicant
Niwa et al., Enhanced natural killer cell binding and activation by low-fucose Igg1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density, Clinical Cancer Research, 11(6):2327-2336 (2005).Applicant
Niwa et al., Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 is independent of FcyRIIIa functional polymorphIsm, Clin. Cancer Res., 10:6248-6255 (2004).Applicant
Ohaegbulam et al., Tumor-expressed immune checkpoint B7X promotes cancer progression and antigen-specific CD8 T Cell exhaustion and suppressive innate immune cells, Oncotarget, 8(47):82740-82753 (2017).Applicant
Palena et al., Review article vaccines against human carcinomas: strategies to improve antitumor immune responses, J. Biomedicine and Biotechnology, 2010(380697):1-12 (2010).Applicant
Parola et al., Integrating high-throughput screening and sequencing for monoclonal antibody discovery and engineering, Immunology, 153:31-41 (2018).Applicant
Persic et al., An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries, Gene, 187(1):9-18 (1997).Applicant
Podojil et al., Potential targeting of B7-H4 for the treatment of cancer, Immunological Reviews, 276(1):40-51 (2017).Applicant
Prasad et al., B7S1, a novel B7 Family member that negatively regulates T cell activation., Immunity, 18(6):863-873 (2003).Applicant
“Specialized knowledge in pharmaceutics (I), 7th Version”, Practicing Pharmacist Qualification Certification Center under State Food and Drug Administration China medical science press, 6 pages (2015).Applicant
Chang et al., Practical approaches to protein formulation development in “Rationale Design of stable protein formulations-theory and practice” (J.F. Carpenter and M.C. Manning eds.) Kluwer Academic/Plenum publishers, New York., pp. 1-25 (2002).Applicant
GenBank, immunoglobulin, partial [Homo sapiens] CAA69703.1 (Jul. 26, 2016).Applicant
Goswami et al., Development and Challenges for mAb-Based Therapeutics, Antibodies 2013, 2, 452-500 (2013).Applicant
International Application No. PCT/US2018/047805, International Preliminary Report on Patentability, mailed Mar. 5, 2020.Applicant
International Application No. PCT/US2019/056210, International Preliminary Report on Patentability, mailed Apr. 29, 2021.Applicant
International Application No. PCT/US2019/018963, International Preliminary Report on Patentability, mailed Sep. 3, 2020.Applicant
Kang et al., Rapid Formulation Development for Monoclonal Antibodies, BioProcess International, 14(4):1-4 (Apr. 2016).Applicant
Shao et al., Construction of anti-B7-H4-scFv library and screening and identification of anti-B7-H4-scFv, Chin J. Cell Mol. Immunol, 32 (09):1260-1266 (2016).Applicant
Uchiyama S., Liquid formulation for antibody drugs, Biochimica et Biophysica Acta (BBA)—Proteins and Proteomics, 1844(11):2041-2052 (Nov. 2014).Applicant
Verhoeven et al., Reshaping human antibodies: Grafting an antilysozyme activity, Science, 239(4857):1534-1536 (1988).Applicant
Wang W., Instability, stabilization, and formulation of liquid protein pharmaceuticals, International Journal of Pharmaceutics, 185(2):129-188 (Aug. 1999).Applicant
Whitaker et al., A Formulation Development Approach to Identify and Select Stable Ultra-High-Concentration Monoclonal Antibody Formulations With Reduced Viscosities, Journal of Pharmaceutical Sciences, 106(11):3230-3241 (Nov. 2017).Applicant
Xiaoju et al., Screening and Identification of Antigen Epitope of hB7-H4 Recognized by Monoclonal Antibody with 12 phage Display Peptide Library, Letters in Biotechnology, 26(4):505-509 (Jul. 31, 2015).Applicant
Li et al., Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8+ T Cells, Immunity, 48(4):773-786 (Apr. 2018).Applicant
Meyer et al., Better Together: B7H1 Checkpoint Blockade Synergizes with anti-PD1, Immunity, 48(4):621-623 (Apr. 2018).Applicant
Nanda et al., Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib Keynote-012 Study, Journal of Clinical Oncology, 34(21):2460-2467 (Jul. 2016).Applicant